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GENERal INTRoDUCTIoN
Heart failure
Heart failure (HF) can be described as: ‘a clinical syndrome in which patients have the 
following features: symptoms typical of HF, signs typical of HF, and objective evidence 
of a structural or functional abnormality of the heart at rest’.1 Given the central role 
of impairment of cardiac function, measures of cardiac function (e.g. left ventricular 
ejection fraction (LVEF)) are frequently used to describe (patients with) HF. Ejection 
fraction (stroke volume divided by the end-diastolic volume of the left ventricle) 
is typically decreased in patients with HF. However, people can also experience 
symptoms of HF whilst their ejection fraction is largely preserved, which is called HF 
with preserved ejection fraction. It is estimated that almost half of all patients with 
symptomatic HF, actually have a preserved ejection fraction. Although symptoms 
are comparable with HF with diminished LVEF, these two types of HF differ in the 
pathophysiology, epidemiology, diagnosis and prognosis.2 This thesis will focus on HF 
patients with a diminished LVEF. 
Concerning the etiology of HF with (and without) diminished LVEF, coronary artery 
disease represents the most frequent cause of HF and is reported to be responsible 
for HF in up to 68% of the cases.3 This group of HF patients is often defined as ischemic 
HF patients. Other causes of HF with diminished LVEF are dilated cardiomyopathy, 
hypertensive heart disease and valvular heart disease,4 which we will refer to as non-
ischemic HF patients. 
The syndrome of Hf
In HF, the heart is not able to achieve sufficient cardiac output to fulfil the requirements 
of the metabolising tissues. The low cardiac output and, consequently, decreased 
peripheral blood pressure, lead to several homeostatic physiological reactions. 
First, the sympathetic nervous system (SNS) activity is increased, which leads to 
an increase in cardiac contractility and heart rate. Furthermore, the SNS-mediated 
vasoconstriction of veins causes an increase in venous return to the heart, whilst an 
increase in arterial vascular tone contributes to an increase in peripheral resistance. 
Second, the activation of the renin-angiotensin-aldosterone system stimulates 
the kidneys to reabsorb sodium and water to prevent fluid loss. Combined, these 
physiological responses (aim to) increase cardiac output and maintain blood pressure.
 
In a normal situation, these baroreceptor-mediated mechanisms are adequate 
to counteract a decrease in blood pressure. However, in patients with HF, these 
compensatory responses to maintain a stable blood pressure will contribute to 
further malfunctioning of the heart. The increase in afterload through peripheral 
vasoconstriction requires a larger workload from the heart to expel blood, whereas the 
heart is less able to mediate stronger contractions from the larger preload (resulting 
from the increase in venous return), as one may expect based on the Frank-Starling 
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curve in healthy hearts (Figure 1). Consequently, the heart is not able to process the 
enhanced venous return and to sufficiently maintain cardiac output. This causes the 
congestion of fluid and a decreased cardiac output, which lead to symptoms such as 
edema, dyspnea at rest and/or during exercise, and fatigue. 
Based on these clinical symptoms, HF patients can be classified according to the New 
York Heart Association (NYHA) classification. Class I patients do not have symptoms, 
while patients in class II-IV have symptoms during ordinary activities (class II), light 
activities (class III), or all activities and/or at rest (class IV).6 
figure 1
adapted from Brubaker et al.5 frank-starling curve of a normal heart (a) and a heart with systolic dysfunction (b,c). 
an increase in left ventricular end-diastolic pressure/volume (preload) is associated with an increase in stroke 
volume and cardiac output. When a heart develops systolic dysfunction and contractility is decreased, this curve is 
shifted downwards. stroke volume decreases and as a result left ventricular end-diastolic volume increases. The 
fluid retention associated with heart failure generates a further increase in end-diastolic volume. Due to the car-
diac dysfunction this leads to only a minor increase in stroke volume. Therefore, the increase in preload can finally 
lead to pulmonary congestion.
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Whilst the attenuated cardiac function is central, HF is a syndrome which comprises 
various abnormalities, such as an attenuated vascular function,7 skeletal muscle 
abnormalities (e.g. muscle atrophy, reductions in skeletal muscle oxidative enzymes),8 
and neurohumoral derangements, mainly relating to the SNS, the renin-angiotensin-
aldosterone system, and endothelin and vasopressin secretion.9,10 Moreover, HF 
is often associated with co-morbidities, of which the most frequent are: anaemia, 
pulmonary diseases, hypertension, diabetes, depression, cerebral and cognitive 
dysfunction, erectile dysfunction, iron deficiency, kidney and liver dysfunction, and 
sleep disturbances/sleep-disordered breathing.11
figure 2
Incidence rate of Hf (/1000) and 95% confidence band for males (a) and females (b) in a Dutch population. source: 
Bleumink et al.13
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Incidence of Hf
HF is a common syndrome of which the prevalence is increasing due to aging of the 
population and better treatment possibilities of cardiac conditions.12 The prevalence 
of HF increases with age from 0.9% in subjects 55-64 years of age to 17.4% in subjects 
over 85 years of age (Figure 2). At the age of 55, the lifetime risk of developing heart 
failure is about 33% and 28.5% for respectively men and women in the general 
population.13 In 2011, over 140,000 people suffered from HF in the Netherlands, and 
about 26,000 patients were newly diagnosed with HF in this country.14  
Prognosis of Hf and prognostic factors
Despite the improvement in (pharmacological) therapy for HF in the past decades, 
the mortality rates for HF are still high. The 5-year survival of HF patients is 35-55% 
(Figure 3),13,15 which is lower than most common cancers.16 In 2012, over 6,700 subjects 
died due to HF in the Netherlands.14 
Several factors have been demonstrated to negatively influence the prognosis of HF; 
lower LVEF, older age, ischemic etiology (and the extend of coronary artery disease), 
higher NYHA class, comorbidities (e.g. hypertension, diabetes, peripheral vascular 
figure 3
survival rate (%) of male and female Hf patients in a Dutch population. source: Bleumink et al.13
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disease, angina pectoris) and vascular dysfunction.17-19 However, arguably the most 
important prognostic factor is physical fitness.20-22 Myers et al. demonstrated that 
peak oxygen uptake (VO2peak), i.e. the gold standard measure for physical fitness level, 
was a stronger predictor for mortality than any other clinical or hemodynamic variable 
in HF patients.22 Therefore, cardiopulmonary exercise testing is now frequently used 
in HF patients to estimate prognosis and sometimes even to make decisions regarding 
treatment and therapy. For example, Osada et al. demonstrated that patients with 
a VO2peak ≤14 ml/min/kg have a significantly worse prognosis than those with VO2peak 
>14 ml/min/kg, and that therefore patients with a VO2peak ≤14 ml/min/kg can be 
considered eligible for heart transplantation.23 More recent studies have investigated 
other parameters of cardiopulmonary exercise testing in relation to prognosis in 
HF patients and found that the slope of ventilation/carbon dioxide production (VE/
VCO2 slope; a measure of ventilatory efficiency) is an equally well (or possibly better) 
predictor of prognosis in HF patients compared to VO2peak.20,24 Both a decreased VO2peak 
and an elevated VE/VCO2 slope are indicators of exercise intolerance in HF and, more 
importantly, strongly and independently predict survival in HF patients. 
Current pharmacological and non-pharmacological therapy 
The current treatment of HF with diminished LVEF is aimed at diminishing 
symptoms, reducing hospitalization and improving survival.25 Treatment of HF 
primarily constitutes of pharmacological treatment and lifestyle modifications, but 
dependent on the (clinical) situation, implantation of supportive cardiac devices, 
cardiac transplantation or mechanical circulatory support can be necessary.25,26 The 
most commonly used medications are angiotensin converting enzyme-inhibitors, 
beta(β)-receptor-blockers, aldosterone receptor antagonists, and diuretics. Lifestyle 
modifications include patient education, a healthy diet and fluid restriction, limitation 
of alcohol intake, cessation of smoking and regular physical activity. For most of these 
lifestyle modifications and/or non-pharmacological treatments, there is no scientific 
evidence for a reduction in morbidity and mortality, except for the enrolment of 
patients into a multidisciplinary-care management program and for exercise training.25
Exercise intolerance in Hf
Unfortunately, one of the central characteristics of HF is exercise intolerance. 
When performing incremental exercise tests, a commonly used method to assess 
cardiopulmonary fitness, HF patients attain a lower maximal work rate and a lower 
maximal oxygen uptake compared to healthy subjects.27 On average, maximal 
workload and maximal oxygen uptake in HF patients is ~50% of that observed in 
healthy controls.27-29 This means that HF patients demonstrate significant limitations 
that prevent them to perform exercise and utilize oxygen. Interestingly, the decreased 
cardiac performance is not the only factor contributing to this exercise intolerance, but 
also peripheral abnormalities play a role. The importance of peripheral abnormalities 
in exercise intolerance is reinforced by the observation that an increase in cardiac 
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output does not necessarily increase maximal oxygen uptake in HF patients.30 These 
central and peripheral abnormalities in HF patients may relate to a decreased cardiac 
function, ventilatory inefficiency, endothelial dysfunction, inadequate skeletal 
muscle perfusion during exercise, and skeletal muscle deconditioning (Figure 4).5 
factors contributing to exercise intolerance in Hf
SNS. The SNS is believed to contribute to the activation of centrally mediated 
effects of exercise. In this light, some studies suggest a larger increase in plasma 
norepinephrine during exercise in HF patients compared to controls,32,33 which 
indicates early activation of the sympathetic nervous system. This is mediated by 
an enhanced chemoreceptor reflex and overactivity of the muscle ergoreceptors in 
HF patients.34,35 Although, this is an attempt to support the less functioning heart to 
maintain adequate blood pressure during exercise, the increase in sympathetic activity 
contributes to exercise intolerance by vasoconstriction and  subsequent diminished 
muscle blood flow, ischemia, release of reactive oxygen species and inflammation.36  
Cardiac output. At the start of exercise, healthy subjects and HF patients demonstrate 
an increase in stroke volume, heart rate and, therefore, cardiac output. However, 
maximal heart rate is lower in HF patients compared to controls, often caused by 
medication use in HF patients. Furthermore, the exercise-induced increase in stroke 
figure 4
Determinants of exercise intolerance in Hf. source: Conraads et al.31
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volume in HF patients is lower than in controls, most likely due to the limited ability of 
the heart to pump out blood and/or the enhanced peripheral resistance that requires 
the heart to work against a higher afterload. Therefore, the increase in cardiac output 
during exercise in HF patients is markedly attenuated compared to controls, limiting 
maximal oxygen consumption.27 
Ventilation. Another important difference between HF and controls is that ventilation 
increases at a faster rate in HF patients during exercise compared to controls.27 This 
is reflected by the relation between VE (i.e. ventilation) and VCO2 (i.e. carbon dioxide 
production), where HF patients often demonstrate an elevated VE/VCO2 slope.29 This 
means that HF patients demonstrate larger ventilation for a given CO2 production. 
This may be explained through an impaired lung perfusion and therefore an increased 
ventilation-perfusion mismatching.37 Another factor contributing to an elevated VE/
VCO2 slope in HF patients is decreased alveolar-capillary membrane conduction, 
impairing gas exchange.38 The enhanced chemoreceptor reflex may also mediate the 
increased ventilator response to exercise.34 All of these factors can contribute to an 
exaggerated ventilator response to exercise and hereby exercise intolerance.29 
Endothelial function and muscle perfusion. During exercise, the increase in shear 
stress stimulates endothelial nitric oxide release and hereby vasodilation. HF patient 
are characterized by endothelial dysfunction and attenuated nitric oxide-induced 
vasodilation.39,40 Therefore, HF patients are less able to dilate arterioles within active 
muscles and to decrease peripheral resistance during exercise compared to healthy 
subjects. Indeed, a lower (increase in) blood flow to active tissues during exercise and 
an excessive vasoconstriction in inactive tissues is observed in HF patients compared 
to controls.27,41-44 Moreover, vascular resistance was higher at rest and during exercise 
in HF patients.27 Whilst this response is likely to be a compensatory mechanism to 
maintain adequate blood pressure and blood supply to vital organs, it also leads to 
hypoperfusion of active skeletal muscle and hereby exercise intolerance.5 
Muscle oxidative capacity. HF patient are characterized by various skeletal muscle 
abnormalities.45 The presence of marked muscle atrophy, reduction in mitochondrial 
volume and density, and decreased skeletal muscle oxidative enzymes may contribute 
to a decreased muscle oxidative capacity, an early muscular lactate release and 
therefore exercise intolerance in HF.5,46,47 
Core body and skin temperature. Finally, compared to healthy subjects, patients with 
HF show a paradoxical decrease in core body and skin temperature during short-term 
exercise,48,49,50 despite the presence of significant heat production by the physically 
active muscles. The impaired exercise-induced blood flow to active tissues and 
significant vasoconstriction in inactive tissues in HF patients may contribute to the 
(paradoxical) decrease in skin temperature demonstrated in HF patients. The decrease 
in core body temperature is not fully explained but may be related to redistribution of 
cooler blood of the peripheral arteries. Whether and how these abnormal responses 
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contribute to exercise intolerance is currently unknown. Furthermore, whether the 
lower core body temperature sustains during prolonged exercise in HF patients is 
unknown.
Taken together, the severe exercise intolerance HF patients experience is related to 
central factors, such as the failing heart, but also peripheral factors, such as muscle 
hypoperfusion and diminished oxidative capacity of skeletal muscles. Exercise training 
is thought to be an effective therapy in improving (some of) the factors associated 
with exercise intolerance (Figure 5).31 However, some of the effects of exercise in HF 
patients are currently unknown. 
Current questions – training-induced adaptations in HF. To understand and predict 
training-induced adaptations, the acute effects of exercise in HF patients may provide 
figure 5
Beneficial effects of exercise training in Hf. source: Piepoli et al.51
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valuable and novel information. Whilst several training studies indicate improvement 
in vascular function in HF patients, the stimulus for exercise-induced adaptation in 
vascular function, i.e. shear rate, has not been previously investigated in HF patients 
during exercise. Knowledge on the shear rate patterns during exercise in HF patients 
may aid in optimizing training protocols. 
Current questions – core body and skin temperature during exercise. Core body and skin 
temperature responses to exercise have only been investigated in HF patients during 
short-term exercise. Moreover, whether core body and skin temperature responses 
during exercise of longer duration, i.e. a more common form of exercise in HF patients 
during rehabilitation, differ between HF patients and controls is unknown.
Exercise training in Hf in a historical perspective
The benefits of exercise in the general population are well established and therefore 
regular physical activity is recommended. Due to exercise intolerance and symptoms 
of breathlessness, exercise was prohibited in HF patients for a long time whilst bed rest 
was a central component in the treatment.52-55 The first scientific studies investigating 
the effects of exercise training in HF patients emerged in the late 1970s/1980s and 
have demonstrated positive effects of exercise training in HF patients.56-59 Also, 
and perhaps more importantly, they showed that exercise training did not cause 
deterioration of cardiac function.56,57 Nowadays, it is known that when staying inactive 
and physically unfit, the prognosis of HF patients worsens, whilst a higher physical 
fitness level is associated with lower mortality rates. Exercise training, therefore, is 
recommended in the European and American guidelines as an important component 
of the treatment of stable HF patients NYHA class I-III.25,26 Exercise training can be 
applied in different forms, intensity and frequency.60 Knowledge on prescribing the 
‘best practice’ exercise protocol is currently unknown and has large potential for the 
optimal clinical prescription of exercise training.
Endurance aerobic training. Endurance aerobic training at moderate-intensity is 
recommended in current HF-guidelines and is most commonly used in rehabilitation 
settings in HF patients.60 Endurance exercise is typically performed at continuous 
moderate-intensity, meaning at 40-80% VO2peak or at Borg score for perceived exertion 
10-14 (out of 20). The well-established central and peripheral effects of moderate-
intensity endurance training in HF patients represent an improvement in exercise 
capacity, beneficial cardiac remodelling, increase in endothelial function, and 
improvement in quality of life and prognosis.61-65 Summarising, moderate-intensity 
endurance training is regarded as a safe type of exercise and effective in improving 
central and peripheral abnormalities and prognosis in HF patients. Therefore, 
endurance exercise is highly recommended in cardiac rehabilitation.60,66
Resistance/strength training. Resistance training (RT) is an exercise modality in which 
skeletal muscle groups are trained by repetitive lifting of relatively heavy weights, and 
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it is commonly used in training programs in healthy and diseased subjects.67 For a long 
time, RT was prohibited in patients with HF out of concern for an increased afterload 
during the lifting phase of training. This was believed to impair left ventricular 
function and stimulate adverse left ventricular remodelling.68 Studies demonstrating 
that RT induced similar systolic blood pressure compared to cycling exercise, did not 
induce a decrease in ejection fraction during exercise, and did not result in adverse 
cardiac remodelling in HF,69,70 have more recently shifted the focus of RT from risks to 
possible benefits. An established effect of RT is an increase in skeletal muscle mass, 
which can be beneficial in HF patients as loss of muscle mass is characteristic in HF 
patients.68 The results of studies investigating the beneficial effects of RT on exercise 
capacity and quality of life in HF patients are inconclusive.71 Although guidelines 
consider RT in some HF patients, a general recommendation for all HF patients 
remains controversial.60 RT is seen is a complementary training modality, in addition 
to endurance training.60 Indeed a recent meta-analysis has demonstrated superior 
improvement in VO2peak when exercise training was combined with RT.72 
High-intensity interval training. More recently, another type of exercise training has 
drawn special interest; high-intensity interval training (HIT). This type of exercise is 
characterized by periods of exercising at high intensities alternated by periods of 
active or passive rest.73 The central idea behind this type of exercise is that exercise 
at higher intensity induces a larger stimulus for central and peripheral adaptations.74 
Although this type of training seems controversial in HF patients, some studies 
have successfully applied HIT in cardiac patients, with positive results ranging from 
improvements in peak oxygen uptake from 8-46%.75,76 Moreover, a direct comparison 
with HF patients undergoing traditional endurance exercise training suggested a 
potentially superior effect of HIT to improve physical fitness, cardiac remodelling, 
endothelial function and quality of life in HF patients.75,77 However, not all studies 
comparing the effects of HIT and endurance exercise training in cardiac patients have 
found significant differences.76,78-82 Therefore, whether HIT is superior to traditional 
endurance training is still not clear. Moreover, whether an intensive training protocol 
such as applied in some studies applying HIT is feasible for the general HF population 
is unknown. Taken together, despite the potential superior effects of HIT, the optimal 
and feasible HIT-protocol to induce beneficial effects in HF patients is unclear.
Concerns have been raised about the potential higher risk for acute cardiac events 
during HIT in HF patients. A recent study has investigated the risk for cardiovascular 
events during HIT and moderate-intensity training in a cardiovascular rehabilitation 
setting for patients with coronary heart disease, and found relatively low risks for both 
types of training.83 An important limitation of this study, however, is that this study 
lacks the power to detect relevant differences in the occurrence of cardiovascular 
events between HIT and moderate-intensity training.84 Therefore, the safety of HIT in 
HF patients should be further addressed. As the effects of HIT are less well known, 
this type of training is currently only advised for HF patients with higher fitness levels 
in specialized (research) settings and is not common practice.60,85
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Current questions –HIT. A recent review of Meyer et al. summarizes the current 
knowledge on the acute and long-term effects of HIT in HF patients and addresses 
some issues to further explore.86 Although a recent meta-analysis suggest a potential 
superior effect of interval training compared to traditional continuous/endurance 
training on LVEF and fitness levels,87 the effects of HIT on cardiovascular adaptations 
are less investigated and therefore less clear. Furthermore, previous training studies 
involving HIT have adopted various training protocols with various results. It is likely 
that the ‘optimal’ protocol will be different between HF patients, whilst not all HF 
patients will be able to perform a training program at such high-intensity. This topic 
requires further detailed attention. Moreover, the implementation of high-intensity 
exercise for HF patients raises questions about the safety of HIT for HF patients. 
Although initial results suggest that HIT is a safe mode of exercise training, more 
knowledge on the acute effects of HIT is necessary before recommendations of HIT 
to the general HF population will be possible. Concluding, more information on the 
safety and efficacy of HIT, and the effect of (different) HIT protocols on physical 
fitness and cardiovascular function is needed before translating this type of exercise 
to the general population and HF patients.    
Current questions – limits of exercise in cardiac patients. Because of the general 
recommendations of physical activity and the specific advice for cardiac patients to 
engage in regular exercise, the participation of cardiac patients in exercise events 
such as walking marches in inevitable. However, the effects of such, often prolonged 
and repeated, exercise on the heart in subjects with heart conditions is currently 
unknown. This information can contribute to safe exercise prescription.
oUTlINE of THIs THEsIs
As described previously, the prognosis in HF patients is poor and an important 
prognostic factor is vascular function. A factor that is associated with a negative 
effect on vascular function in the general (healthy) population is an increased body 
mass index (BMI).88 Although obesity is a risk factor for the development of HF,89 
cross-sectional data suggests that an increased BMI may have protective effects in 
HF patients.90,91 Therefore, obesity may have a different effect on vascular function 
in HF patients than in the general population. Whilst the prevalence of obesity in HF 
is high,92 the relation between BMI and vascular function in HF patients is unknown. 
Chapter 2 describes the influence of BMI on the vascular function and structure in HF 
patients. This study provides insight into whether overweight or obesity in HF patients 
is associated with additional deterioration in vascular function or structure compared 
to lean HF patients. 
Since increasing physical fitness is important to improve prognosis in HF patients, 
exercise should be a central component of cardiac rehabilitation. An important 
limiting factor is the (severe) exercise intolerance patients with HF experience, 
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relating to a reduced myocardial function and peripheral abnormalities in perfusion 
during exercise. Disturbed thermoregulatory responses during exercise may further 
limit exercise performance in HF patients. Studies investigating thermoregulation 
during exercise in HF patients have focussed on short-term (maximal) exercise 
only,48,50 which is different to exercise protocols as applied during rehabilitation. 
Moreover, studies in healthy volunteers demonstrate that thermoregulation plays a 
more significant role during exercise of longer duration.93,94 Therefore, in chapter 3 
we describe the effect of endurance exercise at moderate-intensity on core body and 
skin temperature in HF patients and controls. This study provides further insight into 
(patho)physiological processes during exercise in HF patients that may contribute 
to the severe exercise intolerance, but also addresses whether we should be more 
attentive for the development of heat-related problems during exercise in HF patients. 
Exercise training studies in HF patients have demonstrated an improvement in 
endothelial function after training,75,95-97 although the magnitude of improvement 
varies, and the improvement is sometimes limited to the trained extremities only.98 
An important stimulus for the beneficial exercise-induced improvements in vascular 
function is the acute change in vascular shear stress during exercise.99 These acute 
changes in shear stress patterns during exercise are well described in healthy 
subjects,49 and have even been directly linked to vascular adaptations.99,100 However, 
shear patterns during exercise in HF patients have not been explored. In chapter 4 
we will investigate brachial artery blood flow/shear rate patterns during continuous 
moderate-intensity cycle exercise in HF patients and controls. This provides better 
insight regarding the beneficial effects of endurance exercise on the vasculature in 
HF patients, and whether there are differences in effects of exercise on the shear 
stimulus between HF patients and controls.
Current guidelines on the treatment of HF recommend regular exercise performed at 
moderate-intensity. However, recent studies indicate that healthy subjects as well as 
HF patients might benefit more from exercise training at high-intensity.75,101 Although 
there are some studies providing evidence for the beneficial effects of HIT in HF 
patients, the acute effects and safety of HIT in HF patients are not well established.84 
In chapter 5 we investigate whether an acute bout of endurance exercise and HIT leads 
to different responses in the release of cardiac biomarkers indicative for cardiac 
damage (i.e. cardiac troponin) and cardiac load (i.e. B-type natriuretic peptide), and 
we compare this to the biomarker response in healthy subjects.
Based on the strong cardioprotective effects of physical activity, the general 
population and patient populations are encouraged to perform physical activity on 
a regular basis.102,103 Walking is a popular and feasible physical activity, especially for 
the older or diseased population. Consequently, cardiac patients are also likely to 
engage in walking marches in which several hours of exercise is performed. In healthy 
populations, prolonged (moderate-to high-intensity) exercise is known to cause 
an acute, but transient, impairment in cardiac function.104-106 However, the effects 
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of prolonged walking on cardiac function in individuals with an a priori attenuated 
cardiac function have never been investigated. In chapter 6, we describe the effects 
of one day and three consecutive days of prolonged walking on cardiac function in 
healthy subjects and cardiac patients with a history of a diminished left ventricular 
function. This question is of special importance as (walking) exercise is often 
recommended by physicians for cardiac patients, whilst a further reduction of their 
cardiac function may increase symptoms and might temporarily increase the risk for 
acute cardiovascular events. 
As previously described, HIT seems to be very promising in HF patients. Superior 
results of HIT compared to traditional endurance (i.e. continuous) training have been 
observed in studies with very demanding HIT protocols (high-intensity bouts of 4 min). 
However, these long bouts of exercise at high-intensity might not be feasible for all 
HF patients. Therefore, in chapter 7, we propose a novel HIT-protocol in which the 
high-intensity bouts are of moderate duration (1 min). To further explore what type 
of exercise may yield the largest effect size on fitness, cardiac function, vascular 
function and quality of life, we performed a 12-week training study in HF patients 
NYHA class II-III, in which we compare the effects of traditional continuous training 
versus HIT. This study expands on the (limited) data of previous studies on the effects 
of HIT in HF patients, and will contribute to better understand the effects of exercise 
training in HF patients. 
METHoDs aPPlIED IN THIs THEsIs 
To assess subject characteristics, physical fitness, vascular function and structure, 
cardiac function and structure, cardiac biomarkers, core and skin temperature, quality 
of life, and rate of perceived exertion during exercise, we have used the techniques 
described below. A more detailed description of the methods can be found in the 
corresponding chapters of this manuscript.
subject characteristics
All subjects underwent medical screening in which medical history and medication 
use was documented. Body height and weight (Seca 888 Scale, Seca, Hamburg, 
Germany) were obtained to calculate body mass index and body surface area.107 Skin 
folds at four locations (biceps, triceps, sub-scapular and supra-iliac) were measured 
to estimate the percentage of body fat.108 Waist and hip circumference were measured 
(Seca 201, Chino, USA) to obtain waist-to-hip ratio. An electrocardiogram was obtained 
to determine heart rhythm and exclude subjects with abnormalities that represent 
absolute contra-indications to perform exercise. 
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Incremental maximal cycling test
Subjects performed an incremental maximal cycling test to determine physical fitness. 
For contra-indications for exercise testing and for the relative and absolute indications 
for termination of the exercise test, we adhered to the Scientific Statement from the 
American Heart Association for exercise testing.109 The tests were performed on a 
cycle ergometer (Lode, Excalibur v1.52, 1991, Groningen, the Netherlands/Ergoline, 
Ergoselect 200k, Bitz, Germany). The workload was increased by 10-25 Watt per minute, 
depending on the expected physical fitness of the participant (based on sex, age and 
height, or previous exercise tests when available).110 Participants were instructed to 
pedal at a frequency of ≥60 rpm until volitional fatigue. During exercise, oxygen uptake, 
carbon dioxide production, ventilation and respiratory exchange ratio were continuously 
measured (breath-by-breath, CPET Cosmed v9.1b, Rome, Italy/LabManager V5.32.0). 
Exercise testing was performed under continuous electrocardiographic registration, 
and blood pressure was measured every 2-3 minutes. Physical fitness was expressed 
as peak oxygen uptake (VO2peak), which was defined as the maximal average oxygen 
uptake during (usually the last) 30 seconds of the exercise test. Ventilatory efficiency 
was defined as the slope of the ventilation to the carbon dioxide production (VE/VCO2 
slope) calculated over the linear phase of the response up to the anaerobic threshold. 
Vascular ultrasound measurements
To determine vascular function and structure we used a high-resolution ultrasound 
machine (Terason T3000, Burlington, MA, USA). All vascular function measurements 
were done by well-trained sonographers. Below, we will shortly describe the vascular 
ultrasound measurements. Additional information can be found in chapters 2, 4 and 7.
Artery endothelium-dependent dilation. Vascular function was measured by 
determining flow-mediated dilation (FMD), a non-invasive technique to establish 
endothelium-dependent vasodilation, according to previously published guidelines.111 
Brachial and superficial femoral arteries were imaged using ultrasound. A rapid 
inflation and deflation pneumatic cuff (Hokanson, Bellevue (Washington), USA) was 
applied around the lower arm/upper leg. A 1-minute baseline ultrasound recording 
was acquired after which the pneumatic cuff was inflated to supra-systolic pressure 
(220 mmHg) for 5 minutes. After cuff release, recording of artery diameter and blood 
flow velocity was continued for 3-5 minutes. FMD was expressed as the change (in %) 
in arterial diameter compared to baseline diameter. 
Artery endothelium-independent dilation. The brachial artery diameter response to 
an exogenous nitric oxide donor (a sublingual dose of 400 µg glyceryl trinitrate) is 
recorded for 10 minutes and is expressed as the change from baseline diameter.112 
This procedure is shown to induce maximal vasodilation through an endothelium-
independent mechanism, and is an indication of smooth muscle function.
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Artery dilator capacity and peak blood flow. Conduit artery dilating capacity of the 
brachial artery was determined by measuring the dilation response to ischemic 
handgrip exercise (IEx). The peak hyperemic forearm blood flow response to this 
stimulus provides a valid and accepted index of resistance artery size or remodeling.112 
Artery lumen and wall thickness. Arterial wall thickness, measured as intima-media 
thickness (IMT), can be used as a surrogate marker for atherosclerosis113 and as 
a predictor for future cardiovascular events, in the general population114 as well as 
in patients with cardiovascular disease.115 We have measured IMT in the brachial, 
superficial femoral and common carotid artery. Wall thickness was also corrected for 
within and between-subjects differences in diameter using the wall-to-lumen ratio. 
(Exercise-induced) Shear rate pattern. Brachial artery wall and lumen, and Doppler-
velocity signal were obtained under resting conditions as well as during exercise. 
More details can be found in chapter 4.
Echocardiography
Transthoracic echocardiography was performed by well-trained sonographers according 
to the guidelines of the American Society of Echocardiography.116 Images of 3-5 cardiac 
cycles during end-expiration with breath-holding (avoiding Valsalva maneuver) were 
recorded digitally on a disc and analyzed post-hoc using specially designed software 
(Echopac, General Electric Healthcare, Horten, Norway). Below, some important cardiac 
parameters are discussed. More details are given in chapter 6 and 7.
Parameters of cardiac output. We measured end-diastolic volume (EDV) and end-
systolic volume (ESV) of the left ventricle to determine stroke volume (EDV-ESV) and 
ejection fraction ((EDV-ESV)/EDV). Cardiac output was determined by multiplying 
stroke volume with the heart rate. Cardiac index was determined by dividing the 
cardiac output by the body surface area. 
Strain. Left ventricle strain was analyzed by speckle tracking. This measure of cardiac 
deformation during the cardiac cycle provides information on global and regional 
systolic function.117 This measure can detect changes in LV systolic function, which 
are not always detected by changes in LVEF.118 
Flow velocities. The transmitral flow velocities were measured using pulsed-wave 
echo-Doppler. The following flow-derived parameters were measured: peak mitral 
flow velocity during early diastole and peak mitral flow velocity during atrial systole. 
Moreover, the pulsed-wave Doppler signal of the inflow over the pulmonary valve is 
used to describe diastolic function.
Tissue Doppler velocities. We obtained pulsed-wave tissue Doppler imaging 
measurements of peak systolic annular tissue velocities of the mitral and tricuspid 
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annulus. Moreover, we also measured these annular tissue velocities during early and 
late filling (diastolic). 
Cardiac biomarkers
To assess cardiac troponin and B-type natriuretic peptide(BNP) levels after exercise, 
whole venous blood was collected in serum-gel vacutainer tubes and allowed to clot 
for ~30 minutes. After centrifugation, serum was aliquoted, frozen, and stored at −80°C 
for later analysis. The analysis was performed with a highly sensitive cardiac troponin-I 
assay (ADVIA Centaur TnI-Ultra, Siemens Healthcare Diagnostics), with a detection limit 
of 6 ng/L, and BNP-assay (ADVIA Centaur BNP, Siemens Healthcare Diagnostics) with a 
detection limit of 2 pg/mL. More details can be found in chapter 5 and 6.
Core body and skin temperature measurements
Core body temperature. To measure core body temperature, subjects ingested a 
telemetric temperature pill (CorTemp Wireless Monitoring System, HQ Inc., Palmetto, 
USA). Core body temperature was recorded and transmitted to a receiver. Previous 
studies demonstrated that this method is reliable and valid in rest and during 
exercise.119 
Skin temperature. Skin temperature was measured using iButtons (Thermochron 
iButton DS1922L, Maxim Integrated, San Jose, CA, USA). To calculate mean skin 
temperature according to the ISO 9886 guidelines, skin temperature of the left hand, 
right scapula, right shin, and neck was measured.120 Further, we also measured the 
skin temperature of the forearm (mean values from hand, wrist and lower arm) and the 
temperature gradient of the forearm and fingertip, a qualitative index of peripheral 
perfusion/cutaneous vasomotor tone during steady state exercise.121 More details on 
core body and skin temperature measurements can be found in chapter 3.
Questionnaires: quality of life, Hf symptoms, perceived exertion 
Quality of life. To measure health-related quality of life, the Dutch version of the SF-
36 Health Survey was used. This questionnaire is designed to assess heath status 
for the general and diseased population,122 and is also used in HF patients.123 The 
questionnaire is suitable for self-administration and consists of 36 items that are 
scored on a five-choice response scale. All but one item is part of one of eight SF-36 
scales; physical functioning, role-physical, bodily pain, general health, vitality, social 
functioning, role-emotional and mental health. Furthermore, there are two summary 
measures that aggregate scales; physical health and mental health.124 
HF symptoms. We used the Minnesota living with Heart Failure Questionnaire to 
measure patient perceptions of the effects of HF on their physical, psychological 
and socioeconomic lives. The questionnaire is self-administered and consists of 21 
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items that are scored on a six-choice response scale. This questionnaire is reliable, 
reproducible, and valid to measure effects of HF on daily life.125
Borg score. The Borg score is used for the rating of perceived exertion on a scale from 
6-20.126 It is a subjective score which is easy to use, can be used in patients with and 
without β-receptor-blockers, patients with atrial fibrillation, and patients who did not 
underwent exercise testing to determine VO2peak.126,127
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aBsTRaCT 
Introduction. Obesity represents a strong, independent risk factor for all-cause 
morbidity and mortality and is associated with the prevalence of cardiovascular 
disease (CVD). Some previous studies in healthy subjects have demonstrated an 
inverse relationship between obesity and vascular function. We hypothesize that in 
heart failure (HF) patients such a relationship is not present. 
Methods. Forty-one HF patients (64±8 yrs, 33:8 male:female) were divided among 
three groups; body mass index (BMI) <25, BMI 25-30 and BMI >30 kg/m2. Vascular 
function was determined by flow-mediated dilation (FMD) in brachial and superficial 
femoral artery, by brachial artery response to ischemic handgrip exercise, and by 
brachial artery response to an exogenous nitric oxide donor. Intima-media thickness 
(IMT) was measured in the brachial, superficial femoral and common carotid artery.  
Results. Vascular function, IMT and IMT-to-lumen ratio were not significantly different 
among groups (P-values >0.05). Using regression analyses, we found that parameters 
of body fat were not or minimally associated with FMD or peak blood flow. 
Discussion. Vascular function and structure are not significantly different among 
lean, overweight and obese HF patients. These results suggest that the presence of 
obesity in HF patients is not related to a significant further impairment of vascular 
function or structure.
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INTRoDUCTIoN 
Obesity represents a strong, independent risk factor for all-cause morbidity and 
mortality.1,2 Previous studies have demonstrated the detrimental impact of obesity on 
the prevalence of cardiovascular disease (CVD), with a strong positive relation between 
measures of body fat (e.g. body mass index (BMI)) and the prevalence of CVD.3,4 Studies 
have also demonstrated that higher measures of (abdominal) adiposity are associated 
with the presence of micro- and macrovessel dysfunction.5-8 A higher BMI is associated 
with a lower vascular function6 and larger arterial wall thickness9,10 in the general 
population without overt CVD. Obesity is associated with endothelial dysfunction 
through several mechanisms; a larger secretion of inflammatory cytokines, altered 
adipokine secretion and a disturbance of the vascular homeostasis.5 However, the 
relation between BMI and endothelial function is largely described in ‘healthy’ subjects 
without overt CVD, whilst obesity is highly prevalent in this patient group. For example, 
patients with heart failure (HF) demonstrate a prevalence of obesity of 36-41%.11
Obesity is an important risk factor in the development of HF.12 Moreover, HF patients 
are characterized by impaired vascular function,13 which is associated with poor 
prognosis.14 However, little is known about the impact of obesity on vascular function/
structure in HF patients. Previous work in patients with type 2 diabetes mellitus 
demonstrated that vascular function was not different between non-obese and obese 
patients.15,16 Furthermore, in hypertensive subjects, BMI did not seem to correlate with 
artery wall thickness.17 In subjects with coronary artery disease, BMI did not influence 
coronary artery diameter response to acetylcholine.18 To date, no previous study 
examined whether vascular function and structure differ between lean, overweight 
and obese HF patients. 
The purpose of this study is to assess, using a cross-sectional design, whether vascular 
function and structure differ between lean, overweight and obese HF patients. We 
hypothesize that, in agreement with earlier findings in type 2 diabetes mellitus, 
hypertension and coronary artery disease,15-17 overweight and obese HF patients 
have no further impairment in vascular function and structure compared to lean HF 
patients. This information may provide more insight into the relative importance of 
body composition on the vasculature in HF patients.
METHoDs
subjects 
Inclusion criteria were a diagnosis of HF of ischemic or non-ischemic origin, New 
York Heart Association (NYHA) class I-III, and a history of mild-moderate impairment 
in left ventricular ejection fraction (LVEF) (≤45%, measured by echocardiography). 
Patients with HF due to congenital abnormalities or valve disorders were excluded. 
Other exclusion criteria were diabetes mellitus and pre-menopausal women or women 
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on hormone replacement therapy. Patients were recruited from the Departments of 
Cardiology of the Radboud university medical center and Canisius-Wilhelmina Hospital 
(Nijmegen, The Netherlands). All patients were in a pharmacologically and clinically 
stable situation for at least one month, except for one patient who discontinued his 
β-blocker 2 weeks prior to the measurements. This study was approved by the Medical 
Ethical Committee of the Radboud university medical center (CMO Arnhem-Nijmegen) 
and complies with the Declaration of Helsinki. Written informed consent was obtained 
from each subject before participation in this study. 
 
Experimental protocol
Subjects reported to the laboratory three times. During visit 1, a medical screening was 
performed in which medical history and medication use was documented and body 
characteristics were measured. An incremental maximal cycling test was performed 
to determine physical fitness levels on a separate day. During visit 3, subjects reported 
to the laboratory in a fasted state for the vascular function measurements. Subjects 
refrained from consuming coffee, tea, chocolate, vitamin C and alcohol for 18 hours 
prior to testing, and were instructed to avoid any strenuous physical activity within 
the 24 hours before testing. Smokers were asked to refrain from smoking the day of 
testing. Subjects were instructed to continue their medication, but refrained from 
diuretics on the day of testing for practical reasons. Measurements were performed 
in a quiet, darkened and temperature-controlled room (22.4±0.8 °C). To control for 
diurnal variation in FMD, all tests were performed in the morning/early afternoon. 
Prior to testing, subjects rested in the supine position for 10 minutes, followed by 
measurement of blood pressure and heart rate. 
screening and subject characteristics
Medical screening consisted of documentation of medical history and medication use. 
Furthermore, body weight (Seca 888 Scale, Seca, Hamburg, Germany) and height were 
measured to calculate body mass index (BMI), and skin fold thickness was measured 
to estimate body fat percentage.19 Waist and abdominal circumference were measured 
with a measuring tape (Seca 201, Chino, USA), to determine waist-to-hip ratio. An 
incremental maximal cycling test was performed on a cycle ergometer (Ergoline, 
Ergoselect 200k, Bitz, Germany) to determine physical fitness (i.e. peak oxygen uptake).
Vascular function measurement
Flow-mediated dilation. Vascular function was measured by determining flow-
mediated dilation (FMD), a non-invasive technique to establish endothelium-
dependent vasodilation, according to previously published guidelines.20 FMD was 
measured in the brachial artery and superficial femoral artery. All vascular function 
measurements were done by well-trained sonographers. To measure FMD of the 
brachial artery, the right arm was extended ~80° from the torso. A rapid inflation 
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and deflation pneumatic cuff was applied around the lower arm. The right brachial 
artery was imaged in the distal third of the upper arm by a 10-MHz multifrequency 
linear array probe attached to a high-resolution ultrasound machine (Terason T3000, 
Burlington, MA, USA). Ultrasound parameters were optimized to obtain B-mode 
images from artery lumen and wall. Doppler velocity was measured simultaneously 
with an insonation angle of <60°. A 1-minute baseline recording was acquired after 
which the pneumatic cuff was inflated to supra-systolic pressure (220 mmHg) for 
5 minutes. After cuff release, recording of brachial artery diameter and blood flow 
velocity was continued for 3 minutes. The acquired images were recorded and stored 
as a digital AVI file for later analysis. To measure FMD of the superficial femoral artery, 
the pneumatic cuff was positioned proximately around the thigh (although below the 
section of the SFA that was scanned). The superficial femoral artery was imaged ~4 
cm below the bifurcation of the femoral artery. The FMD protocol of the superficial 
femoral artery was similar to the FMD protocol of the brachial artery, although after 
cuff release, the recording was continued for 5 minutes.
Intima-media thickness. Both FMD measurements were preceded by a measurement of 
arterial wall thickness, measured as intima-media thickness (IMT). The IMT can be used 
as a surrogate marker for atherosclerosis21 and a marker for cardiovascular events/
mortality in cardiac patients.22 IMT was measured in the brachial, superficial femoral 
and common carotid artery, using a 10-MHz multifrequency linear array probe attached 
to a high-resolution ultrasound machine (Terason T3000, Burlington, MA, USA). Diameter 
and wall thickness were collected for 2 angles in each artery and recorded for at least 10 
seconds with a sampling frequency of 30 Hz, and stored for later analysis.
Ischemic handgrip exercise. Subsequently, 15 minutes after the FMD of the brachial 
artery, we measured the conduit artery dilating capacity of the brachial artery by 
determining dilation response to ischemic handgrip exercise (IEx).23 The pneumatic 
cuff was placed around the upper arm and the brachial artery was imaged distally 
from the cuff. After a 1-minute baseline recording, the cuff was inflated to supra-
systolic pressure (220 mmHg) for 5 minutes. Within these 5 minutes, a 3-minute 
handgrip exercise (1s contraction, 1s relaxation, 10-15 N) was performed to induce 
a maximal ischemic stimulus. After cuff release, the recording of diameter of the 
brachial artery and blood velocity was continued for 3 minutes. The peak hyperemic 
forearm blood flow response to this stimulus in humans provides a valid and accepted 
index of resistance artery size or remodelling, which has been used extensively the 
past 2 decades in previous human investigations.23,24
Endothelium-independent dilation. Finally, after a 10-minute rest, we examined the 
dilating response of the brachial artery to an exogenous nitric oxide donor, a single 
dose of 400µg glyceryl trinitrate (GTN) sublingually.23 This has been shown to induce 
maximal vasodilation through an endothelium-independent mechanism, an indication 
of smooth muscle function. This recording was continued until 10 minutes after GTN-
administration.
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Data analysis
Brachial artery diameter and flow velocity images were analyzed using custom-
designed edge-detecting and wall-tracking software, which ensures accurate and 
reproducible analysis and is described in previous studies.25,26 The intra-observer 
coefficient of variation is 0.36% and 6.7% for baseline diameter and FMD respectively, 
and the intra-subject coefficient of variation in FMD is 14.7%.26 The software analysis 
is based on an icon-based graphical programming language. A pixel-density algorithm 
automatically identifies the near and far wall of the artery to trace the artery diameter, 
whilst another algorithm traces the red blood cell velocity signal. Average values of the 
diameter are calculated, stored and synchronized with blood velocity data to obtain 
blood flow and shear rate. Blood flow was calculated as the product of cross-sectional 
area of the brachial artery (cm2) and Doppler mean blood flow velocity (cm/s). Shear 
rate was defined as 4 X Vm/D, where Vm is Doppler mean blood flow velocity (cm/s) 
and D is arterial diameter (cm). Increased shear rate is an important stimulus for 
endothelium-mediated dilatation. 
Baseline diameter was assessed as the 1-minute period preceding cuff inflation. 
For the FMD, IEx and GTN responses, peak diameters were automatically detected 
using an algorithm.25 The FMD, IEx and GTN response were expressed as a percentual 
increase in diameter compared to baseline. Peak blood flow during the IEx-response 
was recorded as the highest 10-second area under the blood flow curve data within 40 
seconds of cuff deflation following ischemic handgrip exercise.23
The IMT was also analyzed for each frame by an algorithm that identifies the near and 
far lumen wall and the far wall media-adventitia interface. To correct for differences 
in baseline diameter we also calculated wall-to-lumen ratio. Values for 2 different 
angles per vessel were averaged for the statistical analysis.
statistical analysis
Subjects were divided among three groups; BMI <25, BMI 25-30 and BMI >30 kg/m2. 
Parameters were checked for normality using a Kolmogorov-Smirnov test. Baseline 
characteristics and vascular function/structure of these groups were compared 
with a 1-way ANOVA. When parameters were not normally distributed, means were 
compared with a Kruskal-Wallis test. Categorical parameters were compared with 
a Chi-Square test. When a significant difference was observed, post-hoc tests 
with least-significant difference were used to identify which group differences 
are significant. To control for the potential impact of baseline diameter on FMD 
calculations,27 we used logarithmically transformed diameter data and adopted a 
univariate General Linear Model to compare differences between groups. This model 
incorporated baseline arterial diameter as a covariate. Additionally, a linear regression 
analysis was performed to identify whether BMI or other parameters of body fat 
(i.e. waist circumference, waist-to-hip ratio, body fat percentage) are predictors for 
vascular function (FMD and peak blood flow) in HF patients. FMD and peak blood flow 
were entered as dependent variables and factors known to influence FMD (age, sex, 
baseline diameter, shear rate area-under-the-curve)28 and measures of body fat were 
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Table 1
subject characteristics, cardiac function, clinical status, and use of cardiovascular medication.
Heart failure patients
subject characteristics
Lean 
(n=13)
Overweight 
(n=17)
Obese 
(n=11) P-value
Age (yrs) 66±6 63±8 63±11 0.62
Sex (male:female) 9:4 15:2 9:2 0.43
Body weight (kg) 70±7* 85±6* 111±23* <0.001
Height (cm) 175±7 178±8 177±6 0.60
BMI (kg/m2) 22.9±1.4* 26.9±1.1* 35.4±5.8* <0.001
Fat percentage (%)† 26.2±6.2 28.5±6.0 36.4±5.6* 0.001§
Waist circumference‡ 87±5* 101±3* 119±13* <0.001
Waist-to-hip ratio‡ 0.92±0.06* 1.01±0.07 1.03±0.09 0.002§
Systolic blood pressure (mmHg) 121±22 123±19 117±12 0.69
Diastolic blood pressure (mmHg) 75±10 73±10 70±7 0.38
Resting heart rate (/min) 63±9 59±8 60±6 0.30
Time since diagnosis 7±4 4±4 7±4 0.15
NYHA-class (I:II:III) 0:13:0 1:13:3 0:6:5 0.053
LVEF (%) 37±10 37±5 34±9 0.52
Etiology
(ischemic:non-ischemic)
9:4 9:8 7:4 0.65
Physical fitness (VO2peak) 18.3±5.2
(n=11)
20.6±5.0
(n=14)
17.5±3.6
(n=10)
0.14§
History of 
Smoking (packyears) 19±16 16±15 34±57 0.77§
Active smoking (%) 31# 0 9 0.036
Hypertension (%) 46 47 73 0.33
Hypercholesterolemia (%) 23 29 27 0.93
Blood analysis
Cholesterol (mmol/L) 4.6±1.2 
(n=11)
4.4±0.9
(n=15)
5.2±1.5 
(n=11)
0.23
Glucose (mmol/L) 5.0±0.5 
(n=10)
5.3±0.7
(n=15)
5.6±0.8 
(n=11)
0.12
Medication
ACE-inhibitors 10 (77%) 10 (59%) 5 (46%) 0.28
Angiotensin II receptor 
antagonists
3 (23%) 7 (41%) 6 (55%) 0.28
Aldosterone antagonist 10 (77%) 10 (59%) 11 (100%)# 0.046
Diuretics (loopdiuretics) 8 (62%) 9 (53%) 10 (91%) 0.19
β-blockers 13 (100%) 15 (88%) 9 (82%) 0.31
Antiplatelet drugs 2 (15%) 8 (47%) 5 (46%) 0.16
Coumarin derivatives 11 (85%)* 6 (35%) 7 (64%) 0.023
Statins 10 (77%) 11 (65%) 9 (82%) 0.57
Data is presented as mean±sD. P-value refers to an aNoVa for continuous variables. *Post-hoc significantly dif-
ferent from all other groups at P<0.05. #significantly higher compared to overweight Hf patients. The Chi-square 
test was used for categorical variables. §P-value relate to Kruskal-Wallis test. †fat percentage was missing for 1 
subject. ‡Data on waist/hip circumference was missing for 2 subjects. BMI; body mass index. NYHa; New York Heart 
association Classification. lVEf; left ventricular ejection fraction. aCE; angiotensin converting enzyme.
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entered as independent variables. Data are presented as mean ± standard deviation 
(SD) unless stated otherwise. Significance level was set at P<0.05.
REsUlTs
subject characteristics
As a consequence of our group division, BMI, weight, body fat percentage, waist 
circumference and waist-to-hip ratio were significantly different among groups (Table 
1). Age, sex, blood pressure, heart rate, and NYHA class did not differ significantly 
among groups (Table 1). The three groups did not differ significantly in physical fitness 
(VO2peak), cardiac function (LVEF), etiology and duration of HF (Table 1). Although the 
lean group contained significantly more active smokers compared to the overweight 
group, total packyears were similar among groups (Table 1). Overweight patients 
used less coumarin derivatives compared to the lean subjects and less aldosterone 
antagonists compared to the obese group (Table 1).
Vascular measurements
Endothelium-dependent dilation. Brachial artery diameter was significantly larger in 
obese HF patients compared to lean and overweight HF patients (P=0.047). Brachial 
artery FMD, both unscaled and scaled for differences in baseline diameter, was not 
significantly different among the 3 groups (Table 2). We found no differences in the 
shear rate area-under-the-curve among groups (Table 2). We found no differences in 
superficial femoral artery resting diameter, FMD (both scaled and unscaled), or shear 
rate area-under-the-curve among lean, overweight and obese HF patients.
Intima-media thickness. The groups did not differ significantly in IMT or IMT-to-lumen 
ratios of the brachial, superficial femoral or common carotid artery (Table 2). 
Ischemic handgrip exercise (IEx). We found a significantly lower peak diameter response 
to IEx in overweight, but not obese, HF patients compared to lean HF patients (Table 2). 
However, when correcting for differences in baseline diameter, no differences among 
groups were found for the peak diameter response to IEx (Table 2). No differences 
were found in peak blood flow among groups (Table 2).
Endothelium-independent dilation. We found no differences in the scaled and unscaled 
brachial artery diameter response to sublingual GTN between lean, overweight and 
obese HF patients (Table 2). There were no significant differences among groups in 
FMD-GTN ratio (Table 2).
linear regression analysis
Brachial artery FMD. The linear regression analysis excluded age, sex, waist 
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Table 2
Vascular function and structure in lean, overweight and obese Hf patients.
Heart failure patients
Brachial artery
Lean
(n=13)
Overweight
(n=17)
Obese
(n=11) P-value
Flow-mediated dilation
Baseline diameter (mm) 3.9±0.8 4.3±0.6 4.5±0.7 0.047§
FMD (%) 5.9±2.5 4.8±2.1 6.3±2.6 0.22
FMD (%, scaled) 5.3±2.1 5.0±2.0 6.7±2.1 0.11
SRAUC (s, 103) 16.8±9.1 22.6±11.4 21.5±8.4 0.27
Ischemic handgrip exercise
Peak artery dilation (%) 19.1±4.7 12.1±6.3* 14.3±8.6 0.022
Peak artery dilation (%, scaled) 17.2±5.5 12.4±5.2 15.5±5.4 0.09
Peak blood flow (ml/min) 614±224 723±292 781±246 0.30
Endothelium-independent dilation (n=13) (n=16) (n=9)
GTN (%) 18.2±8.6 16.5±5.0 15.2±5.5 0.57
GTN (%, scaled) 16.5±4.9 16.6±4.8 16.6±4.9 >0.999
FMD-GTN ratio 0.39±0.26 0.31±0.15 0.41±0.22 0.60§
(n=10) (n=14)   (n=8)
IMT 0.51±0.09 0.49±0.09   0.47±0.07 0.55
IMT-to-lumen ratio 0.12±0.03 0.11±0.02   0.10±0.02 0.10
superficial femoral artery (n=13) (n=16) (n=9)
Flow-mediated dilation
Baseline diameter (mm) 6.6±1.0 7.1±1.4 6.4±1.0 0.32
FMD (%) 4.4±2.2 3.1±1.8 5.3±2.8 0.06
FMD (%, scaled) 4.3±2.0 3.3±2.0 5.0±2.0 0.13
SRAUC (s, 103) 12.0±7.2 7.5±4.6 13.4±7.1 0.14§
(n=10) (n=14) (n=8)
IMT 0.78±0.26 0.65±0.12 0.71±0.14 0.25
IMT-to-lumen ratio 0.11±0.04 0.09±0.02 0.10±0.02 0.31§
Common carotid artery (n=12) (n=13) (n=9)
IMT 0.81±0.37 0.80±0.16 0.78±0.15 0.71§
IMT-to-lumen ratio 0.12±0.04 0.12±0.02 0.11±0.02 0.37§
Brachial (Ba) and superficial femoral artery (sfa) endothelium-dependent vasodilation through flow-mediated 
dilation (fMD%), peak diameter and blood flow responses (ischemic handgrip exercise (IEx)), endothelium-inde-
pendent dilation (through glyceryl trinitrate (GTN)), and brachial, superficial femoral artery and common carotid 
artery IMT and IMT-to-lumen ratio in lean (BMI <25 kg/m2), overweight (BMI 25-30 kg/m2) and obese Hf patients 
(BMI >30 kg/m2). Data is presented as mean±sD. P-value refer to aNoVa between the 3 Hf groups. fMD and scaled 
fMD were analyzed with a General linear Model. *Post-hoc significantly different from lean Hf patients at P<0.05. 
§P-value relates to Kruskal-Wallis test. fMD; flow-mediated dilation. sRaUC; shear rate area-under-the-curve. IMT; 
intima-media thickness. 
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circumference, waist-to-hip ratio, fat percentage, and shear rate area-under-the-
curve as factors influencing brachial artery FMD. Baseline diameter was identified 
to negatively influence brachial artery FMD (β=-1.82, P=0.001). Moreover, BMI had a 
small influence on FMD (β=0.15, P=0.021).
Superficial femoral artery FMD. The linear regression analysis for superficial femoral 
artery FMD excluded age, waist circumference, waist-to-hip ratio, shear rate area-
under-the-curve and baseline diameter as factors significantly influencing FMD. Sex 
was found to have an effect on superficial femoral artery FMD (β=-6.49, P<0.001), with 
the male sex correlating to a lower FMD. Moreover, fat percentage and BMI had a small 
influence on leg FMD (β=-0.29 P=0.006; β=0.35, P=0.001). 
Peak blood flow. The linear regression analysis for peak blood flow after IEx excluded 
age, sex, BMI, waist circumference, waist-to-hip ratio, and fat percentage as factors 
significantly influencing peak blood flow. Baseline diameter (β=371.06, P<0.001) and shear 
rate area-under-the-curve (β=0.01, P=0.009) contributed significantly to peak blood flow.
DIsCUssIoN
To our knowledge, this is the first study to investigate the impact of BMI on brachial 
and superficial femoral artery function and structure in HF patients. To examine our 
research question, we have divided our subjects over three BMI-groups. Importantly, 
except body mass, BMI and other measures of (abdominal) adiposity, most other 
subject characteristics were comparable among groups. This allowed us to cross-
sectionally explore whether vascular function and structure differed between lean, 
overweight and obese HF patients. Our results indicate that, in contrast to several 
previous studies in healthy populations,8-10 obese HF patients do not demonstrate 
impaired conduit artery vascular function and structure or resistance artery size 
compared to overweight or lean HF patients. Indeed, linear regression analysis 
suggests that measures of body fat have only a minor influence on FMD and peak 
blood flow. These results suggest that the presence of obesity in HF patients may not 
lead to further impairment of vascular function or structure.
Advanced age, low physical fitness, high BMI, high body fat percentage, increased 
blood pressure, hyperglycemia and smoking have all been associated previously with 
the presence of an impaired FMD in healthy subjects,6,29-32 although some conflicting 
results regarding the effect of BMI on the vasculature have been presented.6,29 
Interestingly, several studies in populations with cardiovascular risk and/or disease 
have demonstrated no major impact of obesity on the vasculature. Specifically, studies 
in patients with type 2 diabetes mellitus indicate no difference in FMD between non-
obese and obese diabetes mellitus patients.15,16 Another study indicated that FMD is 
mainly affected by the duration of diabetes mellitus rather than by BMI.33 Moreover, in 
hypertensive subjects, BMI does not affect carotid artery IMT in contrast to results found 
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in normotensive controls.17 Finally, in patients with coronary artery disease, a high BMI 
was associated with coronary microvascular impairment, but no decrease in coronary 
macrovascular function.18 This suggests that the relation between vascular function/
structure and obesity may not be consistent across various (clinical) populations.  
We have demonstrated no differences in vascular function among lean, overweight 
and obese HF patients. Possible explanations may relate to the presence of various 
(neurohumoral) abnormalities in HF.34 These abnormalities may be the primary 
determinants of vascular dysfunction in HF patients, rather than traditional risk 
factors (e.g. BMI). Consequently, BMI per se does not seem to affect vascular 
function and structure in patients with HF. An alternative explanation may relate to 
the pharmacological therapy in HF patients (e.g. statins, aldosterone antagonists, 
angiotensin converting enzyme-inhibitors and angiotensin II receptor blockers). 
These drugs have well-established beneficial effects on vascular function and lower 
cardiovascular risk.35 Intake of these medications, may override the potential impact 
of traditional risk factors, such as BMI, on the vasculature. The small between-group 
differences in medication use, may therefore have exerted a small influence on our 
results.
Clinical relevance. With a 5 year-survival of 35-55%, HF patients have a poor 
prognosis.36,37 Vascular function seems to be an important determinant for predicting 
prognosis in HF.14 The role of obesity in HF is controversial; whilst obesity is a risk 
factor for developing HF, several studies have reported the presence of an ‘obesity-
paradox’, indicating a higher survival among obese HF patients compared to lean HF 
patients.38,39 Our results suggest that in optimally medicated HF patients NYHA class 
I-III, a high BMI is not related to further impairment of vascular function. Although 
our finding that obese HF patients do not have a lower vascular function than lean HF 
patients seems remarkable, it may fit with the ‘obesity-paradox’. Interestingly, studies 
investigating the effects of intentional weight loss in overweight and obese cardiac 
patients, demonstrate improvements in vascular function after weight reduction.40 
In conclusion, whilst a higher BMI is not related with further impairment of vascular 
function in HF patients using a cross-sectional design, weight reduction may still have 
beneficial effects on vascular and general health in HF patients. 
Limitations. Because of the small sample size we calculated our power post-hoc (alpha 
of 0.05; G*Power 3.0.10, Heinrich Heine University of Düsseldorf, Germany) and found 
that we had a power of 44%, 48% and 27% to observe differences in FMD of brachial 
and superficial femoral artery and peak blood flow respectively. Furthermore, due to 
practical reasons, we have chosen a cross-sectional design in this study and therefore 
caution should be taken regarding any causal relationships. Finally, the degree of 
vascular impairment in our sample of HF patients remains speculative as no healthy 
control group was included. Since this group was not necessary to answer our primary 
research question, we have not included such a healthy control group. 
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In conclusion, our results suggest that the presence of obesity in HF patients is not 
related to further impairment of peripheral vascular function or structure. Moreover, 
parameters of body fat were not or minimally associated with measurements of 
vascular function and/or structure. 
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aBsTRaCT
Introduction. Exercise training represents a central aspect of rehabilitation of 
heart failure (HF) patients. Previous work on passive heating suggests impaired 
thermoregulatory responses in HF patients. However, no previous study directly 
examined thermoregulatory responses to an exercise bout, i.e. active heating, as 
typically applied in rehabilitation settings in HF. 
Design. Cross-sectional observational study to compare changes in core body 
temperature (Tcore) and skin temperature (Tskin) during exercise between HF patients 
and controls.
Methods. Fourteen HF subjects (65±7 yrs, 13:1 male:female) and 14 healthy controls 
(61±5 yrs, 12:2 male:female) were included. Tcore (telemetric temperature pill) and 
Tskin (skin thermistors) were measured continuously during a 45-minute cycle 
exercise at comparable relative exercise intensity. 
Results. Tcore increased to a similar extend in both groups (controls 1.1±0.4°C, HF 
0.9±0.3°C, ‘time*group’: P=0.15). Tskin decreased during the initial phase of exercise 
in both groups, followed by an increase in Tskin in controls (1.2±1.0°C), whilst Tskin 
remained low in HF patients (-0.3±1.4°C) (‘time*group’: P<0.001). Furthermore, we 
found that a given change in Tcore was associated with a smaller increase in Tskin in 
HF compared to controls. When comparing HF patients and controls who performed 
exercise at similar absolute workload, between-group differences disappeared 
(P-values >0.05).
Discussion. HF patients and controls show comparable exercise-induced increase 
in Tcore, whilst HF patients demonstrate altered Tskin responses to exercise and 
attenuated elevation in Tskin per increase in Tcore. These impaired thermoregulatory 
responses to exercise are, at least partly, explained by the lower absolute workload 
and lower physical fitness level in HF patients.
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INTRoDUCTIoN
Physical fitness is an important factor in the progression and prognosis of heart 
failure (HF) patients.1,2 Therefore, exercise programs are increasingly important in 
cardiac rehabilitation and HF patients are recommended to perform regular physical 
activity.3 However, HF patients are limited in their exercise performance, as a result 
of a reduced myocardial function and abnormalities of peripheral tissues that prevent 
sufficient blood supply to active muscles during exercise.4 Furthermore, disturbed 
thermoregulatory responses during exercise may limit performance in HF patients.5-7 
In healthy subjects, core body temperature (Tcore) rises during exercise as a result of 
the production of heat in active muscles.8 Consequently, cutaneous perfusion, skin 
temperature (Tskin) and sweat evaporation will increase to dissipate heat.8 Studies 
that have examined changes in Tcore and Tskin in HF patients during exercise have 
largely focused on the initial responses during exercise. During the onset of exercise, 
a paradoxical decrease in core body temperature is observed in HF patients compared 
to healthy subjects,5,7 possibly as a result of redistribution of cooler blood from the 
skin to the core. In addition, HF patients show excessive cutaneous vasoconstriction 
and a persistent decline in Tskin compared to controls.5,6 However, these exercise 
studies adopted a short (≤11 min) period of exercise at low absolute intensity, leading 
to low heat production. As thermoregulatory responses are more important during 
prolonged exercise, these previous studies provide only limited insight into the 
potential impact of HF on changes in Tcore and Tskin during exercise.
To date no previous study comprehensively examined the thermoregulatory responses 
in HF patients to a typical bout of exercise training as applied in cardiac rehabilitation. 
Therefore, the main question of our study was whether HF patients and healthy 
controls differ in thermoregulatory responses during a moderate-intensity endurance 
exercise bout. To study this, we measured changes in Tcore and Tskin during a 
45-minute cycle exercise bout (10 min warm-up, 30 min moderate-intensity, 5 min 
cooling-down) at comparable relative exercise intensity in HF patients and controls. 
We hypothesize that exercise in HF patients leads to a larger increase in Tcore and 
lower Tskin compared to healthy controls, suggesting an impaired thermoregulatory 
response to exercise in HF patients. 
METHoDs
subjects
Fourteen patients with HF (65±7 yrs, 13:1 male:female) New York Heart Association 
(NYHA) class I-III and a left ventricular ejection fraction (LVEF) lower than 45% (based 
on an echocardiogram) were recruited from the departments of Cardiology of the 
Radboud university medical center and the Canisius Wilhelmina Hospital (Nijmegen, 
The Netherlands) (Table 1). Furthermore, we recruited 14 healthy controls (61±5 yrs, 
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12:2 male:female) from the local population (Table 1). We included patients who 
were in a pharmacologically and clinically stable situation for at least one month. 
One patient increased the dosage of fosinopril one week prior to the measurements. 
Control subjects had to be free of cardiovascular diseases and medication affecting 
the cardiovascular system. All subjects were non-diabetic. This study was approved 
by the Medical Ethical Committee of the Radboud university medical center (CMO 
Arnhem-Nijmegen, 2012/355) and complies with the Declaration of Helsinki. Written 
informed consent was obtained from each subject before participation in this study. 
Experimental protocol
Subjects reported to the laboratory twice. On day 1, a medical screening was 
performed after which subjects underwent a maximal incremental cycling test to 
determine physical fitness. On day 2, subjects were instructed to ingest the telemetric 
temperature pill six hours prior to testing to ensure stable and valid recording of 
Tcore.9 Measurements were performed in a temperature-controlled room (21.9 ± 0.8 
°C). After instrumentation, subjects rested in the supine position for 10 minutes, 
followed by measurement of blood pressure and heart rate. Subsequently, subjects 
were positioned on the cycle ergometer for moderate-intensity cycling exercise. 
The exercise protocol started with a 10-minute warm-up, followed by 30 minutes 
of moderate-intensity exercise, and concluded by a 5-minute cooling down. During 
the study protocol we continuously measured: 1. Tcore, 2. average Tskin (4-point 
measurement), 3. skin temperature gradient between forearm and finger (Tskforearm-
finger), and 4. heart rate. 
Day 1: Medical screening and maximal incremental cycling test
Medical screening consisted of a medical history and a physical examination in which 
blood pressure and heart rate (by palpation) were obtained. Furthermore, body weight 
and height were measured to calculate body mass index (BMI) and body surface area 
(BSA) using the Du Bois formula, and skin fold thickness was measured to estimate 
body fat percentage.
The incremental maximal cycling test was performed on a cycle ergometer (Lode, 
Excalibur v1.52, 1991, Groningen, the Netherlands/Ergoline, Ergoselect 200k, Bitz, 
Germany). After a 2-minute baseline measurement, subjects started cycling and 
workload was increased by 10-25 Watt per minute, depending on the sex, age and 
height of the participant. Subjects were instructed to pedal at a frequency of >60 
rpm until volitional exhaustion. During the maximal exercise test we continuously 
measured oxygen consumption (breath-by-breath, CPET Cosmed v9.1b, Rome, Italy/
LabManager V5.32.0), to determine peak oxygen uptake (VO2peak), which was defined 
as the average oxygen uptake during the last 30 seconds of the exercise test. Maximal 
heart rate was determined from the electrocardiogram.
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Day 2: Cycle exercise bout
A 10-minute warm-up at a heart rate corresponding with 40% of VO2peak was performed, 
followed by 30-minute moderate-intensity exercise at 65% of VO2peak. A 5-minute 
cooling down at 30% of VO2peak concluded each session. To verify exercise intensity, 
heart rate was registered continuously using a heart rate monitor (Polar Electro Oy, 
Kempele, Finland). At the end of the warm-up and at 10-minute intervals, we assessed 
the rate of perceived exertion using the Borg score (scale 6-20).10 Due to differences 
in absolute workload between HF patients and controls, we performed a subgroup 
analysis between HF patients (i.e. highest workload) and controls (i.e. lowest workload) 
who performed exercise at comparable absolute workload.
Tcore and Tskin measurements
To measure Tcore, subjects ingested a telemetric temperature pill (CorTemp Wireless 
Monitoring System, HQ Inc., Palmetto, USA). Tcore was recorded every 30 seconds 
and transmitted to a receiver which was worn in a pouch around the waist. Previous 
studies demonstrated that this method is reliable and valid in rest and during 
exercise.9
Tskin was measured every 30 seconds using iButtons (Thermochron iButton DS1922L, 
Maxim Integrated, San Jose, CA, USA). Skin thermistors were attached to the skin 
using medical tape at the left hand (dorsal side), right scapula, right shin (at the 
fibula head) and neck to calculate mean Tskin according to the ISO 9886 guidelines; a 
weighted average of the neck (0.28), left hand (0.16), right scapula (0.28) and right shin 
(0.28). Moreover, Tskin was also registered at the right lower arm and middle fingertip 
(ventral side) to calculate Tskinforearm-finger, a qualitative index of peripheral perfusion 
during steady state exercise.11 This is a validated index of peripheral cutaneous 
vasomotor tone during steady-state exercise.11
Tcore and Tskin data were analyzed using custom made software (Fysitemp, Radboud 
university medical center, Nijmegen, The Netherlands) based on Matlab (Matlab 
R2008a, MathWorks, Natick, MA). Baseline values were determined from the average 
over 5 minutes preceding exercise. As previous work found changes in thermoregulatory 
responses during exercise of short duration (<11min),5,7 Tcore and Tskin values were 
averaged over 2-minute intervals during the first 10 minutes of exercise (warm-up). 
Thereafter, 5-minute intervals were calculated during the remainder of the exercise 
bout. To explore the relationship between exercise-induced increases in Tcore and 
changes in Tskin, Tskin was plotted against changes in Tcore. 
statistical analysis
The statistical analysis was performed using SPSS version 20.0 (IBM SPSS, IBM Corp., 
Armonk, NY, USA). Primary outcome parameters were tested for normality using a 
Kolmogorov-Smirnov test. Baseline characteristics of HF patients and controls were 
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compared using independent Student’s t tests. A 2-way repeated measures ANOVA 
was used to examine whether exercise-induced changes in Tcore and Tskin across 
time (‘time’; within-subject factor) differed between HF patients and healthy controls 
(‘group’; between-subject factor, ‘time*group’; interaction effect). When a significant 
main or interaction effect was observed, least-significant difference post-hoc tests 
were used to identify differences. Data were presented as mean ± standard deviation 
(SD) unless stated otherwise. Significance level was set at P<0.05.
REsUlTs
subject and exercise characteristics
HF patients demonstrated a higher BMI and a lower VO2peak compared to controls, 
whilst no significant differences between groups were found for age, body weight, 
BSA, and systolic and diastolic blood pressure (Table 1). HF patients engaged in 5±4 h/
week of physical activity prior to inclusion in the study, whereas controls engaged in 
4±4 h/week of physical activity (mostly walking, cycling, running or fitness). Although 
HF patients were physically active, none of the HF patients participated in a cardiac 
rehabilitation program. We included 8 HF patients with ischemic HF and 6 with non-
ischemic HF. Cardiovascular medication use by HF patients is presented in Table 1. 
Both groups exercised at comparable relative intensity (%max workload) and rate 
of perceived exertion (Table 1). Absolute workload of the cycle exercise bout was 
significantly higher in controls compared to HF patients (Table 1). During the exercise 
bout, one control subject and two HF patients drank water (50-150 mL). The other 
participants did not receive hydration during the exercise.
Thermoregulatory responses to exercise
Tcore. Tcore measurements were performed in 5 HF patients and 12 controls due 
to specific contra-indications of the telemetric pill (e.g. pacemaker).12 Tcore was 
comparable for HF patients and controls at baseline (P=0.90). After the onset of 
exercise, Tcore gradually increased in both groups to a similar extend (controls 
1.1±0.4°C, HF 0.9±0.3°C, ‘time*group’-interaction: P=0.15, Figure 1A). 
Tskin. At baseline, Tskin was comparable between groups (P=0.48). Tskin decreased 
during the initial phase of exercise in both groups (Figure 1C). In control subjects, Tskin 
returned to baseline values after 30 minutes, whilst in HF patients Tskin remained 
low throughout the exercise period (‘time*group’-interaction: P<0.001, Figure 1C). 
When exercise-induced changes in Tskin are plotted against changes in Tcore, control 
subjects showed a larger increase in Tskin for a given increase in Tcore compared to 
HF patients (Figure 2A). 
Tskinforearm-finger. Data on Tskinforearm-finger was available for 11 HF patients and 11 controls 
and was comparable between both groups at baseline. Controls showed a persistent 
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Table 1
subject characteristics, cardiovascular medication use and exercise characteristics in Hf patients (n=14) and 
healthy controls (n=14). Data is presented as mean±sD.
Hf patients  Controls P-value
subject characteristics
     Age (yrs) 65±7 61±5 0.06
     Sex (male:female) 13:1 12:2 0.54
     Weight (kg) 91±21 79±16 0.12
     Height (cm) 175±5 179±5 0.044
     BMI (kg/m2) 29.4±6.7 24.7±4.6 0.037
     BSA (m2) 2.06±0.20 1.97±0.18 0.27
     Fat percentage (%)† 29±6 25±7 0.17
     LVEF (%) 35±8
     NYHA class (I:II:III) 1:10:3
     Systolic blood pressure (mmHg) 130±17 129±15 0.87
     Diastolic blood pressure (mmHg) 81±10 85±9 0.29
     Resting heart rate (beats/min) 59±8 60±10 0.76
CPET
     Peak heart rate (beats/min) 132±18 166±18 <0.001
     Peak workload (Watt) 138±31 248±66 <0.001
     Peak oxygen uptake (mlO2/min/kg) 19.9±4.1 38.6±11.4 <0.001
Medication use
     ACE-inhibitors 9 (64%)
     Angiotensin II receptor antagonists 5 (36%)
     Aldosterone antagonists 10 (71%)
     Diuretics 7 (50%)
     β-blockers 13 (93%)
         Selective β1-blockers 11 (79%)
         Non-selective β-blockers 2 (14%)
     Coumarin derivatives 9 (64%)
     Antiplatelet drugs 5 (36%)
     Statins 11 (79%)
Characteristics exercise bout
     Absolute workload (Watt) 73±23 122±29 <0.001
     Relative workload (% of max) 53±12 50±6 0.43
     Heart rate, warm-up (/min) 80±12 96±14 0.005
     Heart rate, 20 min (/min) 93±14 125±18 <0.001
     Heart rate, 30 min (/min) 96±16 134±19 <0.001
     Heart rate, 40 min (/min) 97±18 139±20 <0.001
     Average heart rate (/min)‡ 94±15 130±19 <0.001
     Average heart rate (% of peak)‡ 72±8 79±8 0.041
     Relative oxygen uptake (%VO2peak) 65±14 68±16 0.68
     RPE (Borg 6-20), 20 min 12±2 12±2 0.54
     RPE (Borg 6-20), 30 min 13±2 13±2 0.62
     RPE (Borg 6-20), 40 min 14±3 14±2 0.59
Chi-square test was used to compare the sex distribution between groups. †data was missing for 1 control subject 
and 1 Hf patient. ‡average heart rate during minute 20-40. BMI; body mass index. Bsa; body surface area. CPET; car-
diopulmonary exercise test. aCE; angiotensin converting enzyme. RPE; rate of perceived exertion. 
P-value
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figure 1
Core body temperature (a) during exercise in Hf patients (n=5; i.e. subgroup of Hf patients in whom these measure-
ments were performed) and controls (n=12). skin temperature (C) during exercise in Hf patients (n=14) and controls 
(n=14). In a subgroup of Hf patients with the highest workload and healthy controls with the lowest workload, we ex-
amined changes in core body temperature (B) during exercise in Hf patients (n=4) and controls (n=5), but also skin 
temperature (D) during exercise in Hf patients (n=8) and controls (n=5). Error bars represent standard error.
figure 2 
Change in core body temperature related to change in skin temperature (a) during exercise in Hf patients (n=5; i.e. 
subgroup of Hf patients in whom these measurements were performed) and controls (n=12). In a subgroup of Hf 
patients with the highest workload (n=4) and healthy controls (n=5) with the lowest workload, we examined the 
relation between changes in core body temperature and changes in skin temperature during exercise (B). Error bars 
represent standard error.
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decrease in this index during exercise, indicative of an increase in cutaneous blood 
flow, which was not present in HF patients (‘time*group’-interaction: P=0.019). 
Subgroup analysis. In our subgroup analysis, HF patients with the highest workload 
(male:female 8:0, 63±7 yrs, peak oxygen uptake 21.5±4.1, LVEF 32±7%) and control 
subjects with the lowest workload (male:female 3:2, 64±7 yrs, peak oxygen uptake 
28.4±8.2) were included, allowing us to correct for differences in workload. These 
groups exercised at comparable workload (89±15W and 90±22W respectively, P=0.89). 
Tcore demonstrated a comparable exercise-induced increase in HF patients (n=4) and 
controls (n=5, ‘group’-effect; P=0.83, ‘time*group’-interaction; P=0.47, Figure 1B). 
Tskin decreased during the initial phase of exercise, after which Tskin increased to 
baseline values after 40 minutes of exercise (‘time’-effect; P<0.001, Figure 1D). This 
change was similarly present in HF patients and controls (‘group’-effect; P=0.18, 
‘time*group’-interaction; P=0.31, Figure 1D). When changes in Tskin are plotted 
against exercise-induced changes in Tcore, HF patients show a similar pattern as 
controls (Figure 2B). 
DIsCUssIoN
This study compared thermoregulatory responses to moderate-intensity cycle exercise 
between HF patients and healthy controls. First, we found that HF patients and controls 
show a comparable increase in Tcore when exercise is performed at comparable relative 
exercise intensity (but lower absolute workload). Second, after an initial decrease in 
Tskin at the onset of exercise, controls demonstrate an increase in Tskin towards baseline 
values, whilst Tskin remains low in HF patients. Furthermore, when analyzing the 
relation between Tcore and Tskin, HF patients consistently demonstrate an attenuated 
increase in Tskin for a given increase in Tcore during exercise. These differences in Tcore 
and Tskin responses to exercise disappear when examining a subgroup of controls and 
HF patients who performed cycle exercise at comparable absolute workload. 
When exercise is performed at similar relative exercise intensity, a comparable 
and gradual increase in core body temperature is observed in HF patients and their 
controls. In line with previous work,5,7 these changes in core body temperature are 
accompanied by distinct changes in skin temperature between HF and controls at 
the start of exercise. However, we importantly extend these previous findings by 
demonstrating that these differences in skin temperature responses to exercise 
remain present when continuing exercise. More specifically, similar to previous 
literature we found that healthy subjects demonstrate skin temperature to return 
to (or even exceed) baseline skin temperature after the initial drop.5,13 In contrast, 
HF patients demonstrate a consistent decreased skin temperature throughout the 
exercise bout. The absence of a normalization of skin temperature may relate to an 
inability to increase skin perfusion. As an index of cutaneous vasomotor function during 
exercise, we measured Tskinforearm-finger.11 In line with previous work in healthy volunteers 
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using laser-Doppler,14 the decrease in Tskinforearm-finger index in healthy controls reflects 
forearm skin vasodilation during cycling exercise. In contrast, exercise in HF patients 
did not evoke a change in Tskinforearm-finger index, suggesting an impaired skin perfusion 
in response to moderate-intensity cycle exercise in HF patients.  
To provide further insight into the impact of exercise on thermoregulation, we 
examined the relation between a change in core body temperature and change in 
skin temperature, and observed that a given increase in Tcore was associated with 
an attenuated increase in Tskin. Similar comparisons were performed in previous 
studies that have examined changes in core and skin temperature in HF patients and 
controls during passive heating.15 In agreement with our exercise-based study, these 
previous studies suggest the presence of an attenuated increase in skin perfusion for 
a given increase in Tcore in HF patients. Accordingly, these observations support the 
presence of impaired thermoregulatory responses to passive heat exposure as well as 
exercise-related heat generation in HF patients.
The impaired thermoregulatory responses during exercise in HF patients may relate 
to impairment of cutaneous vascular function, which has been described in several 
previous reports.16,17 These vascular impairments may lead to the attenuated exercise-
induced skin vasodilation. A second explanation for our observations may relate to 
the enhanced sympathetic tone in HF.18 Skin sympathetic nerve activity is found to 
contribute to thermoregulatory responses in humans.19 The increased sympathetic tone 
in HF patients under resting conditions, but also a possible exaggerated sympathetic 
activation during exercise,20,21 may interfere with the normal skin blood flow and 
temperature responses to exercise. Previous studies have found enhanced as well 
as attenuated sympathetic activation during exercise in HF, depending on absolute 
and relative exercise intensity and the severity of HF.20-23 Another explanation is that 
the impaired cardiac output reserve in HF patients is a limiting factor, since this may 
lead to an attenuated blood supply to the skin (as HF patients need to centralize their 
circulatory volume to increase cardiac output). This latter hypothesis is supported 
by the observation of preserved thermoregulatory responses to prolonged walking 
exercise in cardiac patients without HF.24 
Whilst elevation in core body temperature during exercise relates to the relative 
exercise intensity,25,26 others have suggested an important role for the absolute level 
of exercise as this is related to the amount of heat generation.27,28 Given the marked 
differences in physical fitness level between HF patients and controls, absolute 
workload in HF patients was ~60% of that in control subjects (Table 1). Therefore, 
we performed a subgroup analysis in subjects with comparable absolute workload. 
Interestingly, comparable changes in Tcore and Tskin were observed during exercise 
between these subgroups. This suggests that, at least some of the differences can be 
explained by an a priori difference in workload, which is a direct result of difference in 
physical fitness level. The subgroup analysis indeed included relatively fit HF patients, 
in combination with moderately fit controls, resulting in a comparison of HF patients 
400341-L-bw-Benda
Thermoregulatory responses to exercise in heart failure
57
3
with fitness levels of ~75% of that of the subgroup of controls (rather than ~50% in 
the original comparison). The importance of physical fitness level in thermoregulatory 
responses to exercise is reported in several previous reports.14,29,30 Therefore, our 
additional subgroup analysis suggests that, at least some of the differences in 
thermoregulation to exercise between groups, relate to differences in physical fitness 
level. Indeed, a significant positive correlation is seen between VO2peak and change in 
Tskin (r=0.58, P=0.001). 
Clinical relevance. Impaired thermoregulatory responses to exercise may place 
HF patients at increased risk to develop heat-related problems, but may also 
contribute to the relative exercise intolerance in HF patients. Therefore, the altered 
thermoregulation in HF should be kept in mind when HF patients are exposed 
to more challenging thermoregulatory conditions, such as passive exposure 
to extreme heat or performing exercise in the heat. Nonetheless, it should be 
emphasized that, despite the impaired thermoregulatory responses to exercise, 
HF patients were well capable of performing moderate-intensity exercise and 
showed no severe hyperthermia. Furthermore, a lower physical fitness, in addition 
to HF per se, contributes to the impaired thermoregulation during exercise. This 
may suggest that improving physical fitness levels (through exercise training) may 
improve thermoregulatory responses to exercise in HF patients. Future studies are 
warranted to explore this clinically relevant hypothesis. 
Limitations. Medication was continued during the measurements, which may have 
had an effect on thermoregulatory responses to exercise. Previous studies have 
demonstrated attenuated exercise-induced cutaneous blood flow and enhanced 
sweating in healthy subjects taking (non-selective) β-blockers.31,32 However, most 
(79%) of our HF patients were taking selective β-blockers which have a smaller 
effect on thermoregulatory responses. Also the use of antiplatelet drugs can 
affect the thermoregulatory responses, since it shifts the threshold for cutaneous 
vasodilation during exercise.33 Although these studies included healthy subjects and 
studied the effects of single doses/several days of medication, we cannot exclude 
that continuation of medication in the HF patients in our study affected our primary 
outcomes. Nonetheless, continuing medication for HF can also have a positive 
influence on thermoregulatory responses in HF patients, since it can attenuate 
the sympathetic activity of the neurohumoral system. Moreover, assessment 
of thermoregulatory responses in HF patients while discontinuing their regular 
medication would limit extrapolation of the data to daily situations. 
An important limitation is that, as a direct consequence of the exclusion criteria for 
the use of the telemetry pill, we were only able to measure Tcore in 5 HF patients. 
Nonetheless, comparisons in Tcore within and between groups demonstrate 
significant changes during exercise. Another limitation is that we have included HF 
patients with a relatively high fitness level and who regularly engaged in physical 
activity. Given earlier reports that suggest that higher physical fitness levels are 
related to better thermoregulatory responses to exercise,14,29,30 the relatively high 
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physical activity levels of our HF patients may have minimised differences in 
thermoregulatory responses to exercise between HF patients and controls.
In conclusion, our findings demonstrate that, despite performing exercise at lower 
absolute workload and therefore generating a smaller amount of heat, HF patients have 
a comparable increase in core body temperature to a 45-minute moderate-intensity 
cycle exercise bout as healthy controls. This may relate to the distinct exercise-
induced changes in skin temperature, with HF patients reporting an attenuated 
increase in skin temperature during exercise. These differences in thermoregulation 
can, at least partly, be explained by differences in physical fitness between groups. 
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Chapter 4
Heart failure patients demonstrate 
impaired changes in brachial artery blood 
flow and shear rate pattern during 
moderate-intensity cycle exercise
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aBsTRaCT 
Introduction. Repeated elevations in shear rate (SR) in conduit arteries, such as 
present during exercise, represent a key stimulus to improve vascular function. We 
explored whether heart failure (HF) patients demonstrate distinct changes in SR in 
response to moderate-intensity cycle exercise compared to healthy controls.
Methods. We examined brachial artery SR during 40 minutes of cycle exercise at a 
work rate equivalent to 65% peak oxygen uptake in 14 HF patients (65±7 yrs, 13:1 
male:female) and 14 controls (61±5 yrs, 12:2 male:female). Brachial artery diameter, 
SR and oscillatory shear index (OSI) were assessed using ultrasound at baseline and 
during exercise. 
Results. HF patients demonstrated an attenuated increase in mean and antegrade 
brachial artery SR during exercise compared to controls (‘time*group’-interaction: 
P=0.003 and P<0.001, respectively). Retrograde SR increased at the onset of exercise 
and remained increased throughout the exercise period in both groups (‘time*group’-
interaction: P=0.11). In controls, the immediate increase in OSI during exercise (‘time’: 
P<0.001) is normalized after 35 minutes of cycling. In contrast, the increase in OSI 
after the onset of exercise did not normalize in HF (‘time*group’-interaction: P=0.029). 
Subgroup analysis of 5 HF patients and 5 controls with comparable workload (97±13 
versus 90±22 Watt, P=0.59) confirmed the presence of distinct changes in mean SR 
during exercise (‘time*group’-interaction: P=0.030). Between-group differences in 
antegrade/retrograde SR or OSI did not reach statistical significance (‘time*group’-
interactions: P>0.05). 
Discussion. HF patients demonstrate a less favourable SR pattern during cycle 
exercise than controls, characterized by an attenuated mean and antegrade SR, and 
increased OSI. 
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INTRoDUCTIoN 
Patients with heart failure (HF) are characterized by reduced myocardial function 
and impaired peripheral vascular function.1-3 Exercise training has potent effects 
on symptoms and prognosis of HF,4-7 which are, at least partly, mediated through 
direct improvement of peripheral vascular function and structure.8 Previous studies 
demonstrated that (repeated) elevations in shear rate (SR) represent a key stimulus 
for these beneficial vascular adaptations.9,10 Recent studies in healthy humans have 
confirmed that repeated elevations in SR contribute to vascular adaptation in active9 
and non-active11 vascular beds. 
Under resting conditions, SR pattern in peripheral vessels, such as the brachial artery, 
varies across the cardiac cycle, with a large antegrade component during systole 
being followed by a retrograde component in early diastole.12 Previous studies have 
related repeated exposure to elevations in antegrade SR to improvement in vascular 
function, whilst elevations in the retrograde component exert a proatherogenic effect 
on the endothelium.13,14 Immediately after the onset of lower limb cycle exercise, an 
increased retrograde flow or SR is present in the brachial artery,15,16 probably due to an 
increase in vascular resistance in the inactive upper limbs that is mediated through 
sympathetic vasoconstriction.17 This SR pattern at the onset of exercise alters 
when exercise continues, represented by an attenuation of the retrograde SR and 
simultaneous increase in mean and antegrade SR.18 Simmons et al. (2011) demonstrated 
that normalization of retrograde SR is partly related to thermoregulatory responses.18 
More specifically, exercise caused an increase in core body and skin temperatures 
as well as a decrease in peripheral vascular tone, which subsequently resulted in a 
normalization of the retrograde SR during prolonged exercise in healthy volunteers.18  
HF patients are known to have peripheral vascular abnormalities2,3,19,20 and/or altered 
thermoregulatory responses to exercise.21-23 More specifically, HF patients have a 
diminished endothelial function3 and demonstrate an attenuated forearm blood flow 
response to handgrip exercise.24 Moreover, (short-term) exercise causes a decrease 
in core body and skin temperature in HF patients.22,25 These abnormalities could 
affect SR pattern during exercise in HF patients. To our knowledge, no previous study 
examined SR patterns during exercise in HF patients. Therefore, the primary purpose 
of our study was to compare the changes in brachial artery SR pattern during lower 
limb exercise between HF patients and healthy controls. We hypothesize that HF 
patients have different brachial artery SR responses to lower limb cycle exercise 
compared to controls. Specifically, we expect HF patients to have 1) an attenuated 
exercise-mediated increase in mean and antegrade SR and 2) prolonged retrograde 
SR compared to healthy controls. 
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METHoDs
Ethical approval
This study was approved by the Medical Ethical Committee of the Radboud university 
medical center (CMO Regio Arnhem-Nijmegen) and complies with the Declaration 
of Helsinki. Written informed consent was obtained from each participant before 
inclusion in this study. 
Participants
Fourteen patients (657 yrs, 13:1 male:female) with HF New York Heart Association 
class I-III and a left ventricular ejection fraction lower than 45% were recruited 
from the Departments of Cardiology of the Radboud university medical center and 
Canisius-Wilhelmina Hospital (Nijmegen, The Netherlands) (Table 1). Furthermore, we 
recruited 14 healthy controls (61±5 yrs, 12:2 male:female) (Table 1). All patients were in 
a pharmacologically and clinically stable situation for at least one month. One patient 
increased the dosage of fosinopril one week prior to the measurements. Control 
participants were free of overt cardiovascular diseases and did not use medication 
affecting the cardiovascular system. None of the participants were diagnosed with 
diabetes mellitus. 
Experimental protocol
Participants reported to the laboratory twice and were instructed to continue their 
medication (e.g. β-blockers), with the exception of diuretics for practical reasons, 
prior to all measurements. On day 1, a medical screening was performed after which 
participants underwent a maximal incremental cycling test to determine physical 
fitness. Prior to day 2, participants refrained from consuming coffee, tea, chocolate, 
vitamin C and alcohol for 18 hours prior to testing. Participants were instructed to avoid 
any strenuous physical activity within the 24 hours before testing, and to consume 
a light meal at least two hours before testing. The measurements were performed 
in a temperature-controlled room (21.9 ± 0.8 °C). After instrumentation, participants 
rested in the supine position for 10 minutes, followed by measurement of blood 
pressure. Subsequently, the participants were positioned on the cycle ergometer 
for a 30-minute moderate-intensity exercise, preceded by a 10-minute warm-up. We 
continuously measured brachial artery diameter and SR pattern using ultrasound and 
forearm skin temperature using skin thermistors.
Day 1: Maximal incremental cycling test
The incremental maximal cycling test was performed on a cycle ergometer (Lode, 
Excalibur v1.52, 1991, Groningen, the Netherlands/Ergoline, Ergoselect 200k, Bitz, 
Germany). After a 2-minute baseline measurement, participants started cycling 
and workload was increased by 10-25 Watt per minute, depending on the sex, age 
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and height of the healthy participants26 and the estimated physical fitness of the 
HF patients. Participants were instructed to pedal at a frequency of ≥60 rpm until 
volitional fatigue. All participants reached volitional fatigue during this test, whilst 
none of the tests were symptom-limited. During exercise we continuously measured 
oxygen uptake (breath-by-breath, CPET Cosmed v9.1b, Rome, Italy/LabManager 
V5.32.0) to determine peak oxygen uptake (VO2peak), which was defined as the average 
oxygen uptake during the last 30 seconds of the exercise test.
Day 2: Moderate-intensity lower limb cycle exercise
Work rate was matched such that all participants exercised at the same relative 
intensity. We used heart rate to match work rate between participants, by aiming 
for a heart rate that corresponded to a certain percentage of the VO2peak (derived 
from the maximal incremental cycling test). Given the marked differences in fitness 
between HF and controls, matching at absolute workload would result in extremely 
low levels of workload for controls (which are not realistic for real-life situation). A 
10-minute warm-up at a work rate equivalent to 40% VO2peak was performed, followed 
by a 30-minute moderate-intensity exercise at a work rate equivalent to 65% VO2peak. 
To verify intensity during exercise, heart rate was registered continuously using a 
heart rate monitor (Polar Electro Oy, Kempele, Finland). Due to practical and technical 
difficulties, we were not able to continuously measure blood pressure during exercise 
in our participants. At the end of the warm-up and at 10-minute intervals, the Borg 
score (6-20 scale) for perceived exertion was obtained.27 Participants were allowed to 
pedal at their preferred rotation frequency, but at least at ≥50 rotations per minute.
Brachial artery shear rate pattern
To measure brachial artery SR pattern the right arm was extended to the side, 
supported by a memory foam cushion, at an angle of ~80° from the torso. The 
right brachial artery was imaged in the distal third of the upper arm by a 10-MHz 
multifrequency linear array probe attached to a high-resolution ultrasound machine 
(Terason T3000, Burlington, MA, USA) by a well-trained sonographer (N.M.M.B.). 
Ultrasound parameters were optimized to obtain B-mode images from artery lumen 
and wall. Doppler velocity was measured simultaneously with an insonation angle of 
<60°. A 2-minute baseline recording was acquired preceding the exercise protocol. 
During the exercise bout, 1-minute ultrasound recordings were made every 5 minutes. 
The acquired images were recorded and stored as a digital AVI file for later analysis. 
forearm skin temperature 
Previous work has related thermoregulatory changes, or more specifically skin 
perfusion, to changes in the upstream conduit arteries.18 Unfortunately, technology to 
assess skin perfusion such as laser-Doppler was not available at the time of testing. 
In order to acquire information on thermoregulatory changes, we measured forearm 
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skin temperature. Although skin temperature and skin perfusion during exercise 
seem to follow a similar pattern,18,28 relatively little is known about the relation 
between skin temperature and perfusion during exercise and factors influencing 
this relationship.29 Forearm skin temperature was measured every 30 seconds using 
iButtons (Thermochron iButton DS1922L, Maxim Integrated, San Jose, CA, USA). The 
skin thermistors were attached to the skin using medical tape at the right lower arm, 
wrist and hand (dorsal side). Forearm skin temperature was calculated as the average 
skin temperature of these three locations. Baseline values were determined from the 
average over the 5 minutes preceding exercise. Skin temperature data was analyzed 
using Matlab (Matlab R2008a, MathWorks, Natick, MA) and for each time-point 
averaged over the preceding 5 minutes.
Data analysis
Brachial artery diameter and flow velocity images were analyzed using custom-
designed edge-detecting and wall-tracking software, which ensures accurate and 
reproducible analysis.30 This process is described in previous studies.13,15,31 In short, 
the software analysis is based on an icon-based graphical programming language. A 
pixel-density algorithm automatically identifies the near and far wall of the artery to 
trace the artery diameter, whilst another algorithm traces the red blood cell velocity 
signal. Average values of the diameter are calculated, stored and synchronized with 
blood velocity data to obtain blood flow, SR and oscillatory shear index.
Blood flow was calculated as the product of cross-sectional area of the brachial 
artery (cm2) and Doppler mean blood flow velocity (cm/s). SR was defined as 4 X 
Vm/D, where Vm is Doppler mean blood flow velocity (cm/s) and D is arterial diameter 
(cm). Retrograde SR is defined as negative SR, in which an increase in retrograde SR 
entails more negative shear. Oscillatory shear index was determined by |retrograde 
SR|/(|retrograde SR|+antegrade SR).17,18 The oscillatory shear index can range from 
0 to 0.5, in which 0 indicates unidirectional SR and 0.5 represents maximal shear 
oscillations.18     
statistical analysis
Based on pilot work in our laboratory, we calculated that we need 14 participants to 
detect a difference of 0.13 in oscillatory shear index and estimated SD of this difference 
of 0.116 (power of 80%, alpha of 0.05; G*Power 3.0.10, Heinrich Heine University of 
Düsseldorf, Germany).32 Differences in baseline characteristics between HF patients 
and controls were compared using Student’s unpaired t tests. The sex distribution 
between HF patients and controls was compared with a Chi-Square test. A 2-way 
repeated measures ANOVA was used to examine whether exercise-induced changes 
in mean, antegrade and retrograde SR, oscillatory shear index and skin temperature 
(‘time’; within-subject factor) differ between HF patients and healthy controls (‘group’; 
between-subject factor, ‘time*group’; interaction-effect). When a significant main or 
interaction effect was observed, post-hoc tests with least-significant difference were 
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used to identify differences between groups (at the various time points) and within 
groups (when compared to baseline). Due to the large difference in absolute workload 
between HF patients and controls, we included a subgroup analysis with comparable 
absolute workload. For this purpose, we included 5 HF patients with the highest 
and 5 controls with the lowest absolute workload in this explorative, statistically 
underpowered subgroup analysis. Data are presented as mean ± standard deviation 
(SD) unless stated otherwise. Significance level was set at P<0.05.
REsUlTs
subject characteristics
Compared to controls, HF patients demonstrated a higher BMI and lower VO2peak, whilst 
no significant differences between HF patients and controls were found for age, sex, 
body weight and blood pressure (systolic and diastolic) (Table 1). Cardiovascular 
medication use by HF patients is presented in Table 2. Both groups performed exercise 
at comparable intensity when presented as relative workload (%max), and rate of 
perceived exertion (Borg score) (Table 3). 
Brachial artery sR and blood flow pattern
Brachial artery diameter was not different between groups at baseline and did not 
Table 1
subject characteristics in Hf patients (n=14) and healthy controls (n=14). 
subject characteristics Heart failure Controls P-value
Age (yrs) 65±7 61±5 0.06
Sex (male:female) 13:1 12:2 0.54
Body weight (kg) 91±21 79±16 0.12
Height (cm) 175±5 179±5 0.044
BMI (kg/m2) 29.4±6.7 24.7±4.6 0.037
NYHA class (I:II:III) 1:10:3 - -
Systolic blood pressure (mmHg) 130±17 129±15 0.87
Diastolic blood pressure (mmHg) 81±10 85±9 0.29
Resting heart rate (/min) 59±8 60±10 0.76
Peak heart rate (/min) 132±18 166±18 <0.001
Peak oxygen uptake (mlO2/kg/min) 19.9±4.1 38.6±11.4 <0.001
Fasting glucose (mmol/L)† 5.47±0.61 - -
BNP level (pg/mL)‡ 77±95 9±8 0.010
Current smoker (yes:no) 1:13 1:13 >0.999
Data is presented as mean±sD. P-value refers to a student’s unpaired t test for continuous variables. Chi-square 
test was used to compare the sex distribution between groups. P-value refers to a Mann-Whitney U test for BNP 
level. †fasting glucose levels were available for 10 Hf patients. ‡BNP-levels were available for 11 Hf patients and 13 
control participants. BMI; body mass index. BNP; B-type natriuretic peptide.
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Table 2
Cardiovascular medication use in Hf patients (n=14).
Medication Number of patients (%) 
ACE-inhibitors 9 (64%)
Angiotensin II receptor antagonists 5 (36%)
Aldosterone antagonists 10 (71%)
Diuretics 7 (50%)
β-blockers 13 (93%)
Coumarin derivatives 9 (64%)
Antiplatelet drugs 5 (36%)
Statins 11 (79%)
ACE; angiotensine converting enzyme.
Table 3
Characteristics of the cycle exercise bout in Hf patients (n=14) and controls (n=14).
Exercise characteristics Hf patients Controls P-value
Absolute workload (Watt) 73±23 122±29 <0.001
Relative workload (%max) 53±12 50±6 0.43
Average heart rate (/min) 94±15 130±19 <0.001
Average heart rate (%max) 72±8 79±8 0.041
Borg score 20min 12±2 12±2 0.54
Borg score 30min 13±2 13±2 0.62
Borg score 40min 14±3 14±2 0.59
Data is presented as mean±sD. %max; percentage of maximally achieved workload/heart rate.
  
Diameter and
blood flow
Group Time
0 5 10 15 20
Arterial 
diameter (mm)
HF 4.4±0.6 4.4±0.6 4.3±0.6 4.3±0.6 4.3±0.7
C 4.0±0.4 4.0±0.5 4.0±0.6 3.9±0.4 4.0±0.5
Mean blood 
flow (mL/min)
HF 52±33 33±36* 41±35 36±34 50±53
C 47±34 25±34* 34±38* 50±40 81±61*
Antegrade blood 
flow (mL/min)
HF 74±32 93±38* 95±30* 121±36* 134±52*
C 59±31 95±46* 102±50* 143±61* 168±68*
Retrograde blood 
flow (mL/min)
HF -22±26 -60±32* -54±27* -85±35* -84±38*
C -12±10 -70±30* -68±29* -93±40* -87±41*
Heart rate 
(beats/min)†
HF 62±8 75±11* 79±11* 89±12* 93±14*
C 67±12 90±13*# 94±14*# 114±15*# 123±16*#
2-way aNoVa
25 30 35 40 time group time*group
4.3±0.7 4.3±0.6 4.3±0.6 4.3±0.5 0.25 0.16 0.18
4.1±0.4 4.1±0.5 4.1±0.5 4.0±0.6
55±49 85±68 92±73* 96±75* <0.001 0.07 0.001
118±60*# 140±69*# 146±63*# 177±77*#
138±49* 164±63* 166±58* 170±67* <0.001 0.12 <0.001
202±73*# 219±91* 219±72*# 237±86*#
-83±46* -79±39* -74±45* -74±47* <0.001 0.93 0.32
-84±41* -79±47* -72±37* -60±36*
94±14* 96±16* 97±17* 97±18* <0.001 <0.001 <0.001
127±18*# 132±17*# 134±18*# 137±18*#
Table 4
Brachial artery diameter and blood flow at baseline and during exercise in Hf patients (n=14) and healthy controls (C) 
(n=14).
   
Data is presented as mean±sD. *Post-hoc student’s paired t test significantly different compared to baseline at P<0.05. 
#Post-hoc student’s unpaired t test significantly different compared to Hf patients at P<0.05. †Heart rate data was in-
complete and therefore omitted in this analysis for 1 control subject.
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change significantly across the exercise bout in both groups (Table 4, ‘time*group’-
interaction P=0.18). Baseline brachial artery SR and blood flow were not different 
between groups (Figure 1, Table 4). Mean SR (Figure 1A) and blood flow (Table 4) 
initially decreased in both groups at the onset of exercise (warm-up), followed by a 
gradual increase when exercise continued (both ‘time’-effect: P<0.001). Interestingly, 
HF patients demonstrated a significantly smaller increase in mean SR (Figure 1A) and 
blood flow (Table 4) compared to controls (both ‘time*group’-interaction: P<0.05). 
Brachial artery antegrade SR (Figure 1B) and blood flow (Table 4) increased across the 
lower limb cycle exercise bout in both groups, whilst this increase was significantly 
lower in HF patients compared to controls (both ‘time*group’-interaction: P<0.001). 
Retrograde SR (Figure 1C) and blood flow (Table 4) increased at the onset of exercise 
in both groups, and remained increased throughout the exercise period in both groups 
(both ‘time’-effect: P<0.001). To correct for individual differences in antegrade and 
retrograde SR, we also presented oscillatory shear index. After the onset of exercise, 
oscillatory shear index increased immediately in both groups (Figure 1D). In controls, 
oscillatory shear index returned to baseline values after 35 minutes of exercise, whilst 
oscillatory shear index remained elevated in HF patients across the exercise bout 
(Figure 1D, ‘time*group’-interaction: P=0.029). 
forearm skin temperature
Skin temperature of the arm decreased initially in both groups (Figure 2, ‘time’-effect: 
P<0.001). Lower limb cycle exercise induced a significant increase in skin temperature 
in controls after 40 minutes, whilst in HF patients skin temperature did not increase 
above baseline values (Figure 2, ‘time*group’-interaction: P=0.002). 
  
Diameter and
blood flow
Group Time
0 5 10 15 20
Arterial 
diameter (mm)
HF 4.4±0.6 4.4±0.6 4.3±0.6 4.3±0.6 4.3±0.7
C 4.0±0.4 4.0±0.5 4.0±0.6 3.9±0.4 4.0±0.5
Mean blood 
flow (mL/min)
HF 52±33 33±36* 41±35 36±34 50±53
C 47±34 25±34* 34±38* 50±40 81±61*
Antegrade blood 
flow (mL/min)
HF 74±32 93±38* 95±30* 121±36* 134±52*
C 59±31 95±46* 102±50* 143±61* 168±68*
Retrograde blood 
flow (mL/min)
HF -22±26 -60±32* -54±27* -85±35* -84±38*
C -12±10 -70±30* -68±29* -93±40* -87±41*
Heart rate 
(beats/min)†
HF 62±8 75±11* 79±11* 89±12* 93±14*
C 67±12 90±13*# 94±14*# 114±15*# 123±16*#
2-way aNoVa
25 30 35 40 time group time*group
4.3±0.7 4.3±0.6 4.3±0.6 4.3±0.5 0.25 0.16 0.18
4.1±0.4 4.1±0.5 4.1±0.5 4.0±0.6
55±49 85±68 92±73* 96±75* <0.001 0.07 0.001
118±60*# 140±69*# 146±63*# 177±77*#
138±49* 164±63* 166±58* 170±67* <0.001 0.12 <0.001
202±73*# 219±91* 219±72*# 237±86*#
-83±46* -79±39* -74±45* -74±47* <0.001 0.93 0.32
-84±41* -79±47* -72±37* -60±36*
94±14* 96±16* 97±17* 97±18* <0.001 <0.001 <0.001
127±18*# 132±17*# 134±18*# 137±18*#
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figure 1
a. Brachial artery mean (a), antegrade (B) and retrograde sR (C) and oscillatory 
shear index (D) at baseline and during exercise in Hf patients (n=14) and controls 
(n=14). Error bars represent standard error. Results from the 2-way repeated 
measures aNoVa are presented in the figure. *Post-hoc student’s paired t test 
significantly different compared to baseline at P<0.05 for individual groups (i.e. 
significant ‘time*group’-interaction) or both groups combined (i.e. no significant 
‘time*group’-interaction). #Post-hoc student’s unpaired t test significantly differ-
ent compared to Hf patients at P<0.05.
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subgroup analysis (comparable absolute workload)
Subject characteristics. In the subgroup analysis, we included 5 HF patients (64±7 
yrs, 5 males, peak oxygen uptake 22.5±3.4) and 5 controls (64±7 yrs, 3:2 male:female, 
peak oxygen uptake 28.4±8.2). Medication use in the HF patient group was: β-blockers 
(100%), statins (100%), diuretics (60%), angiotensine converting enzyme-inhibitors 
(60%), aldosterone antagonists (40%), coumarin derivatives (60%), antiplatelet drugs 
(40%), and angiotensine II antagonists (60%). The exercise bout was performed at 
comparable absolute workload; 97±13 Watt and 90±22 Watt in HF patients and controls 
respectively (P=0.59). HF patients and controls performed exercise at comparable 
intensity when presented as relative heart rate (77±9% versus 78±9%, P=0.79) and 
rate of perceived exertion (14±2 versus 14±2, P=0.89). 
Brachial artery SR and blood flow. Subgroup analysis at comparable absolute 
workloads revealed that brachial artery diameter and SR were not different between 
groups at baseline (all P>0.05, data not presented). A significant main effect of ‘time’ 
(all P<0.001) was observed for mean, antegrade and retrograde SR and oscillatory 
index in the subgroup analysis. A significant ‘time*group’-interaction effect was found 
for mean SR (P=0.030), with post-hoc analysis revealing a smaller exercise-induced 
increase in mean SR in HF patients compared to controls. Such differences between 
figure 2
skin temperature of the right forearm at baseline and during exercise in Hf patients (n=14) and controls (n=14). 
forearm skin temperature decreased initially in both groups, after which skin temperature increased in con-
trols, but remained decreased in Hf patients. Error bars represent standard error. Results from the 2-way 
repeated measures aNoVa are presented in the figure. *Post-hoc student’s paired t test significantly different 
compared to baseline at P<0.05.
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figure 3 
a. Brachial artery mean (a), antegrade (B) and retrograde sR (C) and oscillatory 
shear index (D) at baseline and during exercise in a subgroup of Hf patients (n=5) 
and controls (n=5). Error bars represent standard error. Results from the 2-way 
repeated measures aNoVa are presented in the figure. *Post-hoc student’s 
paired t test significantly different compared to baseline at P<0.05 for individual 
groups (i.e. significant time*group’-interaction) or both groups combined (i.e. 
no significant ‘time*group’-interaction). #Post-hoc student’s unpaired t test 
significantly different compared to Hf patients at P<0.05.
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groups did not reach statistical significance for antegrade SR, retrograde SR or 
oscillatory index (Figure 3). Similar to the SR data, a significant main effect for ‘time’ 
and ‘time*group’-interaction was observed for mean blood flow, but not for antegrade 
and retrograde blood flow (data not shown). No changes in brachial artery diameter 
were observed for both groups (data not shown).
Forearm skin temperature. A significant ‘time’-effect (P=0.029) was found. A trend 
for an increase in skin temperature in controls, but not in HF, can be observed 
(‘time*group’-interaction; P=0.09, Figure 4).
DIsCUssIoN
This study investigated the impact of HF on brachial artery SR and blood flow pattern 
during lower limb cycle exercise. We have demonstrated that healthy controls as 
well as HF patients demonstrate a marked increase in oscillatory shear index after 
the onset of moderate-intensity cycle exercise, which is largely explained by an 
increase in retrograde SR. Secondly, when exercise continues, oscillatory shear index 
normalizes in controls, which coincides with a further increase in mean and antegrade 
SR and increase in forearm skin temperature. In contrast, HF patients demonstrate 
no normalization of oscillatory shear index, an attenuated increase in mean and 
antegrade SR and no increase in forearm skin temperature when exercise continues. 
When analyzing subgroups in which participants performed exercise at comparable 
absolute workloads, although underpowered, the presence of distinct blood flow 
and shear rate responses between HF patients and controls seems to be confirmed. 
Therefore, the difference in SR is unlikely to be fully explained by the differences 
in absolute workload. Taken together, our findings suggest that HF patients show a 
potentially less favorable SR pattern during exercise than controls. 
Various factors may contribute to the distinct SR pattern during exercise between 
HF and controls. First, SR pattern is directly influenced by peripheral vascular 
resistance.33,34 The inability to attenuate retrograde SR, and hereby oscillatory shear 
index, in HF patients may relate to an elevated peripheral resistance during exercise. 
Indeed, an enhanced forearm vascular resistance in HF patients was found previously 
during cycle exercise,35 supporting this suggestion. One potential explanation for the 
enhanced peripheral resistance is an elevated sympathetic nerve system activity 
in HF patients20,36 that may remain present during exercise.37 Unfortunately, due to 
technical and practical difficulty, we were unable to provide insight into the exercise-
induced changes in blood pressure (and therefore peripheral arterial resistance). 
Alternatively, the distinct SR patterns during cycle exercise may relate to different 
thermoregulatory changes during exercise as skin cooling is demonstrated to 
increase the degree of retrograde SR during cycling.18 The absent increase in skin 
temperature during cycle exercise in HF patients in our study may contribute to the 
inability to normalize retrograde SR and oscillatory shear index. Lower metabolic heat 
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production may contribute to our observations when comparing all participants.38 
However, analysis of subgroups with comparable workload suggests that HF patients 
still demonstrate an absent increase in skin temperature during cycle exercise. 
During the initial phase of exercise an increase in antegrade and retrograde SR and 
oscillatory shear index have been described.15,16 Recently, Simmons et al., found a 
normalization of retrograde SR and an increase in forearm skin temperature when 
exercise continues.18 Interestingly, these findings in young subjects contrast with our 
observations in older humans, as we found that retrograde SR was not normalized 
during cycle exercise and that forearm skin temperature only demonstrated a late 
increase in healthy older controls. Although we did not intend to directly compare 
young and older subjects, these data suggest that advanced age is associated with 
delayed normalization of brachial artery SR pattern during exercise. Future studies 
are required to better understand the impact of advanced age on SR pattern during 
exercise. 
Clinical Relevance. Although previous studies investigating the effects of endurance 
exercise training in HF patients found improvement in brachial artery vascular function 
after training,5,39 the prolonged exposure to a less favorable shear pattern as observed 
figure 4
skin temperature of the right forearm at baseline and during exercise in a subgroup of Hf patients (n=5) and 
controls (n=5). forearm skin temperature decreased initially in both groups. a trend for an increase in skin 
temperature can be observed in controls, but not in Hf patients (‘time*group’-interaction effect P=0.09). Error 
bars represent sE. Results from the 2-way repeated measures aNoVa are presented in the figure. *Post-hoc 
student’s paired t test significantly different compared to baseline at P<0.05 for both groups combined (i.e. no 
significant ‘time*group’-interaction).
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in our study, may prevent HF patients to optimally benefit from exercise training. 
Although the differences in shear pattern may be less pronounced when comparing 
groups who exercised at comparable absolute levels, it should be acknowledged that 
exercise prescription (especially in rehabilitation settings) is based on relative exercise 
intensity levels. Therefore, this study adopted an exercise intensity level and duration 
that is typically applied in rehabilitation settings in HF patients. Importantly, HF 
patients were on optimal pharmacological treatment, which improves extrapolation 
of our findings to daily life situations. Whether different types or forms of exercise 
that are associated with a larger antegrade SR and/or smaller retrograde SR lead 
to larger improvements in vascular function is currently speculative, and should be 
subject for future research.
Limitations. A potential limitation is the difference in BMI between HF and controls, 
because BMI may affect skin temperature responses during exercise. However, with 
some studies indicating that fat mass does not influence skin temperature responses 
to exercise40,41 and others that do show a relation between body fat percentage and 
skin temperature during exercise,42,43 the effect of fat mass on skin temperature 
during exercise is unclear. Given the modest differences in BMI between our groups 
and the conflicting results from previous work, we believe that any difference in BMI 
between groups is unlikely to explain our observations. Another potential limitation 
was the use of β-blockers by HF patients, because this induces lower resting and peak 
heart rates.44 However, since hemodynamic responses to exercise are significantly 
improved in HF patients by β-blocker therapy,45 withdrawing β-blockers is expected 
to enlarge the differences in thermoregulatory responses to exercise between HF 
patients and controls. Moreover, we intended to study thermoregulatory responses 
during real life situations for HF patients and therefore continued medication. Finally, 
other limitations of our study are the underpowered subgroup analysis and that we 
were not able to measure skin perfusion during exercise. 
In conclusion, we found that, when exercise is matched at relative intensity (65% of 
VO2peak), HF patients demonstrate prolonged exposure to a less favourable brachial 
artery SR pattern during lower limb cycle exercise. More specifically, HF patients 
demonstrate an attenuated increase in mean and antegrade SR during exercise, but 
also a prolonged increase in oscillatory shear index. The latter observation coincides 
with an absent increase in forearm skin temperature across the exercise bout. These 
distinct blood flow and SR patterns between groups are unlikely to be fully explained 
by differences in absolute workload, but possibly relate to between-group differences 
in vascular regulation. Therefore, our data suggest that, when HF patients perform 
exercise at a level that is commonly adopted in rehabilitation settings, HF patients 
are exposed to a less favorable shear pattern compared to controls. The exact 
consequences for (vascular) adaptation to rehabilitation should be further explored.
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Exercise training represents a cornerstone of contemporary cardiac rehabilitation. 
Recently, high-intensity interval training (HIT) has been popularized for heart failure 
(HF) patients1 and may serve as a superior mode of exercise compared to traditional 
endurance exercise training. However, there is controversy regarding the safety2 and 
the direct effects of HIT on the heart. Previous studies have demonstrated that an acute 
bout of exercise leads to an increase in cardiac troponin (cTn), a biomarker for cardiac 
injury, and B-type natriuretic peptide (BNP), a marker for cardiomyocyte stress.3,4 
Exercise-induced elevation in these biomarkers is related to exercise intensity and 
duration,4,5 and may occur to a larger extend in patients with cardiovascular risk 
factors.6 To date, no previous study compared changes in cTn and BNP between 
endurance exercise and HIT, ànd explored differences in exercise-induced changes in 
cTn and BNP between HF patients and controls. 
We included 13 pharmacologically and clinically stable HF patients NYHA-class I-III 
(67±7 yrs; male:female 12:1) with impaired left ventricular ejection fraction (35±8%) 
and 14 healthy controls (60±6 yrs; male:female 11:3, Table 1). The study procedures 
conformed to the Declaration of Helsinki and were approved by the local ethics 
committee. All subjects provided written informed consent. A maximal incremental 
cycling test was performed on a cycle ergometer (Lode Excalibur v1.52/Ergoline, 
Ergoselect 200k) to determine peak oxygen uptake (VO2peak). As expected, we found 
that VO2peak was markedly lower in HF patients than in healthy controls (18.7±4.3 versus 
37.2±10.8 mLO2/kg/min, P<0.001).
Table 1
Baseline characteristics of Hf patients and healthy controls. 
subject characteristics Heart failure Controls P-value
Age (yrs) 67±7 60±6 0.014
Sex (male:female) 12:1 11:3 0.315
BMI (kg/m2) 28.5±6.5 24.7±4.6 0.088
LVEF (%) 35±8 N.A. N.A.
Etiology (ischemic:non-ischemic) 7:6 N.A. N.A.
NYHA class (I:II:III) 1:9:3 N.A. N.A.
Systolic blood pressure (mmHg) 130±17 130±14 0.988
Diastolic blood pressure (mmHg) 79±9 85±10 0.168
Resting heart rate (/min) 59±8 60±10 0.792
Peak heart rate (/min) 129±16 165±17 <0.001
Peak oxygen uptake (mlO2/kg/min) 18.7±4.3 37.2±10.8 <0.001
cTnI level (ng/L) 39±133 4±10 <0.001†
BNP level (pg/mL) 80±86 8±7 <0.001†
Data is presented as mean±standard deviation. P-value refers to an unpaired Student’s t test for continuous variables 
and the Chi-Square test for sex. †P-value refers to a Mann-Whitney U test. BMI; body mass index. LVEF; left ventricular 
ejection fraction. N.A.; not available/applicable. cTnI; cardiac troponin I. BNP; B-type natriuretic peptide.
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On visit 2 and 3, subjects performed an isocaloric endurance exercise bout (30-minutes 
at 65%VO2peak) and HIT (10 * 1-minute at 90%VO2peak, alternated by 2.5-minutes at 
40%VO2peak) in randomized order. Both exercise bouts included comparable warm-
up (10-minutes at 40% VO2peak) and cool-down (5-minutes at 30% VO2peak). Exercise 
intensity was verified using a heart rate monitor (Polar Electro Oy, RS800, Kempele, 
Finland). To assess cTnI and BNP levels, venous blood samples were obtained at 
baseline (BASE), post-exercise (POST) and 2-hours post-exercise (2H-POST), and 
analyzed using high-sensitive cTnI-assays (ADVIA Centaur, Siemens, detection limit: 
6 ng/L, upper reference limit: 40 ng/L) and BNP-assays (ADVIA Centaur, Siemens, 
detection limit: 2 pg/mL, upper reference limit: 100 pg/mL). Changes in cTnI and BNP 
levels after exercise (ΔcTnI, ΔBNP) were analyzed using 3-way Linear Mixed Model 
analysis, including ‘time’ (ΔBASE-POST, ΔBASE-2H-POST), ‘group’ (HF, controls), and 
‘exercise-mode’ (HIT, endurance). cTnI data of the HIT session of one HF patient were 
classified as statistical outliers (value>2*SD) and hence excluded from analysis. 
We found that baseline cTnI and BNP levels were higher in HF patients compared to 
controls (cTnI: 39±133 versus 4±10 ng/L, BNP: 80±86 versus 8±7 pg/mL, both P<0.001), 
a characteristic observation when examining HF patients and their healthy peers. 
Interestingly, exercise-induced ΔcTnI was comparable between both exercise bouts, 
but also did not differ between groups (Figure 1A). Exercise-induced ΔBNP was 
significantly larger in HF patients compared to controls. Nonetheless, we found no 
differences in ΔBNP levels between both exercise-modes (Figure 1B). 
This pilot work indicates that exercise-induced changes in cTnI and BNP were similar 
between endurance exercise (performed according to current cardiac rehabilitation 
guidelines)7 and a single bout of HIT. Although a higher exercise-intensity is associated 
with a larger cTn-release,4,5 HIT did not induce a larger release in cTnI compared to 
endurance exercise. We speculate that, despite being performed at high-intensity, 
the short duration of the high-intensity bouts prevents excessive cardiac load8 and, 
therefore, does not induce significant biomarker release. Although our observations 
do not provide information on safety, our data demonstrates that HIT does not cause 
larger release of biomarkers related to cardiac injury compared to endurance exercise.
Previous work suggested that cardiovascular risk and/or disease is associated with 
a larger cTnI-release after exercise.6 In contrast, we found similar changes in cTnI in 
both groups, whilst HF patients show larger BNP increases than controls. Since BNP 
is related to cardiomyocyte stress, this finding suggests a higher cardiac load during 
exercise in HF patients compared to controls. Future studies with hemodynamic 
monitoring are recommended to confirm these observations. Combined, these data 
suggests that, despite larger myocardial stress in HF patients, neither endurance 
exercise nor HIT lead to excessive release of cardiac biomarkers indicative of acute 
cardiac damage. 
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figure 1
Changes in cTnI (a) and BNP levels (B) immediately after (PosT) and 2 h after (2H-PosT) exercise compared to 
baseline. HIT; high-intensity interval training. Error bars represent standard error. *group-effect P<0.05.
400341-L-bw-Benda
Exercise-induced biomarker release in HF patients
85
5
REfERENCEs 
1. Ismail H, McFarlane JR, Nojoumian AH, Dieberg G, Smart NA. Clinical outcomes and cardiovascular responses to 
different exercise training intensities in patients with heart failure: a systematic review and meta-analysis. JACC Heart 
Fail 2013;1:514-522.
2. Keteyian SJ. Swing and a miss or inside-the-park home run: which fate awaits high-intensity exercise training? 
Circulation 2012;126:1431-1433.
3. Shave R, Baggish A, George K, Wood M, Scharhag J, Whyte G, Gaze D, Thompson PD. Exercise-induced cardiac troponin 
elevation: evidence, mechanisms, and implications. J Am Coll Cardiol 2010;56:169-176.
4. Serrano-Ostariz E, Terreros-Blanco JL, Legaz-Arrese A, George K, Shave R, Bocos-Terraz P, Izquierdo-Alvarez S, 
Bancalero JL, Echavarri JM, Quilez J, Aragones MT, Carranza-Garcia LE. The impact of exercise duration and intensity 
on the release of cardiac biomarkers. Scand J Med Sci Sports 2011;21:244-249.
5. Eijsvogels TM, Hoogerwerf MD, Oudegeest-Sander MH, Hopman MT, Thijssen DH. The impact of exercise intensity on 
cardiac troponin I release. Int J Cardiol 2014;171:e3-4.
6. Eijsvogels T, George K, Shave R, Gaze D, Levine BD, Hopman MT, Thijssen DH. Effect of prolonged walking on cardiac 
troponin levels. Am J Cardiol 2010;105:267-272.
7. Piepoli MF, Corra U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D, McGee H, Mendes M, Niebauer J, Zwisler AD, 
Schmid JP, Cardiac Rehabilitation Section of the European Association of Cardiovascular P, Rehabilitation. Secondary 
prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac 
Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc 
Prev Rehabil 2010;17:1-17.
8. Meyer K, Samek L, Schwaibold M, Westbrook S, Hajric R, Lehmann M, Essfeld D, Roskamm H. Physical responses to 
different modes of interval exercise in patients with chronic heart failure--application to exercise training. Eur Heart J 
1996;17:1040-1047.
400341-L-bw-Benda
400341-L-bw-Benda
Nathalie M.M. Benda, Maria T.E. Hopman, arie P.J. van Dijk, David oxborough
Keith P. George, Dick H.J. Thijssen, Thijs M.H. Eijsvogels
submitted
Chapter 6 
Impact of prolonged walking exercise on 
cardiac structure and function in cardiac 
patients versus healthy controls
400341-L-bw-Benda
Chapter 6
88
aBsTRaCT
Introduction. Previous studies have demonstrated that endurance exercise can cause 
an acute transient decrease in cardiac function in healthy subjects. Whether this also 
occurs in cardiac patients is unknown. We investigated the impact of prolonged single 
day and 3-day walking exercise on cardiac function and cardiac biomarkers between 
cardiac patients and healthy controls in an observational study.
Methods. We recruited 10 cardiac patients (9 males, 1 female, 68±5 yrs) and 10 age- 
and sex-matched healthy control subjects (9 males, 1 female, 68±4 yrs) to perform 
30 or 40 km of walking exercise per day for 3 subsequent days. Cardiac function was 
examined using echocardiography and blood samples were obtained for assessment 
of cardiac biomarkers (cardiac troponin and B-type natriuretic peptide). Data was 
collected before walking and directly after walking on day 1 and 3.
Results. Post-exercise early systolic tissue contraction velocity of the left ventricle 
(LV) (P=0.005) and global longitudinal LV strain (P=0.026) were increased in both 
groups compared to baseline. Post-exercise right ventricle peak early diastolic tissue 
filling velocity decreased in both groups (P=0.043). Post-exercise cardiac troponin 
levels increased (P=0.045) but did not differed across groups (P=0.60), whereas 
B-type natriuretic peptide levels did not change (P=0.43).
Discussion. Apart from a subclinical decrease in right ventricular early diastolic 
tissue filling velocity, (repeated) prolonged walking exercise did not impair cardiac 
function in either group. This study suggests that stable cardiac patients are capable 
of performing repeated prolonged walking exercise without a significant acute 
deterioration in cardiac function or a more pronounced increase in cardiac biomarkers. 
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aBBREVIaTIoNs
LV         left ventricle
RV         right ventricle
SBP         systolic blood pressure
DBP         diastolic blood pressure
LVEF         left ventricular ejection fraction
LVEDV         left ventricular end-diastolic volume
LVESV         left ventricular end-systolic volume
E         peak flow velocity of the early rapid filling wave at the mitral leaflet tips
A         peak flow velocity of the late filling wave at the mitral leaflet tips
Em         peak annular tissue velocity during early filling 
Am         peak annular tissue velocity during late diastolic atrial contraction 
Sm         peak annular tissue velocity during systole
TDI         tissue Doppler imaging
cTnI         cardiac troponin I
BNP         B-type natriuretic peptide
SD         standard deviation
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INTRoDUCTIoN
Cardiovascular diseases are a major health problem, associated with a large 
disease burden and high mortality rates.1 Exercise is an important component in the 
prevention and treatment of cardiac diseases.2,3 More specifically, regular exercise 
is recommended in the current guidelines for the rehabilitation of cardiac patients.4,5 
Improvements in physical fitness are associated with reduced risks for future cardiac 
events and mortality in these patients.6,7 
Despite the long-term clinical benefits of an active lifestyle,2,3 multiple studies have 
described an acute transient decline in cardiac function after bouts of prolonged 
exercise in healthy subjects.8-11 This response has been reported for indices of 
systolic and diastolic function, in both the left ventricle (LV) and right ventricle (RV), 
with a recent suggestion that alterations in RV function may precede changes in LV 
function.11 In addition, elevated cardiac troponin (cTn) and B-type natriuretic peptide 
(BNP) levels, biomarkers of cardiac cell injury and cardiac stretch respectively,12,13 
are also reported after prolonged exercise.14,15 To date, studies of these phenomena 
have typically focused on athletes and healthy subjects. Whether bouts of endurance 
exercise result in acute changes in cardiac function or biomarkers of cardiac 
damage/stretch in subjects with an a priori impaired cardiac function is currently 
unknown. 
The aim of this study was to compare the impact of single or multiple days of prolonged 
(>6h) walking exercise on cardiac function and cardiac biomarkers between cardiac 
patients diagnosed with an impaired left ventricular function and healthy age- and 
sex-matched controls. We hypothesized that exercise leads to a greater acute decline 
in cardiac function and larger elevation of cardiac biomarkers in cardiac patients 
compared to healthy controls, and that these changes are more pronounced after 3 
days of prolonged walking. 
METHoDs
subjects
All subjects participated in an annual walking event (Nijmegen Four Day Marches) 
in which participants walk 30 or 40 km per day on 4 consecutive days. Ten cardiac 
patients with left ventricular systolic dysfunction were recruited through an electronic 
questionnaire among participants of the Nijmegen Four Day Marches. The inclusion 
criteria were a clinical history of cardiac disease including a history of an impaired left 
ventricular ejection fraction (LVEF <55%) measured during echocardiography. After 
inclusion of 10 cardiac patients, we recruited 10 healthy age- and sex-matched controls. 
Subjects in the healthy control group were free from (a history of) cardiovascular and 
cerebrovascular diseases and did not use cardiovascular medication. Ethical approval 
for this study was obtained from the Independent Review Board Nijmegen. This study 
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conforms to the principles outlined in the declaration of Helsinki. All subjects provided 
written informed consent prior to participation. 
Experimental protocol
Prior to participation, medical records were obtained for the cardiac patients from 
their cardiologists. Data was collected at baseline (1 day before the start of the walking 
event), and directly after walking day 1 and 3 of the event. At baseline, we examined 
cardiac function using echocardiography, a blood sample for assessment of cardiac 
biomarkers, and anthropometric and blood pressure data. After finishing the walking 
exercise on day 1 and day 3, we repeated cardiac ultrasound measurements within 
30-minutes post-exercise. Furthermore, post-exercise blood samples were collected. 
During exercise, we continuously measured heart rate and the metabolic equivalents 
of task in all subjects. 
Measurements
At baseline, height and weight were measured to calculate body mass index (BMI). A 
4-point skin fold measurement (biceps, triceps, sub-scapular, supra-iliac) was done 
to estimate body fat percentage.16 Finally, waist circumference was measured midway 
between the lower rib margin and iliac crest, and hip circumference was measured at 
the level of widest circumference over the greater trochanters, to determine waist-to-
hip ratio. 
Exercise characteristics
Heart rate was monitored continuously during walking with a heart rate monitor (Polar 
Electro Oy, Kempele, Finland), wore around the chest. Mean heart rate during exercise 
was expressed as a percentage of the maximal predicted heart rate17 to indicate 
exercise intensity. Walking speed was calculated from walking duration and walking 
distance. An activity monitor (SenseWear Pro3 Armband, SWA, Body Media) was used 
to assess the metabolic equivalents of task (METs) during the walking march. 
Echocardiographic measurements
A comprehensive transthoracic echocardiographic examination was performed by 3 
experienced sonographers. All participants were examined by the same sonographer 
on the different test days to minimize inter-operator variability. Echocardiography 
was performed with a 1.6 to 4 MHz multi-frequency phased array probe on a portable 
ultrasound system (Vivid Q, General Electric (GE) Medical, Horten, Norway). Images 
of 3-5 cardiac cycles during end-expiration with breath-holding (avoiding Valsalva 
maneuver) were recorded digitally on a disc and analyzed post-hoc with EchoPAC 
software (version 113, GE Medical, Horten, Norway). Measurements were performed 
according to current guidelines of the American Society of Echocardiography.18 Prior 
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to the cardiac ultrasound, subjects were given a 10-minute supine rest after which 
blood pressure and heart rate were measured.
Estimates of preload. Left ventricular end-diastolic volume (LVEDV) was determined 
from the 2-dimensional echocardiograms in the apical 4- and 2-chamber views using 
the biplane Simpson’s method. We determined the ratio of the peak mitral flow velocity 
during early filling (E) and peak mitral septal and lateral annular tissue velocity during 
early filling (Em), as a surrogate parameter of left atrial pressure. An average of both 
sites is presented (E/Em). 
LV systolic function. We estimated LV ejection fraction from LVEDV and LV end-systolic 
volume (LVESV) using biplane data by ((LVEDV-LVESV)/LVEDV)*100%). We obtained 
pulsed-wave tissue Doppler imaging (TDI) measurements of peak systolic annular 
tissue velocities at the septal and lateral mitral annulus from apical 4-chamber 
images. An average of both sites is presented (SmLV). 
LV strain. Two-dimensional images of the apical LV 4-chamber and 3-chamber view 
were obtained. Images were optimized for speckle tracking by keeping the frame-rate 
between 60-90 Hz, adjusting imaging dept and focal zone for optimal images. Images of 
the apical 4-chamber view were post-processed by a single experienced reader (AvD) 
using EchoPAC software (version 113). Aortic valve closure was marked, relative to the 
QR beginning of the QRS-complex, using pulsed-wave Doppler from apical 3-chamber 
view. By manual end-systolic endocardial border tracing, the region of interest was 
determined and adjusted to include the LV wall. The software calculated the average 
global longitudinal strain from all myocardial segments. Segments judged to be of poor 
tracking quality, also after readjustment of the region of interest, were excluded.
LV diastolic function. To examine diastolic function we measured standard LV inflow 
pulsed-wave Doppler at the mitral leaflet tips. These measurements included peak 
flow velocity of the early rapid filling wave (E) and peak flow velocity of the late filling 
wave due to atrial contraction (A). From these parameters we calculated the E/A ratio. 
From TDI measurements, we obtained peak early diastolic mitral annular tissue velocity 
(EmLV), and peak late diastolic mitral annular tissue velocity during atrial contraction 
(AmLV), for the septal and lateral annulus. An average of both sites is presented.
RV systolic function. Peak systolic tricuspid lateral annular tissue velocity was measured 
by placing the pulsed-wave sample in the lateral aspect of the tricuspid annulus. Care 
was taken to ensure longitudinal movement was in line with the ultrasound beam. 
RV diastolic function. Using the same approach, peak tricuspid lateral annular tissue 
velocities during early diastole (EmRV) and during atrial contraction (AmRV) were 
recorded as indices of RV diastolic function. 
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Cardiac biomarkers
Cardiac troponin I (cTnI) levels and BNP levels were assessed from repetitive venous 
blood samples. Whole venous blood was collected in serum-gel vacutainer tubes and 
allowed to clot for ≈30 minutes. After centrifugation, serum was aliquoted, frozen, 
and stored at −80°C for batch-analysis after completion of the study. Analysis was 
performed on a single day using the same calibration and set-up to minimize variation. 
The samples were analyzed using high-sensitive cTnI-assays (ADVIA Centaur TnI-
ultra, Siemens Healthcare diagnostics, The Hague, the Netherlands) and BNP-assays 
(ADVIA Centaur, Siemens Healthcare diagnostics, The Hague, the Netherlands). The 
detection limit of the cTnI-assay was 6 ng/L, and the coefficient of variation was 5.3% 
at 80 ng/L. The detection limit of the BNP-assay was 2 pg/mL, and the coefficient of 
variation was 4.7% at 29.4 pg/mL.
statistical analysis
No previous study examined the impact of prolonged walking exercise on cardiac 
function in cardiac patients. Therefore, no data was available to perform a sample 
size calculation. Hence, we decided to include 10 cardiac patients and 10 age- and 
sex-matched controls in this explorative, observational study. Statistical analysis 
was done using IBM SPSS Statistics 20.0 (IBM SPSS, IBM Corp., Armonk, NY, USA). 
Parameters were checked for normality using a Kolmogorov-Smirnov test. When 
parameters were not normally distributed, a non-parametric alternative was used. 
Baseline characteristics of both groups were compared with an independent-
samples t test. Echocardiographic variables and cardiac biomarkers were analyzed 
with a 2-way linear mixed model analysis, with ‘time’ (baseline, day 1, day 3) and 
‘group’ (cardiac patients, controls) as factors in the model. Troponin and BNP data 
underwent natural logarithmic transformation before analysis. Due to the presence 
of values of zero for troponin and BNP, to which natural logarithmic transformation 
cannot be applied, all troponin and BNP data were increased with the value 1 
before natural logarithmic transformation was performed. Continuous variables are 
presented as mean ± standard deviation (SD), unless stated otherwise. Significance 
level was set at P<0.05.
REsUlTs
subject characteristics
Age, sex, body characteristics, baseline blood pressure and resting heart rate were 
not different between groups (Table 1). Medication use of the cardiac patients 
included: β-blockers (9/10), diuretics (6/10), statins (5/10), angiotensin converting 
enzyme-inhibitors (6/10), antiplatelet drugs (4/10), angiotensin II receptor antagonists 
(3/10), coumarin derivatives (4/10), and anti-arrhythmic drugs (1/10). Three of the 6 
patients that used diuretics did not use this medication during the days of exercise. 
Control subjects did not use medication. Etiology of the cardiac disease was ischemic 
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heart disease (5/10), (dilated) cardiomyopathy (3/10), valve pathology (1/10), and multi-
factorial (1/10). Some patients reported an intra-cardiac device (6/10). 
Exercise characteristics
All subjects completed the walking event. In both groups, 8 subjects walked 30 km/
day and 2 subjects walked 40 km/day. Controls reported a higher absolute and relative 
heart rate during exercise, whilst walking duration, walking speed and METs were 
comparable between groups (Table 2). 
Table 1
subject characteristics and cardiovascular medication use of healthy controls (n=10) and cardiac patients (n=10) at 
baseline. Data is presented as mean±sD. P-values refer to an independent-samples t test.
subject characteristics Controls Cardiac patients P-value
Age (yrs) 68±4 68±5 0.92
Sex (male:female) 9:1 9:1 -
Weight (kg) 82±14 81±13 0.78
BMI (kg/m2) 25.6±3.2 26.2±4.0 0.75
Waist circumference (cm) 97±12 96±13 0.93
Hip circumference (cm) 100±6 99±6 0.69
Waist-to-hip ratio† 0.96±0.07 0.97±0.09 0.65
Fat percentage (%) 30±6 32±5 0.39
Resting SBP (mmHg) 140±13 126±19 0.09
Resting DBP (mmHg) 80±7 75±9 0.16
Resting heart rate (beats/min) 64±9 57±8 0.09
Total training kilometres (km)‡ 575±711 699±687 0.57
†P-value relate to Mann-Whitney U test. ‡Data on total training kilometers was missing for 1 cardiac patient. BMI; 
body mass index. sBP; systolic blood pressure. DBP; diastolic blood pressure. 
Exercise 
characteristics
Controls
Day 1 Day 2 Day 3
Duration (min) 424±91 470±114* 416±111
Mean heart rate (/min)† 109±23 108±28 109±27
Mean heart rate %max (%)† 68±14 68±17 68±16
METs 5.2±1.0 4.4±0.5* 4.6±0.6*
Walking speed (km/h) 4.7±0.9 4.1±1.0* 4.8±1.0
Cardiac patients P-value
Day 1 Day 2 Day 3 Time Group Time*Group
451±55 474±54* 442±66 0.001 0.60 0.50
91±14 88±13 87±9 0.16 <0.001 0.45
57±8 55±7 54±5 0.16 <0.001 0.46
5.4±0.5 4.8±0.5* 4.7±0.5* <0.001 0.52 0.60
4.3±0.6 4.1±0.5* 4.4±0.6 0.002 0.35 0.44
Table 2
Exercise characteristics of healthy controls (n=10) and cardiac patients (n=10) on the 3 walking days. P-values re-
fer to a linear mixed model analysis that examined whether exercise parameters were different across the 3 walk-
ing days (‘Time’) or between groups (‘Group’), and whether a different change across the 3 walking days was present 
between controls and cardiac patients (‘Time*Group’). Data are presented as mean±sD.
 
*significantly different compared to day 1. †a non-parametric alternative was used to perform the analysis: a fried-
man  test for the time-effect, a Mann-Whitney test for the group effect, and a repeated measures aNoVa on the 
delta’s of day 2 and day 3 compared to day 1. METs; metabolic equivalents of task.
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Exercise 
characteristics
Controls
Day 1 Day 2 Day 3
Duration (min) 424±91 470±114* 416±111
Mean heart rate (/min)† 109±23 108±28 109±27
Mean heart rate %max (%)† 68±14 68±17 68±16
METs 5.2±1.0 4.4±0.5* 4.6±0.6*
Walking speed (km/h) 4.7±0.9 4.1±1.0* 4.8±1.0
Cardiac patients P-value
Day 1 Day 2 Day 3 Time Group Time*Group
451±55 474±54* 442±66 0.001 0.60 0.50
91±14 88±13 87±9 0.16 <0.001 0.45
57±8 55±7 54±5 0.16 <0.001 0.46
5.4±0.5 4.8±0.5* 4.7±0.5* <0.001 0.52 0.60
4.3±0.6 4.1±0.5* 4.4±0.6 0.002 0.35 0.44
Cardiac function
Post-exercise heart rate was higher compared to baseline in both groups (P=0.001, 
Table 3). Systolic (SBP) and diastolic blood pressure (DBP) were significantly lower 
after exercise compared to baseline in both groups (SBP: P<0.001; DBP: P=0.001; Table 
3). SmLV increased post-exercise to the same extent in both groups (P=0.005, Table 3). 
We observed a significant improvement in global longitudinal LV strain after day 1, but 
not after day 3, in both patients and controls (P=0.026, Table 3). Exercise resulted in a 
decrease in EmRV after walking day 3 for both groups (P=0.043, Table 3). 
Cardiac biomarkers
Cardiac patients reported higher cTnI and BNP levels compared to controls at baseline 
and post-exercise on day 1, 2 and 3. Prolonged walking resulted in a significant 
increase in cTnI levels in both groups (P=0.045, Figure 1A). Prolonged walking did not 
change BNP levels in both groups (Figure 1B). 
DIsCUssIoN
To our knowledge, this is the first study to investigate the effects of single and/
or repeated exercise on cardiac function in cardiac patients compared to healthy 
age- and sex-matched controls. We report a number of novel observations. First, we 
demonstrate that single or repeated walking exercise does not impair LV function, 
whilst a small decrease in RV diastolic filling is observed after 3 days of walking. 
Secondly, exercise induced a significant increase in cTnI, but not BNP, after walking. 
Most importantly, we found that cardiac patients and healthy controls demonstrate 
comparable exercise-induced changes when exploring the acute impact of prolonged 
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walking exercise on cardiac function and cardiac biomarkers. These data emphasize 
that cardiac patients are well capable of performing strenuous, prolonged walking 
exercise, even when performed repeatedly (i.e. 3 consecutive days), without evidence 
for a larger impact on cardiac function or cardiac biomarkers compared to their 
healthy peers. 
A post-exercise decrease in LV function in healthy volunteers after prolonged, strenuous 
exercise is reported in previous studies.8-10 Moreover, Middleton et al. demonstrated 
a cumulative decrement in LV systolic function after repeated running exercise.19 In 
contrast, we found no decrease in LV function after 1 day or 3 days of walking 30-40 km. 
    
 
Controls
Blood pressure and preload Pre Day 1 Day 3
Heart rate (/min) 65±8# 70±14* 77±12*
SBP (mmHg) 141±13# 128±9* 130±10*
DBP (mmHg) 81±7# 75±9* 76±6*
LVEDV (mL) 97±19# 99±20 99±9
E/Em† 8.1±2.7 7.2±2.2 6.5±2.1
lV systolic function
LVEF, biplane (%) 60±10# 56±9 55±6
LV strain (%) -20±3# -21±3* -19±3
SmLV (m/s) 0.08±0.01 0.09±0.02* 0.09±0.02*
lV diastolic function
E (m/s) 0.59±0.17 0.49±0.11 0.51±0.14
A (m/s) 0.66±0.13 0.65±0.13 0.65±0.10
E/A 0.87±0.12 0.76±0.08 0.77±0.11
EmLV (m/s) 0.08±0.02 0.08±0.01 0.08±0.02
AmLV (m/s)† 0.09±0.01 0.10±0.02 0.10±0.02
RV systolic function
SmRV (m/s) 0.13±0.02# 0.13±0.03 0.14±0.04
RV diastolic function
EmRV (m/s)† 0.10±0.04# 0.09±0.03 0.08±0.02*
AmRV(m/s)† 0.14±0.05 0.16±0.06 0.16±0.05
Cardiac patients P-value
Pre Day 1 Day 3 Time Group Time*Group
58±8 63±13* 64±11* 0.001 0.037 0.35
126±19 110±14* 110±17* <0.001 0.004 0.70
75±9 65±8* 65±5* 0.001 0.002 0.43
141±33 123±23 123±29 0.31 0.003 0.15
9.8±5.7 9.8±5.9 9.2±6.5 0.37 0.27 0.82
48±10 46±12 42±10 0.06 0.008 0.91
-13±3 -16±4* -14±3 0.026 <0.001 0.053
0.07±0.01 0.08±0.02* 0.08±0.02* 0.005 0.08 0.66
0.61±0.27 0.59±0.20 0.59±0.20 0.06 0.31 0.82
0.74±0.32 0.71±0.27 0.77±0.29 0.34 0.34 0.48
0.86±0.29 0.85±0.22 0.77±0.13 0.12 0.58 0.33
0.07±0.02 0.07±0.02 0.07±0.02 0.73 0.43 0.73
0.09±0.01 0.09±0.03 0.09±0.01 0.55 0.22 0.54
0.10±0.03 0.10±0.03 0.10±0.03 0.17 0.014 0.71
0.08±0.02 0.08±0.03 0.06±0.02* 0.043 0.006 0.56
0.10±0.04 0.12±0.04 0.11±0.04 0.13 0.001 0.53
Table 3
Cardiac function and structure of healthy controls (n=10) and cardiac patients (n=10) at baseline and immediately 
after exercise on day 1 and day 3. P-values refer to a linear mixed model analysis that examined whether cardiac 
function and structure were different from baseline across the 3 walking days (‘Time’) or between groups (‘Group’), 
and whether a different change across the 3 walking days was present between controls and cardiac patients 
(‘Time*Group’). Data are presented as mean±sD.
†a non-parametric alternative was used to perform the analysis: a friedman test for the time-effect, a Mann-Whit-
ney test for the group effect, and a repeated measures aNoVa on the delta’s of day 1 and day 3 compared to base-
line. *significantly different compared to baseline (pre). #significantly different compared to cardiac patients at 
baseline. sBP; systolic blood pressure. DBP; diastolic blood pressure. lVEDV; left ventricular end-diastolic volume. 
E; peak flow velocity of the early rapid filling wave at the mitral leaflet tips. Em; peak annular tissue velocity during 
early filling. lVEf; left ventricular ejection fraction. lV; left ventricle. RV; right ventricle. sm; peak annular tissue 
velocity during systole. a; peak flow velocity of the late filling wave at the mitral leaflet tips. am; peak annular tis-
sue velocity during late diastolic atrial contraction.
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In fact, we demonstrated a small increase in some parameters of LV systolic function 
(i.e. LV strain and SmLV). Heart rate was higher after exercise compared to baseline 
levels, which may have influenced cardiac function parameters. However, a previous 
animal study demonstrated that a higher heart rate does not lead to an increase in 
longitudinal strain,20 accordingly, we believe that the increased heart rate after exercise 
in our study does not importantly influence our outcome measures. The absence of an 
exercise-induced decrease in LV function might relate to the relatively low intensity of 
walking exercise (54-68% of maximal estimated heart rate), as most previous studies 
included exercise with higher intensity such as long-distance running (84% of maximal 
heart rate19) or cycling (71-76% of maximal heart rate21). 
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SBP (mmHg) 141±13# 128±9* 130±10*
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58±8 63±13* 64±11* 0.001 0.037 0.35
126±19 110±14* 110±17* <0.001 0.004 0.70
75±9 65±8* 65±5* 0.001 0.002 0.43
141±33 123±23 123±29 0.31 0.003 0.15
9.8±5.7 9.8±5.9 9.2±6.5 0.37 0.27 0.82
48±10 46±12 42±10 0.06 0.008 0.91
-13±3 -16±4* -14±3 0.026 <0.001 0.053
0.07±0.01 0.08±0.02* 0.08±0.02* 0.005 0.08 0.66
0.61±0.27 0.59±0.20 0.59±0.20 0.06 0.31 0.82
0.74±0.32 0.71±0.27 0.77±0.29 0.34 0.34 0.48
0.86±0.29 0.85±0.22 0.77±0.13 0.12 0.58 0.33
0.07±0.02 0.07±0.02 0.07±0.02 0.73 0.43 0.73
0.09±0.01 0.09±0.03 0.09±0.01 0.55 0.22 0.54
0.10±0.03 0.10±0.03 0.10±0.03 0.17 0.014 0.71
0.08±0.02 0.08±0.03 0.06±0.02* 0.043 0.006 0.56
0.10±0.04 0.12±0.04 0.11±0.04 0.13 0.001 0.53
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The absence of a change in LV function in our study was seen in controls as well as 
cardiac patients. This indicates that an a priori impairment in LV function does not 
necessarily relate to an exercise-induced change in LV function. An explanation for the 
comparable exercise-induced changes in cardiac patients and controls may relate to 
the comparable training status (control: 575±711 walking km versus cardiac patients: 
699±687 walking km in the previous year, P=0.57) and similar exercise duration of 
the two groups (control: 7±2h versus cardiac patients: 8±1h, P=0.60). These factors, 
training status and exercise duration, have previously been associated with a decrease 
in LV systolic function after exercise.10 Taken together, we reject our hypothesis as 
data from this study show that an a priori impaired LV function is not associated with 
a (larger) decrease in LV function after prolonged walking exercise. 
Due to a relatively large increase in RV afterload during exercise, the hemodynamic 
demand placed on the RV is larger than the demand placed on the LV.11 Indeed, 
some studies indicate that the RV function is more prone to (early) exercise-induced 
changes, and these RV-changes may precede changes in LV function.22,23 Whilst we 
demonstrated a small decrease in RV diastolic function, similar to previous literature,24 
it was only observed after 3 days of prolonged walking exercise. This suggests the 
presence of a small but statistically significant cumulative effect of exercise on RV 
diastolic function. However, not all RV indices were diminished, as we did not find a 
decrease in RV systolic function. These findings can be related to the relatively low 
exercise intensity and corresponding smaller increase in heart rate and blood pressure 
during walking exercise compared to running or cycling activities like performed in 
figure 1
cTnI levels (a) and BNP levels (B) before exercise (baseline) and immediately post-exercise on day 1, day 2 and day 
3 for controls (white circles) and cardiac patients (black squares). P-values refer to a linear mixed model analy-
sis to examine whether changes in biomarkers across the 3 testing days (‘Time’) differs between groups (‘Group’, 
‘Time*Group’). Error bars represent standard error. *cTnI levels significantly increased compared to baseline.
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previous work.22,23 Our study thus confirms earlier reports in healthy volunteers of a 
small decrease in RV diastolic function after prolonged exercise,24 whilst RV systolic 
function remains unaffected. 
An increase in cTnI after prolonged walking exercise was seen in both of our groups. 
The exercise-induced increase in cTnI in our study was not accompanied by an 
increase in BNP. Previously, it has been suggested that patients with cardiovascular 
diseases or associated risk factors are more likely to demonstrate an increase in 
cTnI in response to prolonged exercise.25,26 Although baseline cTnI and BNP levels 
were higher in cardiac patients, the relative change after exercise was not different 
between our patients and controls. A factor contributing to this finding might be the 
similar exercise intensity (measured in METs and walking speed) and exercise duration 
in cardiac patients and controls, considering that these are important parameters in 
exercise-induced biomarker release.27,28 Since the exercise-induced increase in cTnI 
is not accompanied by significant changes in cardiac function, we suggest that the 
change in cTnI most likely does not reflect considerable cardiac damage, which is also 
in line with the current theory on exercise-induced increase in troponin levels.29 
Clinical relevance. Absence of impairment in cardiac function in cardiac patients 
after exercise is clinically relevant as physical activity, in various forms, represents a 
cornerstone of contemporary cardiac rehabilitation.4,5,30 Moreover, regular exercise at 
moderate-intensity, such as walking, is recommended in recent guidelines for cardiac 
patients.5,30 Since exercise is recommended for cardiac patients, it is not uncommon for 
these patients to participate in exercise events such as walking marches. Characteristic 
in these marches is that exercise is performed for several hours and, often, on 
consecutive days. Our observations suggest that walking exercise represents a safe 
type of exercise, even when performed for multiple hours and on consecutive days, and 
is not related to a significant impairment in cardiac function or excessive biomarker 
response.
Limitations. The number of participants in this study was small and the etiology of 
heart disease was heterogeneous. This may increase the chance for statistical 
errors and influences the generalizability of the results of this study. Therefore, this 
study should be considered as a pilot-study that may be a base for future studies. 
Participants of this study were recruited through self-administered questionnaires. 
Whilst in the patient group the medical history was confirmed through records of their 
cardiologists, we did not exclude the presence of cardiovascular disease in control 
subjects. Therefore, it is possible that the controls had some degree of (latent or 
silent) cardiovascular disease. Moreover, cardiac patients included in this study do 
not represent the general cardiac patient population as they were (highly) physically 
active and capable of performing prolonged walking exercise. Therefore, extrapolation 
of our results to all cardiac patients is difficult. Finally, some of the medication used 
by the patients affects the cardiac response to exercise, such as the use of β-blockers 
that attenuate heart rate during exercise. This explains that cardiac patients, whilst 
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performing exercise at similar intensity (i.e. walking speed and METs), demonstrate a 
lower heart rate during exercise. Moreover, angiotensin converting enzymes-inhibitors 
may affect blood pressure response to exercise. Nonetheless, we believe that our 
design to continue this medication is clinically relevant as this represent the normal 
situation for these patients. Furthermore, as parameters of preload demonstrate 
similar changes after exercise between cardiac patients and controls, we believe 
medication use of the patients did not alter the main findings of our study.  
Conclusion. Repeated prolonged walking exercise did not significantly impair cardiac 
function in cardiac patients or controls. Both groups demonstrated a subclinical 
decrease in right ventricular early diastolic filling and an increase in cTnI levels after 
repeated bouts of exercise, without having significant negative consequences for the 
LV function. Interestingly, these findings were similarly present in both groups. This 
suggests that stable cardiac patients are capable of performing repeated, prolonged 
walking exercise without a significant deterioration in cardiac function or a more 
pronounced release of cardiac biomarkers compared to controls.
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Chapter 7
Effects of high-intensity interval training 
versus continuous training on physical 
fitness, cadiovascular function and quality 
of life in heart failure patients
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aBsTRaCT 
Introduction. Physical fitness is an important prognostic factor in heart failure (HF). 
To improve fitness, different types of exercise have been explored, with recent focus 
on high-intensity interval training (HIT). We comprehensively compared effects of 
HIT versus continuous training (CT) in HF patients NYHA II-III on physical fitness, 
cardiovascular function and structure, and quality of life, and hypothesize that HIT 
leads to superior improvements compared to CT. 
Methods. Twenty HF patients (male:female 19:1, 64±8 yrs, ejection fraction 38±6%) 
were allocated to 12-weeks of HIT (10*1-minute at 90% maximal workload - 
alternated by 2.5 minutes at 30% maximal workload) or CT (30 minutes at 60-75% of 
maximal workload). Before and after the intervention, we examined physical fitness 
(incremental cycling test), cardiac function and structure (echocardiography), vascular 
function and structure (ultrasound) and quality of life (SF-36, Minnesota living with HF 
questionnaire (MLHFQ)).
Results. Training improved maximal workload, peak oxygen uptake (VO2peak) related to 
the predicted VO2peak, oxygen uptake at the anaerobic threshold, and maximal oxygen 
pulse (all P<0.05), whilst no differences were present between HIT and CT (N.S.). 
We found no major changes in resting cardiovascular function and structure. SF-36 
physical function score improved after training (P<0.05), whilst SF-36 total score and 
MLHFQ did not change after training (N.S.). 
Discussion. Training induced significant improvements in parameters of physical 
fitness, although no evidence for superiority of HIT over CT was demonstrated. No 
major effect of training was found on cardiovascular structure and function or quality 
of life in HF patients NYHA II-III.
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INTRoDUCTIoN 
Heart failure (HF) is a common disease with an increasing prevalence worldwide,1 and is 
characterized by a low 5-year survival of 35-55%.2-4 Several studies have indicated that 
physical fitness is an important prognostic factor for HF patients, in which a low physical 
fitness is associated with higher mortality rates.5,6 Previous studies demonstrate that 
exercise training can improve physical fitness,7 cardiac function,8 vascular function,9,10 
and quality of life7 in HF patients.11 Therefore, exercise training is recommended for HF 
patients and encompasses a central component of cardiac rehabilitation.12 
Most previous studies examining the impact of exercise training in HF patients have 
adopted exercise at moderate-intensity. Recent studies explored the impact of high-
intensity interval training (HIT), which can be described as short periods of exercise 
performed at high-intensity (>80-85% peak oxygen uptake13-15), alternated by periods 
of active or passive rest. Wisløff et al. suggested a superior effect of HIT compared 
to continuous training (CT) on physical fitness, cardiovascular function and quality of 
life in HF patients.16 This study applied an intensive HIT training regimen in HF patients 
and found large improvements in fitness levels. After this promising study, Fu et al. 
found similar results,17 but not all subsequent studies,18-22 reinforced the superior 
effect of HIT compared to CT in HF patients. 
Previous studies that revealed a superior effect of HIT adopted relatively long bouts 
of high-intensity exercise (3-4 min),16,17 followed by active ‘rest’ periods of 3 minutes 
at an intensity up to 70% of maximal heart rate. Performance of such long bouts of 
exercise at high-intensity and/or ‘rest’ periods at such vigorous intensity levels may 
not be feasible for all HF patients. Furthermore, most previous training studies have 
applied a training frequency of three times per week, which is time consuming. Whilst 
training frequencies of twice per week can be sufficient to induce a positive effect 
on fitness levels,23 no previous study examined the efficacy of HIT with lower training 
frequency or whether there is a difference between such HIT and CT training protocols. 
Therefore, we explored the benefits of a feasible HIT-protocol with high-intensity 
bouts of moderate duration (i.e. 1 min), the active rest at relatively low intensity (i.e. 
30% maximal workload), and a training frequency of twice a week.
In this study, we examined whether 12-weeks of CT or HIT is effective and feasible 
for HF patients, and whether this HIT-protocol leads to superior effects on fitness, 
cardiovascular function and quality of life compared to CT. We hypothesize that the 
HIT-protocol is feasible, whilst the effects on physical fitness, cardiovascular function 
and quality of life in HF patients New York Heart Association (NYHA) class II-III are 
superior compared to CT.
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METHoDs
subjects
We included 29 patients (65±8 yrs) diagnosed with HF classified as NYHA class II-III, 
with a history of left ventricular ejection fraction (LVEF) ≤45% (assessed by 2D/4D 
echocardiography). Patients were recruited from the department of Cardiology of the 
Radboud university medical center and the Canisius-Wilhelmina Hospital (Nijmegen, 
the Netherlands) and through advertisements. Patients with HF due to congenital 
heart disease or HF caused by valve pathology were excluded. Other exclusion criteria 
were: diabetes mellitus (type 1 or 2), hypercholesterolemia (total cholesterol >6.5 
mmol/L), severe renal failure (glomerular filtration rate <30 mL/min/1.73m2), exercise-
induced ischemia (i.e. ECG abnormalities suggestive for ischemia on maximal exercise 
testing), severe co-morbidities (e.g. COPD GOLD ≥3), pathology that restricts patients 
from participation to exercise (e.g. orthopedic/neurological disorders interfering with 
movement), pre-menopausal women or women on hormone replacement therapy, and 
subjects with contra-indications for maximal exercise testing.24 Subjects had to be in 
a clinically and pharmacologically stable situation (>3 months) prior to participation. 
The Medical Ethical Committee of the Radboud university medical center approved 
this study (CMO region Arnhem-Nijmegen) on October 26th 2010. This trial is registered 
in the Dutch Trial Register (NTR3671) 3 months after the start due to practical 
reasons. The authors confirm that all ongoing and related trials for this intervention 
are registered. Written informed consent was obtained from each subject before 
participation in this study. Subject recruitment was done between July 2011 and 
September 2014. Follow-up lasted until February 2015. This study was monitored by a 
data safety monitoring board, which also approved the submission of this study.
Experimental protocol
Subjects reported to our laboratory for a medical screening, after which they were 
allocated to 12-weeks moderate-intensity CT or HIT. In addition, to assess changes 
over time in HF patients, we included a control group consisting of HF patients who 
were unable to participate in the training program due to geographical reasons or 
time-constraints, which was tested before and after a 12-week control period. Before 
and after the 12-week intervention/control period, subjects underwent a maximal 
incremental cycling test to determine physical fitness, echocardiography to examine 
cardiac function and structure, and vascular ultrasound measurements to examine 
peripheral artery vascular function and structure. Finally, questionnaires were used 
before and after the intervention to assess health-related quality of life and HF 
symptoms. All measurements were performed in the Radboud university medical 
center (Nijmegen, the Netherlands). Due to the nature of the study design and practical 
reasons, blinding participants and researchers was not possible.
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Measurements 
Subject characteristics. We determined height, weight (Seca 888 Scale, Seca, 
Hamburg, Germany), body mass index, body fat percentage,25 and waist and 
hip circumference. Furthermore, we obtained heart rate and blood pressure 
(manually, WelchAllyn, Maxi-Stabil 3, NY, USA), an electrocardiogram to determine 
heart rhythm, and a venous blood sample to determine fasted glucose and (total) 
cholesterol concentrations. 
Primary outcome - Physical fitness. An incremental maximal cycling test was 
performed on a cycle ergometer (Ergoline, Ergoselect 200k, Bitz, Germany). Subjects 
were instructed to pedal (>60rpm) whilst workload was increased 10-15 Watt/min, 
depending on the expected physical fitness of the participant (based on sex, age, 
height, and previous results on exercise testing). During exercise, breath-by-breath 
gas analysis was recorded continuously (LabManager V5.32.0). For the termination 
of maximal exercise testing we adhered to recent guidelines.24 Peak oxygen uptake 
(VO2peak) was defined as the highest oxygen uptake during the test (30-second average). 
Secondary outcome - Physical fitness. Oxygen uptake at the anaerobic threshold (AT) 
was determined using the V-slope method.26 Peak oxygen uptake and oxygen uptake 
at the AT was also expressed as a percentage of the predicted maximal oxygen 
consumption.27 Ventilatory efficiency was defined as the slope of the ventilation to 
the carbon dioxide production (VE/VCO2 slope) calculated over the linear phase of 
the response up to the AT. The maximal oxygen pulse (oxygen consumption per heart 
rate, O2/HR) was determined (10-second average). The presence of chronotropic 
incompetence, defined as a heart rate reserve <80% of predicted,28 was noted. Prior 
to testing, all medication was continued.
Secondary outcome - Vascular function and structure. Subjects were prepared 
according to guidelines for the assessment of flow-mediated dilation (FMD).29 
Subjects were instructed to continue medication, but to refrain from diuretics the day 
of testing for practical reasons. The measurements were performed in a temperature-
controlled room (22.5±0.7 °C). Prior to testing, subjects rested in the supine position 
for 10 minutes. Vascular function measurements were performed using a 10-MHz 
multifrequency linear array probe attached to a high-resolution ultrasound machine 
(Terason T3000, Burlington, MA, USA). We examined brachial and superficial femoral 
artery endothelial function using the FMD according to the guidelines.29 Subsequently, 
we measured the brachial artery maximal diameter and blood flow responses to 
ischemic handgrip exercise, as described in previous studies.30,31 The peak blood flow 
provides a valid and accepted index of resistance artery size and remodelling and 
the brachial artery diameter response for maximal dilating capacity.30 We examined 
carotid artery intima-media thickness (IMT), which represents a surrogate measure 
for atherosclerosis.32 Finally, we examined the endothelium-independent dilation of 
the brachial artery by examining the diameter response to an exogenous nitric oxide 
donor (sublingual administration of 400µg glyceryl trinitrate (GTN)). 
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Secondary outcome - Cardiac function. Transthoracic (4D) echocardiography was 
performed with an ultrasound scanner (Vivid E9, General Electric Healthcare, 
Horten, Norway) with M5-S and V4 probe according to the guidelines of the American 
Society of Echocardiography.33 Echocardiographic images were analyzed post-hoc 
with EchoPAC software (version 112, General Electric Healthcare, Horten, Norway). 
From 4D-images we assessed: left ventricular end-diastolic volume, left ventricular 
end-systolic volume, stroke volume, LVEF, cardiac output, and cardiac index. Left 
ventricular longitudinal, circumferential, radial, and area strain were analyzed by 4D 
speckle tracking. Moreover, we measured the isovolumetric contraction and relaxation 
time from tissue Doppler tracings of the lateral and septal mitral annulus. To describe 
diastolic function we obtained the following parameters by (tissue) pulsed-wave 
Doppler tracings: peak mitral flow velocity during early (E) and late (A) diastole, the 
systolic (S) and diastolic (D) inflow velocity over the pulmonary valve, and the peak 
mitral annulus velocity during early filling (E’) of the lateral and septal mitral annulus. 
The E/A-ratio, S/D-ratio, and E/E’-ratio were calculated. 
Secondary outcome - Questionnaires. To measure health-related quality of life, the 
SF-36 Health Survey was used.34,35 Additionally, we used the Minnesota living with 
Heart Failure Questionnaire (MLHFQ), to measure patient perceptions of the effects 
of HF on their physical, psychological and socioeconomic lives.36 
12-week intervention
Training was performed twice a week for 12 weeks in a rehabilitation setting or 
hospital and was supervised by physiotherapists. When a participant missed a 
training session, this session was rescheduled to ensure a total of 24 training 
sessions (i.e. 100% compliance). Training was performed on a cycle ergometer (Lode 
Corival, Procare, Groningen, The Netherlands). Both the CT- and HIT-session started 
with a warm-up of 10-minutes at 40% of maximal workload (Watt) as obtained 
from the cardiopulmonary maximal exercise test at baseline, and concluded with a 
cooling-down of 5-minutes at 30% of maximal workload. Workload was increased 
during the 12-week training period based on the Borg scores of perceived exertion, 
to maintain a sufficient training stimulus when physical fitness was expected to 
improve. 
CT-group. CT consisted of 30-minutes at 60-75% of maximal workload. Training 
intensity was controlled using the Borg score (scale 6-20),37 aiming at a Borg score of 
12-14 during the training session, as recommended in the current exercise guidelines 
for HF patients.12 Borg score and heart rate were determined after the warm-up, at 20, 
30 and 40 minutes of exercise, and after the cooling-down.  
HIT-group. HIT consisted of 10 periods of 3.5-minutes of exercise, consisting of 
intervals of 1-minute at 90% of maximal workload, and 2.5-minutes at 30% of maximal 
workload, aiming at a Borg score of 15-17 during the high-intensity intervals. Borg 
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score and heart rate were determined at the end of the warm-up, after repetition 1, 3, 
7 and 10, and after the cooling-down.
Control group. Control subjects were instructed not to alter their daily physical 
activities.
statistical analysis
We have made a pre-study sample size calculation based on previous studies examining 
the difference in effect between CT and HIT. Some studies suggest n=2-3 per group 
is sufficient,16,17 whilst data from others suggest several thousand subjects must be 
recruited to detect differences between CT and HIT.19 We rationalized that n=10-20 
will provide (clinically) meaningful insight into the effect of CT versus HIT. Therefore, 
using a conservative approach (accounting for drop-outs), we aimed for n=20 for both 
exercise training groups (and n=10 in the control group). Data was analyzed using IBM 
SPSS Statistics 20.0 (IBM Corp., Armonk, NY, USA). Parameters were checked for 
normality using a Kolmogorov-Smirnov test. When data was not normally distributed, 
a non-parametric alternative was used or natural logarithmic data transformation 
was applied. Categorical and nominal parameters were compared with a Chi-Square 
test. Baseline characteristics of the groups were compared with a 1-way ANOVA 
or Kruskal-Wallis test when data was not normally distributed. A 2-way repeated 
measures ANOVA was used to examine the impact of exercise training (time-effect), 
and whether the change differs between HIT and CT (time*group-effect). When a 
significant main effect (time) or interaction-effect (time*group) was observed, post-
hoc tests with least-significant difference were used to identify differences between 
and within groups. When data for this 2-way comparison was not normally distributed, 
we used individual tests to examine the effect of time, group and time*group. Changes 
in the control group were tested with a paired Student’s t test, or Wilcoxon test when 
data was not normally distributed. To control for the potential impact of baseline 
diameter on FMD,38 we used logarithmically transformed diameter data and adopted 
a univariate General Linear Model with baseline arterial diameter as a covariate, 
to compare differences between groups. Potential drop-outs were left out of the 
analysis and were not replaced. A Pearson correlation coefficient was determined for 
the relation between baseline quality of life and exercise-induced changes in quality 
of life. Data are presented as mean ± standard deviation (SD), unless stated otherwise. 
Significance level was set at P<0.05. 
REsUlTs
For this study, 59 HF patients were screened. Fifteen patients did not meet inclusion 
criteria (screen failures) and 11 patients declined to participate after screening due 
to lack of time (n=10) or change in health (n=1) (Fig. 1). We allocated 24 patients to 
HIT or CT. Nine HF patients were included in the control group (non-randomized). 
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In both the HIT- and CT-group, 2 drop-outs were reported after allocation (71±2yrs; 
male:female 3:1; NYHA class II:III 3:1), which makes the total drop-out 17%. A patient 
in both training groups dropped out due to musculoskeletal complaints and a patient 
in both training groups dropped out due to progression of HF. Twenty patients in the 
training-groups and nine controls completed the study and were available for final 
analysis. The groups were not significantly different in age, body mass index, NYHA 
class, etiology of HF, blood pressure, heart rate, LVEF and physical fitness (Table 1). 
The control group consisted of significantly more females than the CT-group (P=0.028, 
Table 1). Cardiovascular medication use is documented in Table 1.
Exercise training
When averaging all training sessions, CT was performed at 66±5% of maximal 
workload, whilst the high-intensity intervals during HIT were performed at 102±7% 
of maximal workload (P<0.001). CT was performed at 81±7% of maximal heart rate, 
and the high-intensity intervals during HIT were performed at 83±9% of maximal heart 
rate (P=0.70). Borg-scores during CT and HIT were 13±1 and 14±1 respectively (P=0.27). 
Impact of exercise training
Physical fitness. VO2peak tended to increase after training (P=0.06), whilst VO2peak/kg did 
figure 1
flow-chart of the inclusion of subjects.
 
 
 
Assessed for eligibility (n=59 ) 
Excluded  (n=26) 
   Not meeting inclusion criteria (n=15) 
   Declined to participate (n=11) 
 
Discontinued intervention (n=2) 
 Musculoskeletal complaints (n=1) 
 Progression of HF (n=1) 
Allocated to HIT (n=12) 
Discontinued intervention (n=2) 
 Musculoskeletal complaints (n=1) 
 Progression of HF (n=1) 
 
Allocated to CT (n=12) 
Training group (n=24) Control group (n=9) 
Available for  
final analysis  
(n=10) 
Available for  
final analysis  
(n=10) 
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Table 1
subject characteristics and cardiovascular medication.
Data is presented as mean±sD. P-values refer to a 1-way aNoVa. †Data was unavailable for 1 subject in the CT-group 
and 3 subjects in the control-group. *significantly less females compared to the control-group. #lower compared to 
CT-group and HIT-group. 
subject characteristics CT (n=10) HIT (n=10) Control (n=9) P-value
Age (yrs) 64±8 63±8 67±7 0.57
Sex (male:female) 10:0* 9:1 5:4 0.028
Body weight (kg) 89.7±11.9 87.6±23.6 77.0±10.5 0.16
Height (cm) 177±5 177±3 174±9 0.66
Body mass index (kg/m2) 28.9±4.7 28.1±7.5 25.4±2.7 0.24
NYHA class (II:III) 8:2 8:2 8:1 0.84
Etiology (Isch:Non-isch) 8:2 7:3 5:4 0.51
Systolic blood pressure (mmHg) 132±23 132±18 130±25 0.98
Diastolic blood pressure (mmHg) 83±11 79±10 78±14 0.48
Resting heart rate (/min) 59±11 57±7 60±10 0.80
Maximal heart rate (/min)† 129±19 126±16 120±15 0.53
Chronotropic incompetence (yes:no)† 5:4 8:2 6:1 0.33
VO2peak† (mL/min/kg) 21.0±3.4 19.1±4.1 17.4±5.8 0.26
VO2peak† (% of predicted VO2peak) 86±8 79±17 81±22 0.63
LVEF (%) 38±6 37±6 40±11 0.84
Medication
 Angiotensin converting enzyme-inhibitors 5 (50%) 6 (60%) 8 (89%) 0.19
 Angiotensin II receptor antagonists 4 (40%) 4 (40%) 1 (11%) 0.30
Aldosterone antagonist 6 (60%) 7 (70%) 8 (89%) 0.36
Diuretics (loopdiuretics) 7 (70%) 6 (60%) 4 (44%) 0.50
β-blockers 10 (100%) 9 (90%) 9 (100%) 0.37
 Antiplatelet drugs 6 (60%) 4 (40%) 3 (33%) 0.47
 Coumarin derivates 4 (40%) 7 (70%) 4 (44%) 0.35
 Statins 10 (100%) 9 (90%) 4 (44%)# 0.007
Table 2
Maximal incremental cycling test.
Parameters of  
maximal cycling test
CT (n=10) HIT (n=10) P-value
Pre Post Pre Post Time Group Time*Group
VO2peak (mL/min) 1881±214 1887±27 1662±562 1792±559 0.06 0.44 0.08
VO2peak (mL/min/kg) 21.2±3.6 21.3±3.7 19.1±4.1 20.4±4.3 0.10 0.14 0.09†
VO2peak (% pred. VO2peak) 86±8 87±10 79±17 85±16 0.044 0.48 0.08
Max. workload (Watt) 145±22 152±26 126±38 142±45 <0.001 0.24 0.07
Max. heart rate (/min) 129±19 132±24 126±16 125±15 0.78 0.30 0.51
VE/VCO2 slope 32.2±3.3 32.7±5.8 28.7±5.8 29.4±7.7 0.52 0.18 0.91
VO2 at AT (mL) 1030±287 1248±388 1033±319 1090±225 0.041 0.54 0.22
Max. O2/HR (mL) 16.2±2.2 16.7±2.8 14.0±4.0 15.4±3.8 0.006 0.25 0.13
Data is presented as mean±sD. P-values refer to a 2-way repeated measures aNoVa between the two training groups. 
one subject in the CT-group did not reach Vo2peak, and therefore only VE/VCo2 slope and Vo2 at aT could be determined. 
†for statistical reasons, data was analyzed with three separate tests to determine time, group and time*group P-values.  
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not change after exercise (P=0.10). A significant increase after training was found in 
the VO2peak related to predicted VO2peak (%), maximal workload, oxygen uptake at the 
AT and maximal oxygen pulse (Table 2). No significant differences were observed 
between both interventions (Table 2).
Vascular function/structure. We found no significant changes in brachial and 
superficial femoral artery diameter, peak blood flow, and FMD (Table 3). No change in 
endothelium-independent dilation of the brachial artery was observed after training 
for both groups (Table 3). Furthermore, we found no significant impact of HIT or CT on 
carotid artery IMT or IMT-to-lumen ratio (Table 3). 
Cardiac function/structure. Most of the parameters of cardiac systolic function, left 
ventricle strain, or diastolic function demonstrated no change after HIT or CT (Table 
4). Negligible but significant changes were found in area strain and isovolumetric 
contraction time (Table 4). 
Table 3
Brachial (Ba) and superficial femoral artery (sfa) endothelium-dependent vasodilation through flow-mediated dilation 
(fMD), peak diameter and endothelium-independent dilation (GTN), and common carotid artery (CCa) intima-media 
thickness (IMT).
 
 
Vascular function
CT (n=10) HIT (n=10) P-value
 
Pre
 
Post
 
Pre
 
Post
 
Time
 
Group
Time* 
Group
BA diameter (mm) 4.5±0.5 4.5±0.5 4.4±0.9 4.4±0.8 0.83 0.68 0.86
BA FMD (%) 5.2±2.5 4.8±3.0 5.3±2.6 4.7±2.5 0.33 0.92 0.98
BA FMD (%, scaled) 5.3±2.5 4.8±2.5 5.2±2.5 4.6±2.5 0.47 >0.999 0.91†
BA SRAUC (s, 103) 19.9±9.6 18.6±7.4 17.8±9.2 22.3±7.7 0.42 0.80 0.14
BA GTN (%) 17.6±7.0 16.3±6.5 16.8±8.7 15.2±4.9 0.33 0.74 0.92
BA GTN (%, scaled) 17.9±4.5 16.6±4.5 16.1±4.5 14.6±4.5 0.42 0.27 0.94
BA FMD-GTN ratio 0.34±0.21 0.33±0.24 0.42±0.30 0.34±0.15 0.46 0.63 0.82
BA CADC (%) 10.6±6.4 11.3±4.8 16.1±7.4 13.4±5.5 0.52 0.12 0.26
BA CADC (%, scaled) 11.0±4.2 12.0±4.2 15.0±4.2 12.8±4.2 0.72 0.11 0.27
BA peak blood flow  
(mL/min)
794±139 862±261 711±264 556±165 0.38 0.56 0.46
SFA diameter (mm) 7.1±1.2 6.9±1.2 6.7±1.1 6.5±1.0 0.38 0.48 0.88
SFA FMD (%) 3.3±1.9 5.1±4.8 4.2±1.8 3.4±2.8 0.58 0.74 0.19
SFA FMD (%, scaled) 3.5±2.9 5.1±2.9 4.1±2.9 3.1±2.9 0.74 0.50 0.19
SFA SRAUC (s, 103) 9.2±5.6 10.4±10.8 13.5±7.2 6.9±3.9 0.11 0.80 0.07
CA IMT (mm) 0.80±0.13 0.76±0.20 0.72±0.12 0.67±0.16 0.20 0.24 0.96
CA IMT-to-lumen ratio 0.12±0.02 0.11±0.02 0.11±0.02 0.11±0.02 0.40 0.59 0.45
Data is presented as mean±sD. P-values refer to 2-way repeated measures aNoVa between the 2 training groups. †for 
statistical reasons, data was analyzed with three separate tests to determine time, group and time*group P-values. Due 
to technical problems, Ba GTN/fMD-GTN ratio/peak blood flow was available for 9 subjects in the HIT-group and sfa 
fMD was available for 8 subjects in the HIT-group. CCa IMT and IMT-to-lumen ratio were available for 8 subjects in each 
group. sRaUC; shear rate area-under-the-curve. CaDC; conduit artery dilating capacity. 
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Quality of life. There was no significant change in the SF-36 total score (Table 5). There 
was a significant increase in the SF-36 subscale ‘physical function’ after training 
(P=0.004, Table 5), which did not differ between groups (time*group P=0.11). A trend 
for an inverse correlation was found between baseline SF-36 scores and training-
induced change in SF-36 scores (r=-0.51, P=0.052). We found no change in the MLHFQ 
for both groups (Table 5). No significant correlations were found between baseline 
MLHFQ scores and training-induced change in MLHFQ.
Table 4
Echocardiographic left ventricular volumes, systolic function, strain and diastolic function.
systolic function
CT (n=10) HIT (n=10) P-value
 
Pre
 
Post
 
Pre
 
Post
 
Time
 
Group
Time* 
Group
LVEDV (ml) 154±24 159±28 194±39 204±44 0.26 0.002 0.64†
LVESV (ml) 98±14 102±19 134±32 132±40 0.87 0.037 0.63
Stroke volume (ml) 56±13 57±13 61±14 72±16 0.06 0.16 0.12
LVEF (%) 36±4 36±5 32±7 36±9 0.09 0.57 0.07
Cardiac output (L/min) 3.5±0.6 3.4±0.7 3.5±0.8 4.3±1.0 0.20 0.21 0.07
Cardiac index (L/min/m2) 1.7±0.3 1.6±0.3 1.7±0.4 2.1±0.5 0.22 0.14 0.08
Longitudinal strain (%) -9±3 -9±3 -9±3 -8±3 0.60 0.47 0.38†
Circumferential strain (%) -10±2 -10±3 -9±3 -8±3 0.22 0.43 0.19
Radial strain (%) 23±7 22±6 23±8 20±8 0.13 0.71 0.48
Area strain (%) -17±4 -15±6 -17±5 -14±5 0.044 0.73 0.97
IVCT-L (ms) 52±7 50±10 49±12 58±7 0.18 0.56 0.029
IVCT-S (ms) 57±14 59±11 53±9 56±11 0.35 0.46 0.87
Diastolic function
IVRT-L (ms) 145±32 149±27 142±27 159±27 0.13 0.75 0.38
IVRT-S (ms) 160±36 148±22 164±41 170±37 0.60 0.45 0.22†
E/A 1.15±0.71 1.17±0.89 1.53±1.42 1.60±1.53 0.49 0.36 0.59†
S/D 1.38±0.74 1.17±0.34 1.00±0.40 1.26±0.59 0.85 0.48 0.14
E/E’-L 6.8±1.9 6.7±1.9 10.3±4.4 9.8±6.3 0.71 0.07 0.74
E/E’-S 10.1±4.1 11.1±5.2 12.6±9.8 11.8±11.2 0.93 0.67 0.42
Data is presented as mean±sD. P-values refers to 2-way repeated measures aNoVa between the 2 training groups. 
†for statistical reasons, data was analyzed with three separate tests were performed to determine time, group and 
time*group P-values. 4D data was available for 7 patients in the CT-group and 8 patients in the HIT-group. IVCT-l, 
IVRT-C, IVRT-s and E/E’-l was available for 9 patients in the HIT-group. IVCT-s and E/E’-s was available for 8 pa-
tients in the HIT-group. IVCT-l and s/D ratio was available for 9 subjects in the CT-group. IVRT-l and E/a ratio was 
available for 8 subjects in the CT-group.
lVEDV; left ventricular end-diastolic volume. lVEsV; left-ventricular end-systolic volume. IVCT-l/s: isovolumetric 
contraction time, lateral/septal. IVRT-l/s; isovolumetric relaxation time, lateral/septal. E/a ratio; peak mitral flow 
velocity during early filling/peak mitral flow velocity during atrial contraction. s/D; systolic flow velocity pulmonary 
vein/diastolic flow velocity pulmonary vein. E/E’-l/s; peak mitral flow velocity during early filling/peak mitral annu-
lus velocity during early filling, lateral/septal.
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Control group
We found no changes over the 12-week period in maximal oxygen uptake (17.4±5.9 
versus 17.5±5.8 ml/min/kg, P=0.79) or in any of the other parameters of physical fitness 
(all P>0.05, Supplementary Table). Except for a decrease across time in the superficial 
femoral artery FMD and an increase in lateral E/E’-ratio, we found no changes in 
cardiac and vascular structure or function or in the SF-36 score and MLHFQ in controls 
(all P>0.05, Supplementary Table). 
DIsCUssIoN
This study comprehensively compared physical fitness, vascular function, cardiac 
function and quality of life between a feasible and practical HIT-protocol versus 
traditional CT in HF patients. We have demonstrated that CT and HIT are both feasible 
in HF patients and induced a significant improvement in measures of (sub)maximal 
exercise performance and fitness, with no significant differences between both types 
of exercise training. Despite these changes in fitness, we did not find improvement in 
measures of resting cardiac and vascular structure and function. Furthermore, except 
an improvement in the subscale ‘physical function’ that may be related to the change 
in fitness, no effect of training was found on quality of life. Therefore, our data suggest 
that both types of exercise training successfully improve measures of physical fitness 
within 12-weeks, but not cardiovascular function at rest or quality of life. Moreover, 
we found no evidence for superiority of this more feasible HIT-protocol over traditional 
CT on the parameters presented in our study.
Table 5
Results of the sf-36 and Minnesota living with Hf questionnaire (MlHfQ).
sf-36
CT (n=9) HIT (n=8) P-value
Pre Post Pre Post Time Group Time*Group
Physical functioning 74±22 78±17 57±21 69±17 0.004 0.16 0.11
Physical health subscore† 73±20 76±16 60±22 67±19 0.15 0.26 0.52
Mental health subscore†,‡ 81±9 83±10 83±5 82±10 0.75 0.87 0.54
Total score†,‡ 75±16 78±13 68±14 73±14 0.18 0.42 0.76
CT (n=9) HIT (n=10) P-value
MlHfQ Pre Post Pre Post Time Group Time*Group
Total score 18±14 16±16 21±15 20±14 0.81 0.56 0.89
Data is presented as mean±sD. P-values refers to 2-way repeated measures aNoVa between the 2 training groups. 
Results of the sf-36 were scored on a 0-100 scale, in which a high score represents a better quality of life. Results 
of the MlHfQ were scored on a 0-105 scale, in which a low score indicates few Hf-related complaints. †Data was 
available for 7 subjects in the HIT-group. ‡Data was available for 8 subjects in the CT-group. 
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Physical fitness
Previous work found improvements in physical fitness in HF after HIT ranging from 
8-46%,16,20,21 whilst studies adopting CT found changes ranging between 0-22%.17,19 
Most of these training studies have included low numbers of participants, which 
may explain the large variation in results. The largest HF exercise training study so 
far (>1,000 participants), the HF-ACTION trial, reported a median increase in fitness 
of 4%.39 Although in the lower ends of the spectrum, the change in physical fitness 
in our study (~4%) is within the range of improvements as reported in previous 
work. As demonstrated in various previous studies, training characteristics (e.g. 
frequency, intensity and duration) are important factors determining training 
responses.40 Nonetheless, our relatively low-frequency protocols were sufficient to 
induce significant improvements in fitness levels. Similar observations were made by 
Belardinelli et al.,23 who adopted a long-term (10-year), low-frequency exercise training 
program in HF patients. They reported improvement in physical fitness levels in trained 
subjects after 1 year of training, whilst fitness levels remained higher than in controls 
across the 10-year intervention. In addition to the low frequency of training, the 
relatively modest changes in fitness in our study may relate to characteristics of the 
included participants, such as genetic factors41 or to a priori higher levels of physical 
fitness as lower physical fitness levels are associated with larger training-induced 
improvements in HF patients.42,43 Indeed, some previous HIT-studies demonstrated 
large improvement after exercise training in HF patients with low baseline levels of 
physical fitness.16-18 Moreover, patients with chronotropic incompetence (i.e. 68% in 
our study) have attenuated exercise-induced improvement in parameters of fitness, 
which could have affected the effect size in our study.44 Despite the relatively modest 
effect sizes, our exercise training protocols were successful in improving parameters 
of physical fitness.
We did not demonstrate significant differences between CT and HIT on the change in 
physical fitness, a finding which is in agreement with some,18,19,22 but not all previous 
studies.16,17 Interestingly, recent meta-analyses suggest that (high-intensity) interval 
training results in superior effects on physical fitness compared to CT in HF.45,46 Despite 
these promising results of HIT in HF, larger trials that focus on clinical end-points are 
needed.47 Also, limitations of a meta-analysis should be taken into consideration, as 
both HIT and CT interventions included in these meta-analyses comprise of many 
different protocols and exercise intensities. Especially for HIT, it is suggested that the 
time spent at a high percentage of peak oxygen uptake, determined by intensity and 
duration of the work and rest intervals, importantly contributes to the effect size.48 
Whilst the intensity of our high-intensity-bouts is high, the time spent at these high-
intensity bouts was lower than in previous studies demonstrating superior effects of 
HIT compared to CT.16,17 Furthermore, to validly compare exercise training regimes, it 
is important that total workload is not significantly different. A study that compared 
training-effects of HIT and CT and applied individually designed training programs 
with specific emphasis on comparable workloads for HIT and CT, found no differences 
between training modalities.19 Therefore, more rigorous exercise programs (both in 
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frequency, duration, and training load) rather than the type of training per se may 
contribute to larger improvements in physical fitness. 
Cardiac and vascular adaptation
Exercise in HF patients is associated with beneficial cardiac remodelling.8 After 
12-weeks of training, we found no improvements in cardiac structure and function at 
rest, although the increase in maximal oxygen pulse suggests an increase in stroke 
volume during exercise. Previous studies that reported significant changes in cardiac 
function or structure generally applied training periods ≥6 months.8 Therefore, the 
relatively short duration of training may contribute, at least partly, to the lack of 
cardiac remodelling in our study. Moreover, the largest proportion of our training-
participants reported ischemic HF etiology. This could be of special importance, since 
a recent study suggested that cardiac adaptation during outpatient rehabilitation is 
more prominent in HF patients with non-ischemic etiology.49 Furthermore, our results 
are in line with a recent meta-analysis that could not confirm that HIT is superior to CT 
to induce cardiac adaptations.46
In our study, we found no superior effect of HIT to improve vascular function, which 
contrasts with the findings of a recent meta-analysis.50 However, 4 out the 7 studies 
included in this meta-analysis showed a superior effect of HIT. Interestingly, these 
studies were all from the same laboratory and did not follow contemporary guidelines 
to assess endothelial function. We found no overall effect of exercise training on 
vascular function. As previous literature has reported a wide range of exercise-induced 
responses (and also demonstrated non-responders) in vascular function, Green et 
al. investigated which factors predict this response.51 They concluded that exercise-
induced improvements in vascular function are associated with a lower pre-training 
vascular function. When comparing the baseline FMD values of our subjects to normal 
values published previously,52 the endothelial function of the subjects in our study was 
within the normal range for their age. This may relate to the optimal pharmacological 
therapy of the HF patients we included.53 Moreover, we have previously demonstrated 
that the shear rate pattern during exercise (i.e. an important stimulus for exercise-
induced adaptation in vascular function) is less beneficial in HF patients compared to 
controls.54 Preserved FMD before training and a suboptimal shear rate stimulus during 
exercise training may contribute to the absence of a significant training-induced 
change in vascular function. 
Quality of life
Quality of life after exercise training in HF patients is previously demonstrated to 
improve.7,55 In our study, we indeed found improvement in the subscale for physical 
functioning after exercise training, but not for total quality of life. The lack of 
improvement in quality of life may relate to the relatively ‘good’ quality of life at 
baseline, which was well above that of previous studies17,56,57 and consequently, 
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provides little space for further improvement. In support of this idea, we observed 
a trend for an inverse relation between baseline SF-36 and change in SF-36 in the 
training groups. This indicates that subjects with lower quality of life prior to exercise 
training demonstrate a larger benefit from the intervention. Furthermore, the 
inclusion of more relatively old HF patients in our study may also contribute to the 
smaller effect size of exercise training on quality of life, as demonstrated in a previous 
study.58 This latter study found that older HF patients (>60 yrs) demonstrate a smaller 
effect of exercise training on quality of life compared to younger HF patients (<60 yrs).
Clinical relevance
Given the importance of (even small improvements in) fitness levels for the prognosis 
of HF patients,5,6,59 finding both a feasible and effective training program is clinically 
relevant. Another important factor is adherence to exercise training, which often 
is reported to be low in HF patients due to time-constraints and lack of energy.60 A 
HIT-program with lower training frequency and high-intensity intervals of moderate 
duration might address these two major factors of non-compliance. Therefore, we 
have studied whether such a program is effective and whether it is superior to CT. 
The results of this study suggest that low frequency HIT with high-intensity intervals 
of moderate duration is feasible and successful in improving fitness. Such findings 
may be of clinical relevance and future studies should therefore focus on finding the 
optimal exercise protocol for HF patients to achieve long-term benefits and adherence.
limitations
Although we have included a relatively small number of patients, our sample size 
was in line with previous studies that demonstrated differences in effects of HIT and 
CT on physical fitness16,17 and vascular function.50 Moreover, we have used state-of-
the-art techniques for measuring physical fitness and vascular function, in contrast 
to some previous studies that used suboptimal techniques to assess endothelial 
function. Therefore, we a priori expected to have sufficient power to detect significant 
differences between HIT and CT. Post-hoc power analysis revealed a power of 54% to 
detect differences in change in physical fitness between the two types of training. 
Finally, we did not provide a comparison between HIT with short high-intensity bouts 
and HIT with long high-intensity bouts. We encourage future studies to investigate 
whether different HIT-protocols render different results and to elucidate the optimal 
HIT-protocol.
In conclusion, we have demonstrated that 12-weeks of exercise training in HF 
patients is associated with improvements in parameters of physical fitness, whilst no 
improvements in cardiovascular function at rest or (total) quality of life are observed. 
Moreover, our data does not provide strong evidence for a potentially superior 
improvement in physical fitness, cardiovascular function or quality of life after 
12-weeks of HIT compared to CT in HF patients NYHA class II-III. 
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supplementary table 
Results of the control group.
Physical fitness (n=7)
Control group
Pre Post P-value
VO2peak (mL/min) 1363±564 1386±599 0.50
VO2peak (mL/min/kg) 17.4±5.8 17.5±5.8 0.79
VO2peak (% pred. VO2peak) 81±22 82±21 0.74
Max. workload (Watt) 103±35 103±41 0.91
Max. heart rate (/min) 120±15 120±23 0.97
VE/VCO2 slope 30.7±7.2 31.4±8.9 0.51
VO2 at AT (mL) 836±173 914±204 0.08
Max. O2/HR (mL) 12.6±2.4 12.7±3.2 0.84
Vascular function/structure (n=9)
BA diameter (mm) 4.1±0.8 4.0±0.8 0.38
BA FMD (%) 5.3±2.0 5.4±2.4 0.83
BA FMD (%, scaled) 5.3±1.3 5.3±1.3 0.92
BA SRAUC (s, 103) 17.7±13.4 22.5±15.5 0.77
BA GTN (%) 13.9±4.0 18.2±6.3 0.07
BA GTN (%, scaled) 14.2±3.5 17.8±3.5 0.07
BA FMD-GTN ratio 0.39±0.14 0.30±0.08 0.16
BA CADC (%) 13.6±5.6 12.1±5.7 0.62
BA CADC (%, scaled) 13.3±5.0 12.1±5.0 0.62
BA peak blood flow (mL/min) 579±235 654±375 0.43
SFA diameter (mm) 6.2±1.0 6.1±1.4 0.68
SFA FMD (%) 4.3±1.7 2.5±2.0 0.038
SFA FMD (%, scaled) 4.4±1.7 2.5±1.7 0.038
SFA SRAUC (s, 103) 11.3±6.7 12.2±7.7 0.65
CCA IMT (mm) 0.73±0.13 0.65±0.06 0.31
CCA IMT-to-lumen ratio 0.11±0.02 0.11±0.02 0.75
Cardiac function/structure (n=9)
LVEDV (ml)† 123±41 131±64 0.53
LVESV (ml)† 79±40 81±59 0.58
Stroke volume (ml)† 44±9 50±15 0.22
LVEF (%)† 38±12 41±13 0.18
Cardiac output (L/min)† 2.7±0.6 3.1±1.0 0.14
Cardiac index † 1.4±0.3 1.6±0.5 0.15
Longitudinal strain -9±4 -10±4 0.61
Circumferential strain† -9±3 -9±4 0.91
Radial strain 22±9 24±10 0.74
Area strain -16±6 -17±6 0.81
IVCT-L (ms) 57±14 54±13 0.19
IVCT-S (ms) 63±14 57±8 0.10
IVRT-L (ms) 158±46 187±38 0.16
IVRT-S (ms) 187±38 176±27 0.48
E/A 0.96±0.55 0.98±0.63 0.68
S/D 1.29±0.36 1.58±0.27 0.08
E/E’-L 8.7±3.9 12.9±12.1 0.015
E/E’-S 8.8±2.2 12.5±8.6 0.11
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supplementary table
continued.
Control group
sf-36 (n=5) Pre Post P-value
Physical functioning 66±20 59±21 0.08
Physical health subscore† 76±8 71±7 0.07
Mental health subscore† 91±6 88±2 0.47
Total score† 81±7 77±5 0.07
MlHfQ (n=7)
Total score 8±8 8±7 0.96
Data is presented as mean±sD. †Data missing for 1 control subject. Vo2peak; peak oxygen uptake. aT; anaerobic thresh-
old. Ba; brachial artery. sfa; superficial femoral artery. GTN; glyceryl trinitrate. CaDC; conduit artery dilating capacity. 
IMT; intima-media thickness. sRaUC; shear rate area-under-the-curve. CaDC; conduit artery dilating capacity. lVEDV; 
left ventricular end-diastolic volume. lVEsV; left-ventricular end-systolic volume. IVCT-l/s: isovolumetric contraction 
time, lateral/septal. IVRT-l/s; isovolumetric relaxation time, lateral/septal. E/a ratio; peak mitral flow velocity during 
early filling/peak mitral flow velocity during atrial contraction. s/D; systolic flow velocity pulmonary vein/diastolic flow 
velocity pulmonary vein. E/E’-l/s; peak mitral flow velocity during early filling/peak mitral annulus velocity during early 
filling, lateral/septal. MlHfQ; Minnesota living with heart failure questionnaire.
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GENERal DIsCUssIoN
Exercise training in HF patients has come a long way. Until the 1970s, bed rest was a 
central component in the treatment of HF and physical activity was avoided as this 
would induce symptoms of breathlessness.1-4 Moreover, the first scientific studies that 
have demonstrated potential positive effects of exercise training in HF patients were 
performed in the late 1970s/1980s.5-8 Nowadays, exercise is a central component in 
cardiac rehabilitation and even recommended in guidelines on the treatment of HF.9,10 
Moreover, novel exercise therapies, such as high-intensity interval training (HIT) are 
currently investigated in HF patients. HIT can be described as ‘repeated short to long 
bouts of exercise at rather high-intensity interspersed with recovery periods’.11 It is 
usually performed at exercise intensities above 85% of maximal oxygen uptake/heart 
rate, alternated by active or passive rest.12 The rationale behind HIT is that it enables 
subjects to spend more time at a higher percentage of their maximal oxygen uptake 
during exercise training compared to traditional continuous exercise training. This is 
hypothesized to induce a large stimulus for exercise-induced adaptations in central 
and peripheral tissues, such as the heart, muscles, and the vasculature.13-16 For a long 
time, this type of training was mainly used in athletes, but over the past years, HIT 
has gained significant attention in exercise training for healthy subjects as well as for 
subjects with various (cardiovascular) diseases and even heart failure (HF).17 Some of 
the first results of HIT in HF patients were very promising, with spectacular results on 
physical fitness, cardiovascular function and quality of life, which were even superior 
to the effects observed after traditional continuous training (CT).18 However, none of 
the subsequent studies that compared both types of exercise training confirmed the 
presence of superior effects of HIT of the same magnitude. Actually, some studies 
even reported similar effects of HIT and CT in HF patients or patients with coronary 
artery disease.19-21 Therefore, whilst exercise training is an important and structural 
component of cardiac rehabilitation,22 it remains unclear whether HIT leads to superior 
results.
  
High-intensity – high risk?
Considering this historical perspective, some hesitation of applying HIT, or other types 
of exercise training, in HF patients is understandable but possibly unjustified. Meyer 
et al. demonstrated that, whilst the total training work rate is higher, cardiac stress 
is lower during HIT compared to a traditional form of CT (i.e. at 75% maximal peak 
oxygen uptake).23 Rognmo et al. investigated adverse events in almost 130,000 hours 
of moderate-intensity exercise and ~46,000 hours of high-intensity exercise in almost 
5,000 patients with coronary heart disease. They concluded that the risk for training-
related adverse events in cardiac patients is low in moderate-intensity training as 
well as high-intensity training.24 Despite these studies, the safety of HIT in cardiac 
patients cannot be guaranteed due to the small number of subjects and low amount 
of total training hours that has been investigated. Moreover, knowledge regarding the 
acute effects of HIT on the release of cardiac biomarkers has only been studied after 
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HIT with relatively short high-intensity exercise bouts (15-30sec).25,26 More knowledge 
on the direct effects of (high-intensity versus endurance) exercise in HF patients and 
whether these effects differ compared to healthy controls, might aid the discussion 
on the safety of HIT.    
In chapter 5 we have examined the exercise-induced response in cardiac biomarkers 
indicative of cardiac cell injury (i.e. cardiac troponin) and cardiac load (i.e. B-type 
natriuretic peptide (BNP)) in HF patients after HIT and traditional endurance exercise 
(CT at 65% of peak oxygen uptake) and compared these with the responses observed 
in healthy subjects. As expected and in agreement with previous work, baseline 
levels of troponin and BNP were higher in HF patients compared to controls.27,28 
This observation indicates the inclusion of characteristic HF patients. Although the 
increase in BNP after exercise did not reach significance among the whole group 
(i.e. HF patients and controls), we observed a larger increase in BNP in HF patients 
compared to controls (Figure 1). This was not accompanied by an increase in cardiac 
troponin nor a larger increase in troponin in HF patients compared to controls (Figure 
1). Importantly, we found no indication of a higher biomarker release in response to 
HIT compared to CT. This indicates that, whilst exercise poses a significantly larger 
load on the heart in HF patients compared to controls, it does not seem to induce 
significant cardiac cell damage. 
Besides relatively short-duration exercise (≈45 min) such as applied in cardiac 
rehabilitation, some cardiac patients participate in exercise events of longer duration 
such as walking marches. From (unpublished) data from the Nijmegen Exercise Study 
we know that subjects with cardiovascular diseases (CVD) and/or CVD risk factors 
participate in such walking marches. Indeed, out of the 5,997 subjects that completed 
the questionnaire of the Nijmegen Exercise Study in 2013, 191 subjects (3.3% of the 
total study population) self-reported the presence of HF. 
Although walking generally represents a feasible and safe mode of exercise, due to 
the relatively low-to-moderate exercise-intensity, the effect of prolonged walking 
(>6h) in cardiac patients is unknown. Previously, an increase in cardiac troponin and 
NT-proBNP (which is formed simultaneously with BNP) after prolonged exercise (e.g. 
running, cycling, walking) was observed in healthy volunteers.29-31 To learn more about 
the direct effect of prolonged walking exercise on the heart in patients with an a priori 
impaired cardiac function, we have examined the effect of prolonged (>6h) walking 
exercise on biomarker release in cardiac patients with a history of left ventricular 
impairment and healthy controls (chapter 6, Figure 1). Although prolonged walking 
increased troponin levels, no increase in BNP was demonstrated. Moreover, biomarker 
release after exercise was comparable between patients and controls. This reinforces 
the idea that this increase in troponin is likely to be related to a ‘normal’ phenomenon 
associated with endurance exercise, and does not implicates considerable cardiac 
damage. This is in line with the current hypothesis on exercise-induced increase in 
cardiac troponin.30
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From literature, an acute transient decrease in cardiac function after prolonged 
exercise is described in healthy subjects or athletes.32 Whether cardiac function also 
demonstrates deterioration after exercise in cardiac patients was unknown. We have 
demonstrated that the effect of prolonged (>6 h) walking exercise on cardiac function 
figure 1
Troponin (a) and B-type natriuretic peptide (BNP) levels (B) at baseline, direct-
ly after and 2 hours after a CT- and HIT-session, and tropinin (a) and B-type na-
triuretic peptide (B) levels at baseline and at 3 consecutive days of prolonged 
walking exercise.
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in cardiac patients with a history of left ventricular impairment is not different 
compared to healthy controls, even though baseline cardiac function was significantly 
impaired in these patients (chapter 6). Importantly, measures of left ventricle function 
demonstrate no significant impairment after one or three days of endurance exercise, 
with some markers of systolic function even suggesting an improvement after 
prolonged walking exercise in both cardiac patients and healthy controls.
In conclusion, after short-term exercise (≈45 min), HF patients show a larger increase 
in BNP compared to controls, whilst troponin levels demonstrated no significant 
change. Moreover, there is no difference in exercise-induced increases in troponin 
and BNP between HIT and CT in both healthy controls and HF patients. After prolonged 
exercise, a significant increase in troponin is demonstrated in cardiac patients and 
controls. However, this increase after prolonged exercise is not accompanied by a 
deterioration of cardiac function (Figure 2). After prolonged exercise, BNP was not 
significantly increased in both patients and controls. Moreover, no correlation was 
demonstrated for changes in BNP and changes in cardiac function (e.g. left ventricular 
ejection fraction, Figure 2). 
figure 2
The change in left ventricular ejection fraction (lVEf, %) in relation with change in cardiac biomarkers troponin 
and BNP after 1 day and 3 days of prolonged walking. This figure combines data of cardiac patients and healthy 
controls. 
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Although larger studies or meta-analysis on the safety of HIT are necessary to better 
understand the impact of exercise on cardiac function, our results consistently 
suggest that acute bouts of (prolonged and/or strenuous) exercise in cardiac patients 
induces largely comparable cardiac (biomarker and function) responses compared to 
healthy subjects.
High-intensity – high gain?
High-intensity training has become a popular area of research. A Pubmed search 
on ‘high-intensity training’ indicates the enormous popularity, especially during the 
recent years (Figure 3).
Despite the safety-issues regarding HIT, it is currently a popular training strategy in HF 
patients as it has demonstrated promising results, and sometimes even superiority to 
CT.18,33 In chapter 7 we have compared 12-weeks of HIT and CT and found that exercise 
training induces an increase in various parameters of physical fitness in HF patients, 
whilst we did not find evidence for a superiority of HIT compared to traditional CT. 
Moreover, there was no improvement in cardiovascular function or structure at rest or 
overall quality of life. In comparison with previous training studies in HF patients, our 
training-effects can be considered low-to-normal. Below, we will discuss potential 
figure 3
esults of a Pubmed search on ‘high-intensity training’. This graph demonstrates the number of studies pub-
lished on high-intensity training over the past years (1966-2014).
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explanations for our findings of a moderate effect size after 12-weeks of HIT and CT in 
HF patients.   
Hypothesis 1: Exercise-induced adaptations in patients with HF are attenuated
Physical fitness. After training, we observed improvements in measures of physical 
fitness (i.e. maximal workload, oxygen uptake at the anaerobic threshold, peak oxygen 
uptake related to the predicted peak oxygen uptake (chapter 7)). However, we did not 
demonstrate a significant improvement in absolute peak oxygen uptake, i.e. one of the 
most important prognostic factors in HF patients.34 Below, we explore what factors 
could have contributed to the non-significant change in peak oxygen consumption 
after exercise in our study.
Peak oxygen consumption is dependent on central factors (e.g. cardiac output) and 
peripheral factors (e.g. muscle oxidative capacity and exercise-induced blood flow), 
both of which are usually impaired in HF patients.35,36 Improvements in peak oxygen 
uptake, therefore, can be achieved by improvement in these parameters, although 
peripheral adaptations are suggested to be the most important determinants in 
inducing improvements in peak oxygen uptake.35 Southern et al. investigated skeletal 
muscle oxidative capacity and training-induced changes in oxidative capacity in HF 
patients and healthy controls. The oxidative capacity was determined by the recovery 
kinetics of muscle oxygen consumption after wrist-flexor exercise, before and after 
a 4-week training intervention. This study demonstrated a lower oxidative capacity 
in HF patients compared to controls before exercise training, and moreover, no 
improvements in skeletal muscle oxidation after endurance training in HF patients 
compared to a significant improvement in healthy controls.36 The authors seek 
a possible explanation in the medication use of the HF patients. In support of this 
hypothesis, it was shown that statins can attenuate the training-induced adaptations 
in physical fitness and skeletal muscles in subjects with obesity and risk factors for 
the metabolic syndrome (e.g. hypertension, abnormal lipid spectrum, etc).37 Mikus 
et al. randomised subjects with obesity and risk factors for the metabolic syndrome 
to exercise training with or without simvastatin. After 12 weeks of exercise training, 
the increase in physical fitness was significantly smaller in the training group with 
concomitant statin use compared to the training group without statins (10% versus 
1.5%). Furthermore, skeletal muscle mitochondrial content, measured by citrate 
synthase activity, was increased in the training group without simvastatin, but did 
not change in the training group with simvastatin.37 Statins, therefore, seem to 
impair training-induced beneficial adaptations in skeletal muscle oxidative capacity 
and hereby impair changes in peak oxygen uptake. A large proportion of our HF 
patients used statins (i.e. 95%). Although speculative, the intake of statins may have 
contributed to the attenuated training-induced improvement in peak oxygen uptake.
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Vascular adaptation. It is commonly accepted that endothelial function can improve 
through exercise training in healthy subjects and HF patients.18,38-41 However, we did 
not find improvements in endothelial function after 12 weeks of training. To explore 
potential causes for the lack of an effect of exercise training, we focused on the 
stimulus for vascular adaptations; antegrade and retrograde vascular shear rate. 
Repeated exposure to elevations in antegrade shear rate is related to improvement in 
vascular function, whilst elevations in the retrograde shear rate exert a proatherogenic 
effect on the endothelium.42,43 Exercise induces a strong increase in antegrade shear, 
which is essential for beneficial adaptations in vascular function.44,45 Moreover, a dose-
response relation between the increase in antegrade shear and vascular adaptation is 
suggested.46 Interestingly, in this thesis, we have demonstrated that subjects with HF 
have an attenuated increase in antegrade and mean blood flow and shear rate responses 
to exercise. Specifically, HF patients showed an impaired increase in antegrade shear 
and a higher oscillatory shear index during exercise compared to controls (chapter 
4). Possibly, these less beneficial shear rate patterns during exercise, at least partly, 
contribute to the lack of vascular improvement after 12 weeks of exercise training in our 
patients. 
An alternative explanation for the lack of vascular improvement after exercise 
training is that HF patients may need a larger or stronger (shear) stimulus to induce 
vascular adaptation. Some evidence for this hypothesis, related to attenuated 
vascular responsiveness, is provided in previous work on ageing in animal and human 
studies. Tuttle et al. observed that older rats did not demonstrate an increase in 
arterial diameter in response to an increase in blood flow in contrast to younger rats 
that demonstrated a significant increase in arterial diameter.47 Subsequently, Sun 
et al. found that shear stress-induced release of nitric oxide, the most important 
vasodilator, was impaired in older rats compared to younger rats. This finding was 
related to decreased shear stress-induced activity of endothelial nitric oxide 
synthase, an increase in oxidative stress and lower anti-oxidant capacity.48 In a recent 
study in humans, it was found that endothelial function in young healthy subjects was 
deteriorated after 30-min exposure to an increased retrograde shear. Interestingly, 
such changes in endothelial function were not present in older subjects who were 
exposed to the same stimulus.49 In line with these observations, young subjects, 
but not older humans, demonstrate inward remodelling (i.e. decrease in artery 
diameter and flow-mediated dilation) of the brachial artery after 2 weeks of exposure 
to increases in retrograde shear rate (Thijssen et al., 2015, submitted). Altogether, 
these studies suggest that the endothelium of older subjects may be less responsive 
to changes in shear rate compared to younger subjects. Similarly, HF patients may 
also demonstrate an attenuated vascular responsiveness to stimuli for subsequent 
adaptation.
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Hypothesis 2: The optimal HIT-protocol – does one size fits all?
A second hypothesis for the lack a significant improvement and the lack of a difference 
between HIT and CT, relates to the HIT-protocol in our study (chapter 7). A recent 
meta-analysis of Ismail et al. demonstrated that exercise training at high-intensity 
induced the largest improvement in peak oxygen uptake in HF patients, compared 
to exercise at lower intensities (Figure 4).50 Moreover, in a recent meta-analysis of 
Haykowsky et al. a superior effect of vigorous to maximal aerobic interval training 
compared to moderate-intensity continuous training was demonstrated for improving 
fitness levels.51 Considering these studies and when looking at Figure 4, HIT seems 
a guarantee for success. However, among the studies implementing high-intensity 
exercise/HIT, various protocols have been used, with heterogeneous effect sizes.
In a recent review, Bucheit et al. compared constructing the optimal design of HIT with 
a ‘puzzle’.52 They identified nine variables which determine the design of a HIT-protocol: 
1-4. intensity and duration of work and relative resting periods, 5. work modality, 6-7. 
number of intervals and number of series, and 8-9. time and exercise intensity between 
series. All of these variables can affect the final training response in healthy subjects, 
and probably also in HF patients. Among HIT-studies there is a large variety in training 
protocol (e.g. duration/intensity of work/recovery ratio, and the parameter to quantify 
exercise intensity) and training response (i.e. small to large improvements). In Table 
1 we have provided an overview of training studies in HF patients including HIT. At 
least, Table 1 demonstrates the heterogeneity in protocols and effect sizes, which 
emphasise the difficulty at this stage to make strong and valid conclusions about the 
optimal HIT-protocol. Roughly, you can divide the HIT-studies in HF patients in those 
figure 4
Percentage of improvement in physical fitness (change in peak oxygen uptake(%)) after exercise training of 
different intensities in Hf patients. Vigorous intensity training is depicted with and without inclusion of the 
Hf-aCTIoN trial. adapted from Ismail et al. 2014.50
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with long high-intensity bouts (3-4min) and studies with short high-intensity bouts 
(30-90sec). Below we discuss the various factors that may contribute to the effect of 
HIT for these two training protocols separately.
Long high-intensity bouts. The most spectacular results have been obtained by Wisløff 
et al. in a study applying long high-intensity bouts (4 min), with active resting periods.18 
Table 1
Characteristics of the baseline characteristics, exercise programs and results of HIT-studies (≥80% of maximal work-
load, peak oxygen uptake or heart rate (reserve)) in Hf patients with reduced left ventricular ejection fraction. 
subjects characteristics Training program
 
study
 
N
Age 
(yrs)
Male 
(%)
Interval
(work/rest)
Intensity 
(%max)†
Willenheimer,54 2006
HIT 22 64 73 90sec/30sec 80/0
Control 27 64 70
Dimopoulos,55 2006
HIT 10 59 90 30sec/30sec 100-120/rest
CT 14 62 100 50-60
Wisløff,18 2007
HIT 9 77 78 4min/3 min 90-95/50-70
CT 8 74 78 70-75
Control 9 76 67
Roditis,56 2007
HIT 11 63 91 30sec/30sec 100-120/rest
CT 10 61 90 50-60
Iellamo,21 2013
HIT 8 63 100 4min/3min 75-80/45-50
CT 8 63 100 45-60
Fu,33 2013
HIT 14 68 64 3min/3min 80/40
CT 13 66 62 60
Control 13 68 69
Iellamo,20 2014
HIT 18 67 89 4min/3min 75-80/45-50
CT 18 68 83 45-60
Chrysohoou,57 2014
HIT 33 63 88 30sec/30sec 80-100/rest
Control 39 56 72
Koufaki,58 2014
HIT 8 60 88 30sec/60sec 100/20-30
CT 9 60 76 40-60
only studies that included a control group in the form of CT or no training were included in this table. studies that inves-
tigated a combination of training types (e.g. HIT and resistance training) were not included in this table. Physical fitness 
(measured as peak oxygen uptake) had to be an outcome parameter. †Exercise-intensity is expressed as percentage of 
maximal workload, maximal heart rate reserve or maximal oxygen uptake. ‡Drop-out rates were reported for the whole 
study and per training group when available.
Training program Results
Frequency 
(/week)
Length
(weeks)
Time at HIT 
(min)
Baseline 
VO2peak
Increase 
VO2peak (%)
Drop-out 
(%)‡
2
2-3 16 360-1620 17 5
16 -1
17
3 12 720 15 8
16 6
4
3 12 576 13 46 0
13 15 4
13 2 0
17
3 12 720 14 8
15 8
20
2-5 12 336-672 19 23 10
18 22 10
11
3 12 540 16 23 2
16 1 4
18 -8 4
8
3 12 576 15 19 3
16 16 6
0
3 12 743 16 24 0
17 6 0
48
3 24 713 15 16 24
18 7 24
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Table 1
Characteristics of the baseline characteristics, exercise programs and results of HIT-studies (≥80% of maximal work-
load, peak oxygen uptake or heart rate (reserve)) in Hf patients with reduced left ventricular ejection fraction. 
subjects characteristics Training program
 
study
 
N
Age 
(yrs)
Male 
(%)
Interval
(work/rest)
Intensity 
(%max)†
Willenheimer,54 2006
HIT 22 64 73 90sec/30sec 80/0
Control 27 64 70
Dimopoulos,55 2006
HIT 10 59 90 30sec/30sec 100-120/rest
CT 14 62 100 50-60
Wisløff,18 2007
HIT 9 77 78 4min/3 min 90-95/50-70
CT 8 74 78 70-75
Control 9 76 67
Roditis,56 2007
HIT 11 63 91 30sec/30sec 100-120/rest
CT 10 61 90 50-60
Iellamo,21 2013
HIT 8 63 100 4min/3min 75-80/45-50
CT 8 63 100 45-60
Fu,33 2013
HIT 14 68 64 3min/3min 80/40
CT 13 66 62 60
Control 13 68 69
Iellamo,20 2014
HIT 18 67 89 4min/3min 75-80/45-50
CT 18 68 83 45-60
Chrysohoou,57 2014
HIT 33 63 88 30sec/30sec 80-100/rest
Control 39 56 72
Koufaki,58 2014
HIT 8 60 88 30sec/60sec 100/20-30
CT 9 60 76 40-60
only studies that included a control group in the form of CT or no training were included in this table. studies that inves-
tigated a combination of training types (e.g. HIT and resistance training) were not included in this table. Physical fitness 
(measured as peak oxygen uptake) had to be an outcome parameter. †Exercise-intensity is expressed as percentage of 
maximal workload, maximal heart rate reserve or maximal oxygen uptake. ‡Drop-out rates were reported for the whole 
study and per training group when available.
They found a 46% improvement in physical fitness after HIT, and also a large difference 
between the results of CT (i.e. 15% improvement). Remarkably, the resting periods 
were performed at 50-70% of maximal heart rate, an intensity commonly used during 
endurance training. This indicates that this training program is highly demanding 
and performed at relatively high-intensity throughout the training session. Another 
training study with high-intensity bouts of 3 min, but with lower work and recovery 
Training program Results
Frequency 
(/week)
Length
(weeks)
Time at HIT 
(min)
Baseline 
VO2peak
Increase 
VO2peak (%)
Drop-out 
(%)‡
2
2-3 16 360-1620 17 5
16 -1
17
3 12 720 15 8
16 6
4
3 12 576 13 46 0
13 15 4
13 2 0
17
3 12 720 14 8
15 8
20
2-5 12 336-672 19 23 10
18 22 10
11
3 12 540 16 23 2
16 1 4
18 -8 4
8
3 12 576 15 19 3
16 16 6
0
3 12 743 16 24 0
17 6 0
48
3 24 713 15 16 24
18 7 24
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intensities, found large improvements in fitness and superiority of HIT as well.33 Two 
other studies with long high-intensity bouts (4 min), but with lower intensities for work 
and rest periods, also found significant improvement in fitness after training. However, 
these studies did not show superior effects compared to CT.20,21 Interestingly, these 
studies have focussed specifically on matching the total workload between both 
types of exercise,20,21 whereas not all studies that reported a superior effect of HIT 
compared to CT have done this. This suggests that the total workload may be a more 
important factor contributing to the effect size of exercise training than the type of 
exercise per se (interval versus continuous). Moreover, we must acknowledge that 
these HIT programs with long high-intensity bouts are highly demanding and probably 
not feasible for all HF patients. 
Short high-intensity bouts. Several studies have studied HIT with short (30-90sec) 
high-intensity bouts and often passive resting periods. Effect sizes varied from 5-24% 
improvement in peak oxygen uptake and, overall, demonstrate somewhat smaller 
effect sizes than protocols with longer high-intensity protocols. Interestingly, none of 
these studies that adopted short bouts of high-intensity demonstrated a superiority 
of HIT over CT. These protocols with shorter high-intensity bouts and passive resting 
periods might be more feasible for HF patients. In line with this thought, Meyer et 
al. performed some work in identifying the optimal HIT-protocol in HF patients. They 
varied the duration of the work period (30-90sec, 100% maximal workload) and the 
duration and intensity of the recovery periods (30-90sec, 0-50% maximal workload), 
whilst examining (maximal) exercise duration and how much time could be spend at 
high oxygen uptake. They concluded that in patients who are more severely affected, 
a HIT-protocol with passive rest periods enables them to spend more time at a higher 
percentage of peak oxygen uptake. Furthermore, patients who have better physical 
fitness, a HIT-protocol with active resting periods generates the largest time at high 
peak oxygen uptake.53 This suggests that the “optimal” HIT-protocol differs between 
HF patients and that a more individual approach may be necessary to achieve optimal 
results at an individual level. 
The total number of studies investigating HIT in HF and the total number of participants 
is small, which makes a definite statement regarding the optimal HIT-protocol to 
improve physical fitness and clinical outcomes in HF patients extremely difficult. 
However, based on our study and previous literature we suggest that total workload is 
an important, and possibly the most important, determinant for training effects. In line 
with this hypothesis, superiority of HIT compared to CT in improving physical fitness 
may, at least partly, be related to a higher total workload during HIT compared to CT. 
Importantly, HIT-protocols with substantial total workload may not be feasible for all 
HF patients. Therefore, the optimal HIT-protocol may therefore be different between 
individuals.
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Hypothesis 3: patient-related factors
In line with and elaborating on the discussion in the previous paragraph, we question 
whether there is an optimal training protocol and training dose for the general HF 
population. HF patients comprise a very heterogeneous patient group, due to frequent 
comorbidity, variable medication use, and the different etiologies and severities (NYHA 
class) of HF. All of these patient-related factors might influence training response. In 
healthy subjects and HF patients, responders and non-responders to exercise training 
have been described.59-61 Previous training studies have described the percentage 
of HF patients responding to exercise training with an improvement in fitness level 
between 50-60%.62,63 Below, we will discuss the potential impact of patient-related 
factors on the magnitude and direction of exercise-induced adaptations. 
Baseline levels. In the general population, baseline fitness levels do not have a large 
influence on training-response.59 When examining the overview of studies which have 
included HIT in HF patients (Table 1), the most promising results of HIT on physical 
figure 5
Correlation of baseline aerobic capacity (oxygen uptake at the ventilatory threshold related to predicted maxi-
mum oxygen uptake) and training-induced improvement in oxygen uptake at the ventilatory threshold. source: 
Meyer et al.64
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fitness have been reported in relatively severely affected HF patients with low 
baseline fitness levels.18 This raises the question whether in HF patients, training 
results are larger in patients with relatively more to gain. Meyer et al. has examined 
training-induced improvement in oxygen uptake at the ventilatory threshold (e.g. 
a parameter correlated with peak oxygen uptake) in HF patients after 3 weeks of 
exercise training. They observed a significant inverse correlation between baseline 
fitness levels and improvement in oxygen uptake at the ventilatory threshold (Figure 
5), whilst no correlation was present between central hemodynamics (e.g. ejection 
fraction and cardiac index) and training-induced improvements.64 Moreover, Kemps 
et al. confirmed that baseline peak oxygen uptake is an important predictor for the 
training-induced changes in peak oxygen uptake after a 12-week training program 
in HF patients.63 In our training study (chapter 7) we have included subjects with 
relatively high baseline fitness levels when compared to other studies from Table 1. 
This might have contributed to lower training-induced adaptations. 
Green et al. have identified baseline FMD as important determinant of exercise-
induced changes in healthy subjects and various patient groups, in which a higher 
baseline FMD is associated with smaller exercise-induced improvements.65,66 They 
relate the lack of training response in FMD to the distinct time course of structural 
and functional vascular adaptations to exercise training and/or specifics of the 
exercise training program (e.g. duration), although do not explain the significant effect 
of higher baseline FMD to the lack of response. However, the relatively high baseline 
levels of FMD in our subjects, possibly due to optimal pharmacological treatment,67 
might relate to the lack of significant changes we have observed. As baseline FMD was 
similar between groups, this can explain our similar findings for HIT and CT. 
To further support the hypothesis that higher pre-training levels are related to modest 
or absent effect sizes in exercise-induced improvements, we examined whether 
baseline quality of life levels influenced exercise-induced changes. In chapter 7 we 
demonstrated that a higher baseline quality of life indeed seems to attenuate training-
induced improvements. In conclusion, in parameters of physical fitness, vascular 
function and quality of life, higher baseline levels may contribute to the relatively lower 
exercise-induced improvements and this may (in part) explain our findings in chapter 7.
Patient and clinical characteristics. Age and sex are of minor importance in influencing 
the differential effects of exercise on physical fitness in healthy subjects.59,68,69 When 
comparing studies from Table 1, we observed that the largest results of HIT on fitness 
levels in HF patients is obtained in relatively old mainly male HF patients (77yr). 
Schmid et al. have examined the training-response after 3 months of training in 120 HF 
patients and evaluated the factors predicting this response.62 For this purpose they 
have divided the subjects in two groups; responders (e.g. ≥5% increase in peak oxygen 
consumption, ≥10% increase in peak workload or ≥5% decrease in VE/VCO2 slope) and 
non-responders. Interestingly, age and sex were not different between responders 
and non-responders. This is confirmed by Kemps et al, who found that age and sex 
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did not influence training-response in fitness in HF patients after a 12-week training 
program.63 In HF patients, one previous study associated female sex with low- or 
non-response in physical fitness to exercise training.61 Sandri et al. investigated the 
effect of age on training-induced improvements in diastolic function in HF patients, 
and concluded similar training effects for younger and older HF patients.70 However, it 
has been previously demonstrated that older HF patients (>60yr) show less training-
induced improvement in quality of life compared to younger HF patients (<60 yr).57 
Therefore, we believe that sex and age do not importantly influence training-induced 
changes in fitness and cardiovascular function in HF patients, but possibly did 
influence the exercise-induced change in quality of life in our subjects of which 70% 
was older than 60. 
The previously mentioned study of Schmid et al. did not find a significant difference 
between NYHA class, LVEF, and etiology of HF between responders and non-
responders to exercise training.62 This was confirmed by the study of Kemps et al.63 In 
contrast, a recent study examining out-patient rehabilitation (24-months) suggested 
that patients with an ischemic etiology have less cardiac remodelling during cardiac 
rehabilitation compared to patients with a non-ischemic etiology, but only during the 
first 3 months.71 We included a relatively large proportion of subjects with an ischemic 
etiology of HF (i.e. 75%), which may (partly) contribute to the lack of change in resting 
cardiac function after training. Previously, parameters of chronotropic incompetence 
(i.e. impaired heart rate response to exercise) were associated with lower training-
induced adaptations in HF patients after a 3-month rehabilitation program.62 This 
may relate to that the ability to increase cardiac output significantly during exercise 
is necessary to induce adaptation. In our subjects, the presence of chronotropic 
incompetence was high (i.e. 68%), and this may have attenuated training-induced 
adaptations in fitness levels.
Comorbidity. In training studies in HF patients, patients with comorbidities are often 
excluded from participation. Therefore, the influence of various concomitant diseases 
on training efficacy in HF patients is difficult to assess. Previously, HF patients with 
atrial fibrillation were associated with lower training-induced adaptations in fitness.60 
We included only one subject with atrial fibrillation and therefore the potential 
effect of atrial fibrillation on the outcomes of our study is small. The HF-ACTION 
trial demonstrated that HF patients who also have COPD benefit equally from an 
exercise training program compared to HF patients without concomitant COPD.72 To 
our knowledge, information on other comorbidities and training-response is lacking. 
In conclusion, besides training-related factors also patient-related factors can play 
a role in the magnitude of exercise-induced adaptations. From our data and previous 
literature, we deduct that patients with lower baseline levels of fitness, vascular 
function and quality of life may benefit more from exercise training. In addition, 
few factors can be identified to importantly influence training response. However, 
chronotropic incompetence seems to be an important determinant attenuating 
400341-L-bw-Benda
Chapter 8
144
improvements in fitness. Whilst the effect of comorbidities is largely unknown, this 
represents a clinically relevant issue due to the high prevalence of comorbidity in 
HF patients. Future studies should therefore assess whether and how comorbidities 
influence training-response to be able to accurately predict training-response in 
HF patients. Moreover, future studies should also assess which factors influence 
figure 6
Implementation of exercise training programs for Hf patients in general cardiac centres and rehabilitation cen-
tres. a) Number of centres. B) Number of patients. adapted from Piepoli et al. 2015.73
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parameters other than fitness, such as quality of life and measures of cardiovascular 
function.
Referral and adherence
Even though regular exercise is proven beneficial for HF patients and is recommended 
in most recent European and American guidelines for the treatment of HF,9,10 the 
implementation and referral of HF patients to a regular training program is still 
not common practice. A recently published large survey in 41 European countries 
indicated that 39% of the general or specialized centres, accounting for 47% of the 
HF patients, did not implement an exercise training program for HF patients in their 
health care setting (Figure 6).73 
The main reason why an exercise program for HF patients was not implemented 
related to the lack of resources and, surprisingly, the lack of evidence of safety and 
efficacy of such a program as (incorrectly) assumed by the treating physician. This 
is remarkable since we and others have demonstrated that exercise training induces 
various beneficial adaptations in HF patients, including improvement in (parameters 
of) physical fitness, cardiovascular function, quality of life and prognosis.74-76 
Moreover, the safety of traditional endurance training is well-established. Although 
the safety of HIT is not thoroughly investigated, we and others did not find evidence for 
a larger risk for HF patients when performing HIT compared to CT. Apparently, there is 
a lot to gain in educating health care professionals regarding the benefits and risks of 
exercise training in HF patients.  
Moreover, when a structural exercise training program was available in a healthcare 
setting, cardiac patients were not always referred to training. In the Western world, 
referral rates for cardiac rehabilitation of around 50% are usually reported.73,77 Several 
in- and exclusion criteria in patient-referral to training were applied, rendering in low 
referral rates for HF patients with lower left ventricular ejection fraction, higher NYHA 
class and lower fitness levels. This is unfortunate, since previous literature indicates 
that these patients will benefit from exercise training,73,78 with some suggestions that 
those starting at a lower level of physical fitness may benefit even more.18,63,64 This 
means that HF patients who have the largest need for exercise training and possibly 
have the most to gain, are now often denied a potentially highly effective exercise 
training.
When an exercise training program is available and patients are referred to it, the next 
problem arises; adherence. In exercise training studies in HF patients drop-out rates 
can be high, with some reporting drop-out rates of 48% (Table 1). In the HF-ACTION trial, 
a training study in HF patients which has put a lot of effort into (increasing) exercise 
adherence, the adherence to the exercise prescription was 40-60% after 1-3 years of 
follow up.79 We consider long-term adherence more important than prescribing the 
type of exercise training that yields the largest (short-term) improvements in fitness. 
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Therefore, it is important to evaluate what factors limit adherence. Barbour et al. 
have investigated the most important factors limiting adherence in HF patients; lack 
of motivation, lack of energy or time, financial or medical concerns, the presence 
of physical symptoms, and (psychological) comorbidity.80 Moreover, older subjects, 
women, patients with a longer duration of HF, and subjects with lower socioeconomic 
status are more prone to non-compliance to cardiac rehabilitation.80 Whilst some of 
these factors are fixed and cannot be influenced, other factors may be addressed by 
adapting the current training programs. 
We propose that a possible manner to increase adherence to exercise is to make 
exercise more time-efficient and fun. HIT has been suggested to be time-efficient,81 
but also as more enjoyable.25,82 Surprisingly, in healthy subjects higher exercise 
intensity is associated with lower adherence to exercise prescription.83 However, a 
recent study in cardiac patients suggested better adherence after HIT.84 Moholdt et 
al. performed a long-term follow-up of patients with a myocardial infarction after 
cardiac rehabilitation with HIT or CT, and found that the subjects in the HIT-group 
demonstrated a higher physical fitness up until 30 months of follow-up (Figure 7).84 
Moholdt and coworkers explain these higher values during follow-up by a larger initial 
increase after exercise training and better adherence to post-rehabilitation exercise 
figure 7
Physical fitness after 12 weeks of cardiac rehabilitation (i.e. ‘post-training’) and during long term follow-up at 
6 and 30 months. In the usual care group the cardiac rehabilitation consisted of 60 min of moderate-intensity 
exercise 2/week. source: Moholdt et al. 2011.84
Aerobic interval training
Usual care group exercise
25
Baseline
Post training At 6 months
At 30 months
30
35
40
VO
2p
ea
k 
(m
L.
kg
-1
. m
in
-1
)
400341-L-bw-Benda
General discussion
147
8
training, resulting in a lower decline. After 30 months of follow-up, 82% of the subjects 
in the HIT-group performed exercise≥2 per week, in contrast to 58% in the CT-group. 
Although speculative, HIT might be more fun and therefore stimulates patients to 
continue with exercise after the cardiac rehabilitation program. Whilst short- and 
long-term adherence were not specifically addressed in this manuscript, this is an 
interesting concept worth exploring.
IMPlICaTIoNs of THE sTUDIEs aND fUTURE DIRECTIoNs 
The studies in this thesis deal mainly with various exercise interventions in patients 
with HF and (concurrent) effects on physical fitness and cardiovascular function. 
From this manuscript we can conclude that HIT and (prolonged) endurance exercise 
can be safely performed by cardiac patients, without evidence for significant cardiac 
cell damage or significant decrease in cardiac function (larger than that observed 
in healthy controls). This is relevant, especially since there is still hesitation of 
prescribing exercise training in HF patients, whether this relates to traditional or more 
novel forms of exercise.
We have shown that exercise-induced shear rate shows a less beneficial pattern in 
HF patients compared to controls. However, whether this influences the vascular 
adaptations to long-term exercise training and whether this differs between different 
types of training, should be assessed in future research. Possibly, identifying exercise 
protocols which elicit optimal shear rate responses in HF patients can help in optimizing 
training protocols for these patients. Also, other possibilities of influencing shear rate 
during exercise could be explored. Moreover, a recent study has examined whether 
exposure to antegrade shear rate (through heating) prior to handgrip exercise affects 
the exercise-induced blood flow response in the brachial artery in healthy men.85 
They found that exposure to antegrade shear prior to exercise increases exercise-
induced brachial artery vasodilation and induces a faster response in forearm blood 
flow, compared to control exercise without prior exposure to increased antegrade 
shear rate. Whether this effect is present in HF patients as well, and whether this 
can contribute to normalization of shear rate patterns, and hereby optimize exercise-
induced improvement in vascular function, is subject for future research.
We found that traditional exercise training and HIT lead to improvement in measures 
of physical fitness. However, we cannot confirm a superior effect of HIT compared 
to endurance training. Moreover we question whether such large workloads are 
possible in the general HF population. Therefore, we suggest that there is no such 
thing as the optimal training protocol in general, but programs should be optimized 
according to the individual characteristics of the patients. In the future, large (multi-
centre) studies should be performed to address the effect of different HIT-protocols 
in a large group of heterogeneous HF patients. This study should focus on 1). safety 
aspects to further establish the safety of HIT, 2). feasibility of various HIT-protocols in 
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a large heterogeneous group of HF patients, 3). effect size of different HIT-protocols, 
4). explore HIT-protocols which are significantly more time-efficient compared to 
traditional training, and 5). assess the role of HIT in increasing long-term adherence.
A second, possibly important exercise modality to further explore in HF patients is 
walking. The beneficial effects of walking are well-known and include an increase in 
physical fitness.86,87 In this thesis we have shown that for (well-trained) cardiac patients 
with history of diminished left ventricle ejection fraction, walking is feasible and does 
not lead to a significant impairment in cardiac function. We suggest that walking can 
be an exercise modality for HF patients which is effective and safe, but also low-cost, 
simple, feasible, and practical. Therefore, we propose that more emphasize is placed 
on engaging cardiac patients into walking exercise.  
Although many studies focus on how to gain the largest benefits of exercise training in 
HF patients, recent studies indicating poor referral to cardiac rehabilitation suggest 
that most benefits may be achieved by improving implementation and referral of HF 
patients to cardiac rehabilitation. Education of both health care professionals and 
patients seems important and future studies on the safety and efficacy of various 
forms of (high-intensity) exercise in HF patients can contribute to this.
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sUMMaRY
In chapter 1 we introduce the definition and symptoms of heart failure (HF), among which 
the pathophysiology of the characteristic exercise intolerance in HF. Furthermore, the 
incidence, prognosis and prognostic factors of HF are described. Subsequently, the 
role of exercise training in HF patients is addressed. Finally, we describe some of the 
current questions regarding acute and long-term effects of exercise in HF patients 
and introduce how this manuscript aims to answer these questions.
Obesity is a well-established cardiovascular risk factor and, in healthy subjects, 
is related to the development of impairment in vascular function and structure. 
In chapter 2 we investigated whether the effects of obesity on vascular function 
and structure are different between lean, overweight and obese HF patients. We 
concluded that the presence of obesity in HF patients is not related to a significant 
further impairment of vascular function or structure. This suggests that the relation 
between vascular function and structure and obesity may not be consistent across 
various (clinical) populations. 
In this manuscript we have investigated the acute effects of exercise in HF patients 
and healthy controls to various types of exercise; high-intensity interval training 
(HIT), continuous training (CT) and prolonged endurance exercise. First, in chapter 3, 
we compared thermoregulatory responses to continuous moderate-intensity cycle 
exercise between HF patients and healthy controls. We have demonstrated that HF 
patients have a comparable increase in core body temperature, but an attenuated 
increase in skin temperature during exercise compared to healthy controls. We 
conclude that, despite the impaired thermoregulatory responses to exercise, HF 
patients were well capable of performing continuous moderate-intensity exercise and 
showed no severe hyperthermia. 
In chapter 4 we have examined the direct effects of continuous moderate-intensity 
cycle exercise on brachial artery shear rate, an important stimulus for beneficial 
exercise-induced adaptations. Under normal conditions, healthy subjects 
demonstrate an increase in antegrade and retrograde shear rate during exercise, whilst 
continuing exercise causes antegrade shear to increase further and retrograde shear 
to normalize. In chapter 4, we found significant differences in exercise-induced shear 
rate patterns between HF patients and controls. Patients with HF were characterized 
by an attenuated increase in mean and antegrade shear rate compared to controls 
and demonstrated persistently increased retrograde shear rate during exercise. This 
indicates that, during exercise, HF patients are exposed to a less favourable shear rate 
pattern compared to healthy controls. These findings may help to better understand 
the impact of exercise training on the vasculature in HF patients. 
In chapter 5 we examined the impact of a single bout of HIT and CT on the release 
of cardiac biomarkers for cardiac cell damage (troponin) and cardiac stretch (B-type 
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natriuretic peptide (BNP)). Whilst HF patients show a larger increase in BNP, but 
not troponin, after exercise compared to controls, there was no difference in the 
exercise-induced changes in BNP and troponin between HIT or CT. This data adds to 
the discussion regarding the safety of HIT in HF patients.
Due to the importance of exercise in cardiac rehabilitation and the general 
recommendations of an active lifestyle, cardiac patients increasingly participate in 
exercise events, such as walking marches. However, prolonged exercise in cardiac 
patients is not widely recommended as little is known about the potential impact of 
this type of exercise on the cardiovascular system. In chapter 6 we investigate the 
effect of one day and three days of prolonged walking exercise on cardiac function 
in cardiac patients with a history of left ventricular impairment and healthy controls. 
Although we found cardiac troponin (a marker of cardiac cell damage) to increase, 
we found no evidence for significant cardiac impairment after repeated prolonged 
walking exercise. Moreover, we found no differences between the exercise-induced 
change in cardiac function between cardiac patients and healthy controls. 
The long-term effects of exercise in HF patients are addressed in chapter 7. In this 
chapter we present the results of a 12-week exercise training study, and compared the 
effects between a HIT-protocol and a traditional CT-protocol. We have demonstrated 
that both types of training induce significant improvements in measures of physical 
fitness, but do not induce changes in cardiovascular function and structure at rest or 
quality of life. Whilst this study partly reinforces the positive effect of exercise in HF, 
it does not support superiority of HIT over CT.
Chapter 8 summarizes and discusses the results of the studies presented in this 
manuscript. We place our data in the broader perspective of earlier studies that have 
investigated exercise training in HF patients and the mechanisms of exercise-induced 
improvements. We will shortly address the importance of exercise implementation 
and adherence, and give directions for future research.
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In hoofdstuk 1 beschrijven we de definitie en symptomen van hartfalen (HF) en tevens 
de pathofysiologie van de karakteristieke inspanningsintolerantie die patiënten met HF 
ervaren. Verder bespreken we de incidentie, prognose, prognostische factoren en de rol 
van inspanningstraining bij deze patiënten. Tenslotte worden de huidige vragen omtrent 
de directe en langetermijneffecten van inspanning bij patiënten met HF uiteengezet en 
bespreken we hoe dit proefschrift bijdraagt aan het beantwoorden van die vragen.
Obesitas is een belangrijke risicofactor voor het ontstaan van cardiovasculaire 
aandoeningen en is in eerder onderzoek onder de algemene (gezonde) bevolking 
gerelateerd aan een verslechtering van de functie en structuur van de bloedvaten. In 
hoofdstuk 2 onderzoeken we of de vaatfunctie en -structuur verschillend zijn tussen 
slanke patiënten met HF, HF-patiënten met overgewicht en HF-patiënten met obesitas. 
Onze resultaten wijzen erop dat bij patiënten met HF de aanwezigheid van obesitas 
niet geassocieerd is met een verdere verslechtering van de structuur en functie van de 
bloedvaten. Dit suggereert dat de relatie tussen vaatfunctie en –structuur en obesitas 
mogelijk niet consistent is voor verschillende (klinische) populaties. 
In dit proefschrift beschrijven we de directe effecten van verschillende typen inspanning 
bij patiënten met HF en gezonde controlepersonen. In hoofdstuk 3 onderzoeken we 
de temperatuurresponsen op een continue matig-intensieve fietsinspanning. Wij 
hebben aangetoond dat patiënten met HF tijdens de fietsinspanning een vergelijkbare 
stijging hebben van hun kerntemperatuur maar een verminderde stijging van hun 
huidtemperatuur ten opzichte van controlepersonen. We concluderen dat patiënten 
met HF, ondanks de verschillende temperatuurresponsen, goed in staat zijn om een 
inspanning op matige intensiteit te verrichten, zonder daarbij een overmatige stijging 
van hun kerntemperatuur (hyperthermie) te ontwikkelen. 
Gezonde personen demonstreren tijdens een fietsinspanning normaliter initieel 
een toename in de voorwaartse en terugwaartse bloeddoorstroming van de 
arteria brachialis. Bij het continueren van inspanning neemt de voorwaartse 
bloeddoorstroming verder toe terwijl de terugwaartse bloeddoorstroming 
normaliseert. De voorwaartse bloeddoorstroming is een belangrijke stimulus 
voor positieve inspanningsgeïnduceerde vaatadaptaties. In hoofdstuk 4 hebben 
we de directe effecten van een continue matig-intensieve fietsinspanning op de 
bloeddoorstroming van de arteria brachialis onderzocht bij patiënten met HF en 
gezonde controlepersonen. Wij hebben aangetoond dat patiënten met HF een 
verminderde toename in de gemiddelde en voorwaartse bloeddoorstroming hebben 
vergeleken met controlepersonen. Tevens lieten de HF-patiënten een aanhoudende 
toegenomen terugwaartse bloeddoorstroming zien. Dit suggereert dat patiënten met 
HF tijdens inspanning een minder gunstig bloeddoorstromingspatroon hebben dan 
gezonde personen. Deze kennis kan ons helpen om de effecten van inspanningstraining 
op de bloedvaten bij patiënten met HF beter te begrijpen. 
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In hoofdstuk 5 onderzochten we de effecten van één enkele hoog-intensieve 
intervaltrainingssessie en één enkele continue trainingssessie op het vrijkomen van 
biomarkers die kenmerkend zijn voor celschade (troponine) en rek (B-type natriuretisch 
peptide (BNP)) van het hart. Patiënten met HF lieten na inspanning een grotere stijging 
zien in BNP, maar niet in troponine, vergeleken met controlepersonen. Er was geen 
verschil tussen de inspanningsgeïnduceerde verandering in biomarkers tussen de 
intervaltraining en de continue training. Deze gegevens kunnen van belang zijn bij de 
discussie over de veiligheid van hoog-intensieve intervaltraining bij patiënten met HF.
Vanwege de belangrijke rol van inspanning bij hartrevalidatie en de algemene 
aanbevelingen van een actieve levensstijl, nemen steeds meer hartpatiënten deel 
aan sportevenementen zoals loopmarsen. Dit soort duurinspanning van meerdere 
uren achtereen is geen vaste aanbeveling voor hartpatiënten omdat nog grotendeels 
onbekend is wat de effecten van dit soort inspanning zijn op het cardiovasculaire 
stelsel. In hoofdstuk 6 hebben we de effecten van een wandelinspanning van meerdere 
uren, op één dag en op drie achtereenvolgende dagen, op de hartfunctie onderzocht 
bij hartpatiënten met een voorgeschiedenis van een verminderde pompfunctie van het 
hart en gezonde controlepersonen. Ondanks een toename in troponine-concentratie, 
vonden we geen significante achteruitgang in hartfunctie na herhaalde langdurige 
wandelinspanning. Ook vonden we geen verschillen in de inspanningsgeïnduceerde 
veranderingen in hartfunctie tussen hartpatiënten en gezonde controlepersonen. 
De langetermijneffecten van inspanning bij patiënten met HF worden besproken in 
hoofdstuk 7. In dit hoofdstuk presenteren wij de resultaten van een trainingsstudie 
van twaalf weken waarbij we de effecten hebben vergeleken van hoog-intensieve 
intervaltraining en traditionele continue training. Na beide typen training waren 
er verbeteringen in verschillende parameters van fitheid, maar geen significante 
veranderingen in cardiovasculaire functiematen in rust of kwaliteit van leven. Ondanks 
de ondersteunende waarde van dit onderzoek met betrekking tot de positieve 
effecten van inspanning bij patiënten met HF, hebben wij geen bewijs gevonden voor 
een superieur effect van hoog-intensieve intervaltraining vergeleken met traditionele 
continue training. 
In hoofdstuk 8 vatten we de resultaten van de onderzoeken in dit proefschrift samen 
en bediscussiëren we deze resultaten door ze te vergelijken met eerdere studies op 
het gebied van inspanningstraining bij patiënten met HF en studies met betrekking tot 
de mechanismen van de positieve effecten van inspanning. We bespreken het belang 
van een goede implementatie van inspanningstraining bij patiënten met HF en een 
goede opvolging van de trainingsadviezen. Tevens doen we een aantal suggesties voor 
toekomstig onderzoek.
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In juni 2011 ging ik van start met mijn promotietraject, nog grotendeels onwetend over 
wat me precies te wachten stond. Nu, vier jaar later, kan ik zeggen dat dit traject een 
bijzondere periode in mijn leven is geweest, waar ik met plezier én trots op terugkijk. 
Verschillende mensen hebben mij begeleid, gemotiveerd en geholpen, en in dit 
dankwoord wil ik hen graag bedanken. 
Natuurlijk in de eerste plaats, Maria. Jij hebt mij jaren geleden de kans geboden om mee 
te doen aan een wedstrijd om mijn eigen beurs te winnen. Mede dankzij jou heb ik toen 
geleerd hoe ik een project én mezelf moest presenteren; een waardevolle vaardigheid. 
Mede door jouw tomeloze energie, enthousiasme, creativiteit en positieve instelling 
hebben we uiteindelijk voor alle ‘uitdagingen’ in mijn promotietraject een passende 
oplossing gevonden en ligt er nu een mooi proefschrift klaar. De afdeling Fysiologie is 
een ontzettend leuke afdeling om te mogen werken. Jouw gevoel voor humor draagt 
ook zeker bij aan de goede sfeer op de afdeling. Bijvoorbeeld hoe jij ons verplichtte om 
de trap te nemen in plaats van de lift, op straffe van trakteren wanneer we toch de lift 
namen. Hoewel dit bij nader inzien misschien geen grap was, maar bittere ernst. Ik 
vrees dat ik je in dat geval nog een aantal traktaties verschuldigd ben. Maria, dank je 
wel voor het vertrouwen dat je me hebt gegeven.
Dick, als promotor speelde jij een belangrijke rol in mijn traject. Ik heb het voor 
een groot deel aan jou te danken dat ik mijn eindsprint heb gehaald en ik binnen de 
termijn van vier jaar mijn proefschrift heb kunnen afronden. Jouw nakijktijden zijn 
ongeëvenaard. Overigens kan ook niemand het tempo aan waarop jij van de ene naar 
de andere afdeling in het Radboud ‘rent’. Menigmaal heb ik overwogen om naast je te 
gaan joggen om je bij te kunnen houden. Verder vind ik het bewonderenswaardig hoe jij 
je werk hier en in Liverpool combineert met een gezinsleven. Dick, bedankt voor alles 
wat je me hebt geleerd de afgelopen vier jaar!       
Arie, jij bent als copromotor betrokken geweest bij mijn proefschrift. Soms zal ik je 
gek hebben gemaakt met mijn vragen over vreemde hartfilmpjes en hartgeruisen die 
ik tegenkwam. Menigmaal heb je me echter gerustgesteld met goede uitleg. Ik ben me 
ervan bewust dat de onderzoekstijd die jij hebt, direct uit je vrije tijd komt. Dit maakt 
het extra bijzonder dat je betrokken bent geweest bij mijn project. Arie, bedankt voor 
je tijd, geduld en expertise.  
Louise, als hartfalencardioloog werd ook jij een vraagbaak voor mij. Altijd was je 
geïnteresseerd in de voortgang van mijn traject en gaf je me feedback op mijn stukken. 
Ondanks je drukke programma, ben je altijd bereid geweest om mij te helpen en dat 
waardeer ik enorm. 
Beste René, hartelijk dank voor de prettige samenwerking en het bieden van de leuke 
werkomgeving van de afdeling Fysiologie!
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Lisette en Kim, jullie hebben mij bijgestaan met het rekruteren van patiënten. Ik moet 
zeggen dat ik onder de indruk ben van jullie kennis over en contact met de patiënten. 
Dat getuigt naar mijn idee van een enorm hart voor de patiëntenzorg. Bedankt voor 
jullie hulp!  
Shanna, Rosa, Sigrid, Djerr, Caroline en nog meer collega’s van jullie. Dankzij jullie 
zijn alle deelnemers uit de trainingsstudie zo netjes getraind. Het was niet altijd 
gemakkelijk om deze trainingen in jullie drukke schema’s in te passen en mede daarom 
waardeer ik jullie bijdrage zeer. 
Ook wil ik alle mensen die hebben deelgenomen aan de onderzoeken ontzettend 
bedanken. Zonder jullie was er überhaupt geen proefschrift geweest. Ik vind het 
fantastisch dat sommigen van jullie zelfs aan meerdere van mijn onderzoeken mee 
hebben gedaan. Dank daarvoor!
Bregina, naast een lieve en enthousiaste collega, ben jij ook de kunstenares die de 
mooie voorkant van dit proefschrift heeft ontworpen. Jouw positieve, drukke en 
enigszins luidruchtige aanwezigheid op de afdeling bezorgde mij regelmatig een 
glimlach. Bedankt voor de leuke samenwerking!
Jos, dankzij jouw expertise op het gebied van fietstesten, kon ik hierbij veel uit handen 
geven. Het feit dat jij dan al op maandag “fijn weekend!” tegen me zei, vergeef ik je dan 
ook maar. Jos, bedankt! 
Douwe en Annemarie, bedankt voor jullie hulp bij de vaatmetingen!
Beste Jacqueline, bedankt dat je de afgelopen 4 jaar mijn mentor bent geweest.
Marc, bedankt voor je hulp bij mijn project.
Dan mijn lieve collega’s, bij wie ik altijd terecht kon voor advies, gezelligheid en 
sportiviteit (Radboud Sports, Carréloop). Martijn, als ik weer eens op het punt 
stond mijn computer uit het raam te gooien, dan kon ik altijd bij jou terecht voor de 
benodigde ICT-kennis om dit te voorkomen. Dank je wel! Rebecca, aan jou heb ik 
veel te danken: vele lachbuien, Deutsche Donnerstag, filmpjes van katten, maar 
ook goede werkadviezen. Dank je wel voor de leuke tijd en je goede advies! Tim, om 
jou heb ik ontelbare keren moeten schaterlachen! Dank je wel daarvoor. Leonie en 
Joost, wat hadden we een leuke kamer met z’n drietjes! Dank jullie wel voor alle 
gezelligheid en jullie humor. Joost, bedankt ook nog voor de fijne samenwerking op het 
hartfalenproject. Thalijn, jij maakte onze ‘dokterkamer’ compleet en meteen ook heel 
vol met al je tassen en spulletjes. Dank je wel voor de gezelligheid en je steun! Coen, 
dank je wel voor balie-Bongers en veel succes met voetballen. Silvie, bedankt voor 
je gezelligheid en mode-advies en heel veel succes met je project! Femke, je bracht 
altijd veel gezelligheid met je mee. Ik wens je heel veel succes met je nieuwe werk. 
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Matthijs, ook jij bent ondertussen al aan een nieuwe baan begonnen. Toch hoop ik dat 
je ook snel je proefschrift kan afmaken! Thijs, dank je wel voor de drukke en gezellige 
Vierdaagseweken. Anke, veel succes met je project en je nieuwe huisje in Den Bosch! 
Dominique, succes met je onderzoeken en sterkte met je pepermuntverslaving. 
Milène, bedankt voor je altijd nuchtere advies. Ellen, heel veel succes met de laatste 
loodjes! Joost H. bedankt voor je oprechte interesse. Ook de andere collega’s uit 
de toren, bedankt voor de leuke afdelingsuitjes, BBQ’s, et cetera. Voor mijn nieuwe 
collega’s Hugo, Vincent, Yvonne en Ingrid: heel veel succes met jullie trajecten! Ook 
mijn oude collega’s Fleur, Ralph, Jean, Madelijn, Linda, Elvira, Jan, Kjille, Michiel, 
Maurits, Heleen, Piet en Gerwen, dank jullie wel voor jullie hulp, advies en de gezellige 
pauzes.  
Robert, Lando, Berwout, Hai, Guus, Job, Dirk, Janwillem, Annerie, Kim, Margreet, 
Florien, Yvette, en Daisy, wat heb ik veel geluk gehad met jullie! Vele metingen en 
analyses zijn mogelijk geweest dankzij jullie hulp. Ook maakten jullie de afdeling nóg 
wat gezelliger. Veel succes met jullie toekomstige carrières.
Sjoerd, Jorik, Tessel, Saskia, Lotte, Jan en Sanaz, gedurende 1,5 jaar zat ik met jullie in 
de NCEBP PhD Council. We organiseerden leuke workshops en evenementen voor onze 
mede-PhD-studenten, maar daarnaast zagen we elkaar soms ook voor een borrel, 
pubquiz of etentje. Bedankt voor de leuke en leerzame tijd! 
Dan mijn lieve paranimfen. Mandy, we kennen elkaar al zo lang! Daarom vind ik het 
extra bijzonder dat je hier nu als paranimf naast me staat. Dank je wel dat je altijd 
aan mijn kant staat. Renée, jij hebt altijd goede adviezen en gelooft altijd dat ik alles 
kan, ook al denk ik zelf soms van niet. Een perfecte paranimf dus. Bedankt voor je 
vertrouwen, relativeringsvermogen en gezelligheid.
Mijn oude klasgenootjes Inge, Krista, Marieke, Tom, Mark, Jop, Frank, Bart, Jeroen, 
Theo, Joris, Nathalie en Lonneke, bedankt voor de leuke spelletjesavonden met 
ingewikkelde bordspelen, het midgetgolfen en het jaarlijkse ‘Sinterkerst’. Ook (de rest 
van) ons meidengroepje, Inge, Inge, Mariska en Stijntje, en uiteraard jullie mannen, 
dank jullie wel voor de steun, positieve instelling en gezellige weekendjes weg. 
Jennifer, Ellen, Bibi, Carolien en Lizanne, bedankt voor jullie vriendschap.
Sas en Stan, dank je wel voor de leuke tijd die we samen doorbrengen. Ik bewonder jullie 
om hoe jullie de moeilijke tijd rondom de geboorte van Jasper hebben doorstaan. Jasper 
is een fantastisch ventje en zal vast een goede broer worden voor zijn kleine zusje, Anne. 
Oma, in veel dingen ben je een voorbeeld voor mij. Ik hoop dat we nog lang samen leuke 
dingen kunnen doen.
Ook mijn schoonfamilie moet ik hartelijk bedanken voor de steun en gezelligheid de 
afgelopen jaren.
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Dankwoord
Pap en mam, jullie moet ik niet alleen voor de afgelopen vier jaar bedanken, maar 
natuurlijk voor veel langer. Mede dankzij jullie opvoeding, waarin jullie mij hebben 
geleerd dat het belangrijk is je best te doen, behulpzaam en vriendelijk te zijn en hard 
te werken, heb ik dit proefschrift kunnen schrijven. Zonder jullie steun en opvoeding 
was dit me niet gelukt. 
Lieve Peter, je bent zo belangrijk voor mij, dat ik gewoon niet weet waar ik moet 
beginnen om je te bedanken. Jij bent echt mijn steun en toeverlaat, waar ik altijd 
bij terecht kan. Ook doen we samen veel leuke dingen, zoals de mooie reizen die we 
samen hebben gemaakt. Als ik daar aan terugdenk, ben ik blij dat de wereld zo groot 
is. Samen met jou, wil ik er zoveel mogelijk van zien. 
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CURRICUlUM VITaE
Nathalie Benda werd op 24 augustus 1984 geboren te Wijchen. In 2002 behaalde ze 
haar VWO-diploma aan het Maaswaal College in Wijchen. Tussen 2002 en 2008 doorliep 
ze de opleiding Geneeskunde aan de Radboud Universiteit Nijmegen. In september 
2009 begon ze aan de masteropleiding Clinical Human Movement Sciences, ook aan 
de Radboud Universiteit Nijmegen. Begin 2011 sloot ze deze opleiding cum laude af. In 
de laatste periode van deze opleiding liep ze stage op de afdeling Fysiologie van het 
Radboudumc waar ze onderzoek deed naar de vaatfunctie bij patiënten met klachten 
aan arm, nek en schouder (KANS, voorheen RSI). Deze stage werd begeleid door prof. 
dr. Maria Hopman, prof. dr. Dick Thijssen en dr. Jaap Brunnekreef en heeft geresulteerd 
in een wetenschappelijke publicatie waarop Nathalie (gedeeld) eerste auteur is. 
Ondertussen heeft Nathalie ook deelgenomen aan de Radboud PhD-competitie 
waarvoor ze, onder supervisie van prof. dr. Maria Hopman en prof. dr. Dick Thijssen, 
een onderzoeksvoorstel heeft geschreven, gepresenteerd en verdedigd. Via deze 
competitie is haar een persoonlijke PhD-subsidie toegekend waarop ze de afgelopen 
jaren heeft kunnen promoveren. Tussen 2011 en 2015 werkte zij aan meerdere 
onderzoeken naar de effecten van (verschillende typen) inspanning bij hartpatiënten, 
waarvan de artikelen zijn opgenomen in dit proefschrift. Daarnaast heeft Nathalie als 
algemeen lid deel uitgemaakt van de NCEBP (nu RHIS) PhD Council. Vanaf augustus 
2015 werkt Nathalie als arts-assistent op de afdeling Geriatrie in het Radboudumc.
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Name PhD student: NMM Benda 
Department: Physiology
Graduate School: Radboud Institute for Health Sciences
PhD period: 01-06-2011 – 31-05-2015 
Promotor(s): Prof. MTE Hopman, Prof. DHJ Thijssen 
Co-promotor(s):. Dr APJ van Dijk
Year(s) ECTS
TRAINING ACTIVITIES
a) Courses & Workshops
- Cardiovascular Ultrasound in Sport and Exercise Science Summer School
- Basiscursus Regelgeving en Organisatie voor Klinisch onderzoekers 
- NCEBP (now RIHS) Introduction course for PhD students 
- Effectieve individuele begeleiding van studenten 
- Management voor promovendi 
- NCEBP (now RIHS) workshop networking
- Opfriscursus statistiek voor promovendi 
- Academic Writing
2011
2012
2012
2012
2013
2013
2014
2014
0.6
1.4
1.4
1.0
3.0
0.1
1.5
3.0
b) Seminars & lectures
- Exercise in Medicine, Cardiac Exercise Research Group, Trondheim, Norway
- Renal fluid and electrolytes: From genes to bedside, Radboud university 
medical center
2013
2014
0.5
0.6
c) Symposia & congresses
- Papendal Symposium van de Nederlandse Fysiologen Vereniging
- NCEBP (now RIHS) PhD retreat 
- Papendal Symposium van de Nederlandse Fysiologen Vereniging, poster 
presentation 
- NCEBP (now RIHS) PhD retreat, poster presentation 
- European College of Sport Science, poster presentation 
2011
2011
2012
2012
2013
0.25
0.25
0.5
0.75
1.25
d) Other
- Member of the NCEBP (now RIHS) PhD Council 2012-2013 0.75
TEACHING ACTIVITIES
e) Lecturing
- Circulatie en Respiratie, practicum
- Introduction to Clinical Movement Sciences, practicum
- Clinical Exercise Physiology, practicum, lecture
- Fysische factoren, workgroup
- Student education at the Department of Physiology
2012
2012-2014
2011-2012
2012
2011-2015
0.3
0.9
1.0
0.2
0.5
f) Supervision of internships / other
- Robert Mollee; The acute effects of exercise on cardiac autonomic control 
in heart failure patients.
- Berwout van der Woude; The response of the autonomic nervous system 
after different types of exercise in patients with chronic heart failure and 
controls.
- Hai Ngo; Vascular endothelial function in heart failure patients: Is there a 
difference between non-ischemic and ischemic etiology?
- Guus Stevens; Effect of exercise on physical fitness and cardiac function 
in heart failure patients. A comparison between high-intensity interval and 
moderate-intensity training.
- Job Gieling; The effects of high-intensity interval training on peak oxygen 
uptake in patients with heart failure (a review).
- Annerie Beenker; Vascular endothelial function in heart failure patients: Is 
there a difference between non-ischemic and ischemic etiology?
- Margreet van de Zanden; Effect of high-intensity interval training on en-
dothelial function and physical fitness in heart failure patients.
- Florien Hakvoort; Effects of high-intensity interval training and moder-
ate-intensity continuous training on quality of life in heart failure patients. 
- Lando Jansen; honours internship
- Yvette Bouts; honours internship
- Dirk van Lier; voluntary internship
2012
2013
2013
2014
2013
2014
2014
2015
2011
2013
2014
1.0
1.0
1.0
1.0
0.3
1.0
1.0
1.0
1.0
1.0
1.0
TOTAL 30.05
9
PhD Portfolio
400341-L-bw-Benda
168

400341-L-os-Benda Processed on: 10_21_2015
